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Abstract: 
 
There has been very little research into the bioanalytical application of 
Microemulsion High Performance Liquid Chromatography (MELC), a recently 
established technique for separating an active pharmaceutical ingredient from its 
related substances and for determining the quantity of active drug in a dose. Also, the 
technique is not good at separating hydrophilic drugs of very similar chemical 
structures. 
 
Different phase diagrams of oil (octane or ethyl acetate), co-surfactant (butanol), 
surfactant (sodium dodecyl sulphate (SDS) or Brij-35) and buffer (Phosphate pH 3) 
were developed and several nanoemulsion mobile phases identified. Nanoemulsion 
mobile phase that is, prepared with SDS, octane, butanol and a phosphate buffer, 
failed to separate hydrophilic compounds with a very close chemical structure, such 
as terbutaline and salbutamol. A nanoemulsion mobile phase containing a non-ionic 
surfactant (Brij-35) with ethyl acetate, butanol and a phosphate buffer, was, however, 
successful in achieving a base line separation, and the method was validated for 
simultaneous determination of terbutaline and salbutamol in aqueous and urine 
samples. 
 
An oil-in-water (O/W) NELC method was developed and validated for the 
determination of formoterol in an Oxis
®
 Turbuhaler
®
 using pre-column fluorescence 
derivatisation. Although the same mobile phase was extended for separation of 
formoterol in urine, the formoterol peak’s overlap with endogenous peaks meant that 
fluorescence detection could not determine formoterol in urine samples. Solid phase 
extraction, concentrating the final analyte 40 times, enabled determination of a low 
concentration of formoterol in urine samples by UV detection. The method was 
validated and an acceptable assay precision %CV <4.89 inter-day and %CV <2.33 
intra-day was achieved. Then after the application of O/W nanoemulsion mobile 
phase for HPLC was extended for the separation of lipophilic drugs. The 
nanoemulsion liquid chromatography (NELC) method was optimised for the 
determination of salmeterol and fluticasone propionate in good validation data was 
achieved. 
 
This thesis shows that, in general, the performance of O/W NELC is superior to that 
of conventional High Performance Liquid Chromatography (HPLC) for the analysis 
of both hydrophilic and lipophilic drugs in inhaled dosage formulations and urine 
samples. It has been shown that NELC uses cheaper solvents and that analysis time is 
faster for aqueous and urine samples. This considerable saving in both cost and time 
will potentially improve efficiency within quality control. 
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1.1 Introduction 
Asthma is a chronic lung disease characterized by reversible air flow obstruction, 
airway inflammation, and airway hyperresponsiveness. Chronic Obstructive 
Pulmonary Disease (COPD) is defined as a disease state characterized by the 
presence of airflow obstruction due to chronic bronchitis or emphysema. Salbutamol 
and terbutaline (short acting β2-agonists) are widely used in the management of both 
these conditions. Short acting β2 agonists are also recommended by the National 
Institute for Health and Clinical Excellence (NICE) guidelines for the management 
of COPD as a first line choice. NICE recommends treating breathlessness and 
exercise limitation initially with short-acting bronchodilators (β2-agonists or 
anticholinergics) when required. In the British Thoracic Society (BTS)/Scottish 
Intercollegiate Guidelines Network (SIGN) guidelines, short acting β2 agonists are 
recommended as a first line treatment for the management of asthma. Salmeterol and 
formoterol (long acting beta agonists) are also widely used in the management of 
asthma and COPD. Recommendations for their use in BTS/SIGN guidelines on the 
management of asthma and NICE guidelines on the management of COPD have sped 
up the prescribing of these agents. For asthma it is highly recommended to use these 
agents in combination with an inhaled corticosteroid (e.g. budesonide, fluticasone 
propionate).  
 
The quality of an inhalation product is determined both by the ingredients and the 
inhaler device. Therefore it is important to monitor the interaction of the device and 
the formulation to ensure reproducible delivery of the inhalation drug to the patient. 
The in vitro performance of inhalers, including dose content uniformity and particle 
size distribution of the emitted dose as measured by the cascade impactor, must 
satisfy regulatory standards for pharmaceutical products. On the other hand, the in 
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vivo performance of the inhaler and lung deposition can both be measured by 
pharmacokinetic methods. Both in vitro and in vivo assessments of inhalers need 
analytical methods such as HPLC both to quantify the amount of drug deposited on 
the ACI stages and to measure the concentration of drugs in urine/plasma samples. 
 
Microemulsions are based on a specific mixture of surfactants and a specific 
interaction with the oil and water phases that are produced spontaneously at optimum 
composition. The driving force for microemulsion formation is the low interfacial 
energy. Low interfacial tension is produced in most cases by a combination of two 
molecules, referred to as surfactants and co-surfactants (medium-chain alcohol). 
Different types of microemulsions can be formed, but only two of these, oil-in-water 
(o/w) and water-in-oil (w/o) have been used as mobile phases for separation by 
HPLC. O/W microemulsions are employed as eluents for reversed phase HPLC 
while w/o microemulsions are used for normal-phase chromatography. Recent 
reports have found that separations using microemulsion mobile phase can have 
superior speed and efficiency to conventional HPLC modes. Also, this method offers 
a unique selectivity with excellent resolution and the capability for quantitative and 
stability-indicating analysis (El-Sherbiny D, 2003) (Malenovic A, 2004) (El-
Sherbiny D, 2005).   
 
Separation in HPLC is controlled by the partition of molecules to different degrees 
between the mobile and stationary phases. Using a microemulsion mobile phase 
alters these partitioning characteristics due to the layer of surfactant molecules which 
adsorbs onto the stationary phase surface. A secondary partitioning mechanism also 
exists in microemulsion high performance liquid chromatography (MELC) where 
solutes partition with both the mobile and stationary phases and into the oil droplets. 
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For an o/w microemulsion, water-insoluble compounds favour inclusion in the oil 
droplet, the surface of which is not rigid so that solutes can penetrate easily, and their 
retention is predominantly influenced by partitioning into the microemulsion 
droplets. Water-soluble analytes will reside mainly in the aqueous phase and their 
retention is largely controlled by stationary phase interactions. The hydrophobic 
organic solvents used to create the droplets are also distributed to some extent on the 
surface of the column, which increases the amount of stationary phase and also 
affects solute selectivity and retention (El-Sherbiny et al., 2003). Together, all of 
these partitioning mechanisms control the retention and separation of solutes in a 
MELC separation. 
 
1.1.2 Rationale 
Recently, microemulsion has been introduced in pharmaceutical analysis. Isocratic 
o/w microemulsion liquid chromatography (MELC) has been used for the separation 
of mixtures of test solutes or pharmaceutical compounds and for the determination of 
drugs in their pharmaceutical preparations. Several studies have used gradient MELC 
for the separation of different ranges of pharmaceutical compounds. The research in 
this area is still limited, however. Also, previous studies using microemulsion as the 
mobile phase for HPLC have used ionic surfactants (SDS) in the formation of 
microemulsion mobile phase. In reversed phase HPLC the stationary phase of the 
HPLC column is only stable in the pH range 2-7. However, the hydrophilic analytes 
are positively charged in this range and therefore will have an ionic interaction with 
SDS, which results in poor separation of the highly hydrophilic compounds with very 
similar chemical properties. Marsh et al. (2005) have reported a similar observation. 
In the present work, a non-ionic surfactant was used in the formation of the mobile 
phase of the nanoparticles for the separation of highly hydrophilic drugs. 
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Analysis of drugs and their metabolites in biological fluids is essential to provide the 
necessary information required for the evaluation and interpretation of 
bioavailability, bioequivalence, pharmacokinetic, and toxicology study data. The 
conventional mobile phase usually encounters difficulties in separation of the drugs 
in the biological fluid and therefore gradient HPLC is usually considered in the 
bioanalysis. The use of microemulsion as HPLC mobile phase has mainly been 
applied in pharmaceutical analysis, but there are few reports of using this technique 
for bioanalysis where the work was on serum and plasma, and no work to date has 
reported the bioanalysis of drugs in a urine matrix.  
 
One of the greatest difficulties associated with bioanalysis arises in having to resolve 
the compound of interest from interfering substances in a complex biological fluid. 
The presence of oil droplets, hydrophobic phase, in the mobile of NELC, provides 
increased selectivity compared with conventional HPLC methods. This allows better 
manipulation for the separation of biological samples. In addition, all previous 
reports have used microemulsion as an eluent for HPLC to separate drugs from their 
related substances. However, none of these studies has reported the use of 
nanoemulsion as a mobile phase for HPLC. 
 
1.1.3 Aims 
The aim of this work is to explore the capabilities of nanoemulsion liquid 
chromatography (NELC) for the quantitative determination of inhaled drugs in 
dosage form and in biological fluids focusing on urine samples.  
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1.1.4. Objectives 
I. To test the applicability of the procedure by developing several 
microemulsion/nanoemulsion systems using different types of surfactants. These 
systems will then be assessed by constructing a phase diagram to determine the 
potential mobile phases for the HPLC. 
II. To study the effect of nanoemulsion compositions of these mobile phases and 
other parameters such as temperature, pH and flow rate on the separation in reversed 
phase HPLC. 
III. To use o/w nanoemulsion for the determination of drugs with different 
physiochemical properties in in vitro and in vivo samples, as follows: 
a- To apply NELC for in vitro and in vivo determination of the hydrophilic 
drugs such as terbutaline and salbutamol. 
b- To exploit NELC for the determination of the moderately lipophilic drug, 
formoterol in in vitro and in vivo samples. 
c- To use NELC for the determination of the highly lipophilic drugs, salmeterol, 
fluticasone propionate and budesonide, in dosage form. 
 
1.1.5. Thesis structure 
This thesis consists of seven chapters. 
Chapter 1 is an introduction with a brief summary of the research work. The aim and 
objectives of this research work have been highlighted. This also includes a summary 
of the research work. 
 
Chapter 2 is a literature review of the issues related to this research, including 
asthma and its management, microemulsion/nanoemulsion, nanoemulsion liquid 
chromatography (NELC), HPLC, and Dry Powder Inhalation (DPI).  
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Chapter 3 details the materials and methods used in this study. 
 
Chapter 4 describes the preliminary evaluation of the nanoemulsion as eluent in 
HPLC and covers the construction of the phase diagram. 
 
Chapter 5 describes the in vitro and in vivo use of NELC to determine hydrophilic 
drugs (e.g. salbutamol and terbutaline). 
 
Chapter 6 focuses on the in vitro and in vivo use of NELC to determine moderately 
lipophilic agents (e.g. formoterol). 
 
Chapter 7 describes the in vitro use of NELC to determine highly lipophilic drugs 
(e.g. salmeterol, fluticasone propionate). 
  
Finally a general conclusion from these studies and suggestions for future work are 
presented in Chapter 8. 
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2.1. The respiratory system: 
  The respiratory system consists of the upper respiratory tract which includes the 
nose, mouth and pharynx as illustrated in Figure 2.1. The main function of this 
region is heating and moistening of air as well as acting as a filter. The lower 
respiratory tract includes the larynx, the trachea, the bronchi and the lungs. The 
diaphragm and the muscles of the thoracic wall are required for respiratory 
movements. The pharynx is the common opening of both the digestive system at the 
oesophagus and the respiratory system at the larynx. It receives air, food and water 
from the mouth and air from the nasal cavity.  
Respiration includes the following processes:  
(1) Ventilation, which is the movement of air into and out of the lung. 
(2) External respiration: Gas exchange between the air in the lungs and the blood. 
(3) Internal respiration: Transport of oxygen and carbon dioxide in blood and 
tissues. 
Each lung is conical in shape; the lungs are separated into lobes. The right lung has 
three lobes, whereas the left lung has two.  There are approximately 300 million 
alveoli in each lung. The average diameter of the alveolus is about 0.25 mm and its 
wall is extremely thin. They are surrounded by a network of capillaries as shown in 
Figure 2.2. (Tortora & Grabowski, 2003).  The name alveolus comes from the Latin 
word meaning “little cavity”. If spread out, the millions of alveoli in a pair of lungs 
would cover the area of a tennis court.  A very thin barrier separates the air inside the 
alveoli from the blood in the capillaries around them. This barrier is made up of the 
wall of each capillary. The blood in the capillaries is low in oxygen, so oxygen 
passes through the blood. The red cells absorb oxygen, the blood changes from a 
dark bulish-red colour to bright red. 
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Figure 2.1: Schematic diagram of the respiratory system. [Reproduced from 
                                                                                                                 (Berico et al, 1997) 
1 
 
 
Figure 2.2: The alveolar duct, showing the blood supply to the alveoli. 
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2.1.1. Asthma 
2.1.1.1. Introduction  
2 Asthma has been known since ancient times. the name “asthma” comes from the 
Greek word meaning “sharp breath”. 
It is defined as a chronic inflammatory disorder of the airways. This inflammatory 
disorder is associated with hyper-responsiveness to a variety of stimuli which leads 
to recurrent episodes of wheezing, shortness of breath, chest tightness and cough, 
particularly at night and in the early morning. These episodes are generally 
associated with widespread but variable airflow obstruction which is often reversible 
either spontaneously or with treatment (O'Byrne et al, 2006).  
2.1.1.2. Aetiology / Pathophysiology 
There are two predominant types of asthma: - Extrinsic: when it is associated with 
exposure to a specific allergen, such as pollen, dust, or non-specific stimulus such as 
chemical irritant or exercise.  
- Intrinsic:  when no external precipitating factor is identified  (Helms, 2006, Koda-
Kimble, 2008). However, the aetiology of asthma is poorly understood. 
 
The pathophysiology of asthma is characterized by a complex interaction between 
inflammatory cells and mediators. Mast cells, eosinophils, neutrophils, T-
lymphocytes and epithelial cells play important roles in the pathophysiology of 
asthma. Figure 2.3 illustrates the mechanism of cells and mediators associated with 
airway inflammation. When an antigen is inhaled the mast cells and TH2 are 
activated. This leads to release of mediators of inflammation (such as leukotrienes 
and histamine) and cytokines, including interleukin-4 and interleukin-5; they laters 
migrate to the bone marrow and enhances final differentiation of eosinophils. 
Circulating eosinophils in turn moves to the allergic inflammation area. As the 
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eosinophils penetrate the matrix of the airways, their survival is prolonged by 
interleukin-4 and granulocyte-macrophage colonystimulating factor (GM-CSF). 
 
Figure 2. 3: Pathophysiologic findings in asthmatic airway. MCP-1, monocyte chemotactic protein; 
MIP-1, macrophage inflammatory protein GM-CSF granulocyte-macrophage colony-stimulating 
factor [Source:(Koda-Kimble, 2008)]  
 
The eosinophils secrete inflammatory mediators, such as granule proteins and 
leukotrienes, which cause airways tissues injure. Furthermore, eosinophils can 
secrete GM-CSF to increase their survival and contribute to persistent airway 
inflammation. However, it should be kept in mind that over 20 cytokines have been 
reported that could be involved in the inflammation process. Therefore, it is not 
surprising that drugs which target the presence of one cytokine have not been 
successful in treating asthma (Helms, 2006, Koda-Kimble, 2008). 
More recently, remodelling of the airways is thought to be secondary failure to 
control airway inflammation in asthmatic patients. As it is clearly shown in Figure 
2.4, airway remodelling refers to structural changes, causing irreversible narrowing 
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of the airway lumen and airflow obstruction which can eventually decrease lung 
function (Helms, 2006). 
 
Figure 2.4: Remodelling of the airways of asthmatic patients. (reproduced from WebMD medical 
reference 2005, (www.mywebmd.com Accessed in 06-2010) 
 
2.1.1.3. Prevalence of asthma  
In many countries the prevalence of asthma is increasing, particularly in the second 
decade of life where this disease affects 10-15% of the population  (Hill & 
Thomason, 1998). Children have the highest prevalence (Akinbami & Schoendorf, 
2002). There is also a geographical variation, with asthma being common in more 
industrial countries, some of the highest rates being in New Zealand, Australia and 
the UK 
A recent report indicates that there are 5.2 million people in the UK with asthma, 
with 1.1 million of these being children and there is one death every 7 hours from 
asthma. Asthma is estimated to cost the UK over £2.3 billion per year, which 
includes both the cost to the NHS and lost productivity due to absence from work 
(Asthma UK, 2004). 
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2.1.1.4. Diagnosis 
There is no single satisfactory diagnostic test for all asthmatic patients. The diagnosis 
is normally based on symptoms and signs. 
- Symptoms 
The most common symptom recognised by both physicians and patients is wheezing 
with the warning that “not all that wheezes are asthma. “Wheezing is a whistling or 
rumbling sound that comes from the chest expiration and other symptoms such as 
cough episodic breathlessness, cough, and chest tightness” (O'Byrne et al, 2006).  
- History 
The diagnosis is normally based primarily on a good history. The patient may have a 
family history of allergy (DiPiro et al, 2008). 
- Blood and sputum tests 
Patients with asthma may have an increase in the number of eosinophils in peripheral 
blood (> 0.4 x 109/L). The presence of large numbers of eosinophils in the sputum is 
concidered a more useful diagnostic tool. 
- Skin tests 
It is suggested that skin-prick tests should be performed in all cases of asthma to help 
identify allergic causes. 
-Tests of ventilatory function 
These tests are used mainly to assess the degree of airflow limitation present during 
expiration. 
-Peak expiratory flow rate (PEFR) 
This is an extremely simple and cheap test. Subjects are asked to take a full 
inspiration to total lung capacity and then blow out forcefully into the peak flow 
meter (Fig. 2.5), which is held horizontally. The lips must be placed tightly around 
the mouthpiece. The best of three tests is recorded.  
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Figure 2. 5: Peak flow measurements, (a) Peak flow meter: the lips should be tight around the 
mouthpiece, (b) Graph of normal readings for men and women. 
- Spirometry 
  The spirometer measures the forced expiratory volume in one second (FEV1) and 
the forced vital capacity (FVC). Both the FEV1 and FVC are related to height, age 
and sex. The technique involves a maximum inspiration followed by a forced 
expiration (for as long as possible) into the spirometer.   FEV1 / FVC ratio in healthy 
persons generally is 75% to 80%. (BTS, 2008). 
2.1.1.5. Asthma classification 
A classification of asthma severity is important to establish the treatment plan. 
Therefore, asthma can be classified as mild, moderate or severe according to the 
degree of obstruction and its severity. Children born to families with a history of 
allergies or asthma are more likely to have asthma (Koda-Kimble, 2008). 
2.1.1.6. Treatment of asthma 
The treatment of asthma involves avoiding the causative stimulus and administering 
drug therapy, which includes prophylactic measures to reduce inflammation, airway 
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resistance, to maintain flow, and specific actions for acute attacks. Corticosteroids, 
leukotriene inhibitors, and mast cell stabilizers are used to reduce airway 
inflammation. Xanthines (e.g. theophylline), antimuscarinics and β-adrenergic agents 
(e.g. Salbutamol and Terbutaline) are commonly used to cause bronchodilation. 
The British Thoracic Society (BTS, 2007) has recommended a 5-step approach for 
the management of asthma as shown in the Figure 2.6. The stepwise approach to 
treatment is based on the use of inhaled short-acting β2-agonists (SABA) such as 
salbutamol and terbutaline (relievers) as the first line of treatment followed by 
inhaled corticosteroids (preventers). The treatment gradually increases to the addition 
of a long acting β2-agonist (LABA) until the final step, where oral corticosteroids are 
used for more severe cases and during exacerbation as a short course. A summary of 
these guidelines are shown in Figure 2.6. 
Step 1 Relievers drugs such as salbutamol, terbutaline are short acting beta2 agonists 
(SABA), but quick-onset drugs which produce rapid relief from the symptoms of 
asthma. These are inhaled as required. Using two or more canisters of beta2 agonists 
per month or >10-12 puffs per day is a marker of poorly controlled asthma (SIGN, 
2002). If the patient is using a SABA on a regular basis, anti-inflammatory therapy is 
also recommended. 
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 Figure 2.6: Proposed BTS / SIGN stepwise approach for the management of asthma (www.brit-
thoracic.org.uk).   
 
Step 2 would be judged on the ability to improve symptoms, improve lung function, 
and prevent exacerbations, with an acceptable safety profile. Inhaled steroids are the 
most effective therapy for asthmatic patients to achieve overall treatment goals 
(Scottish Intercollegiate Guidelines (SIGN), 2002, Adams et al., 2005). Two recent 
studies have shown a benefit from the regular use of inhaled steroids in patients with 
mild asthma (Pauwels et al, 2003) . Benefit in these studies was seen even with an 
FEV1 of 90% of predicted. Inhaled steroids should be considered for patients with 
any of the following (BTS, 2007): 
 Exacerbations of asthma in the last two years 
 Using inhaled short acting β2-agonist three times a week or more 
 Symptomatic three times a week or more, or waking one night a week. 
STEP 1 
Inhaled short-acting 2-agonist (or other bronchodilator)  
 
STEP 2  
Add inhaled corticosteroid:  800 g/day adult  400 g/day children 
 
STEP 3  
Add long-acting 2-agonist from 200g per day  
STEP 4  
Add any or all of the following as determined by 
empirical trial: increase inhaled corticosteroid up  
to  2000 g/day, oral 2-agonist, leukotriene 
receptor antagonist, theophylline, cromone 
STEP 5  
Add daily oral steroid or regular 
booster courses of oral steroid 
 Literature review                                                                                              Chapter 2  
 18 
Step 3 focuses on add on therapy using steroids. Howevere the use of high doses of 
steroids causes frequent side effects in patients. The BTS (2007) guidelines 
recommend a trial with add-on medications before stepping up the dose of steroids.  
The first recommended choice is the use of a long acting β2-agonist like formoterol 
or salmeterol to improve lung functions and symptoms and to decrease exacerbations 
(SIGN, 2002). Long acting β2-agonist should always be used with an inhaled steroid 
and not alone in the management of asthma.  
Step 4 recommends an increase in the dose of steroids where the patient shows 
evidence of a poor control and also where the patient is given a moderate dose of 
inhaled steroid and then add-on therapy. If there is a response to long acting β2-
agonist but where the control remains poor then the dose of the inhaled steroid 
should be increased and long acting β2-agonist should be continued. If the add-on 
therapy still remains inadequate the use of leukotriene receptor antagonists or 
theophyllines or slow release β2-agonist tablets are recommended in step 4 (SIGN, 
2002). The maximum steroid dose that is recommended is equivalent to 
beclomethasone 2000 µg per day. There is also a recommendation to add leukotriene 
receptor antagonists and theophyllines, however the side effects are considered to be 
high. 
Step 5 recommends the use of oral steroids using the lowest dose that provides 
adequate control. A highest dose of inhaled steroid is suggested to be no more than 
2000 µg per day. It is also essential that airway inflammation to be minimised or 
prevented in younger patients, because years of persistent inflammation can increase 
the potential for the chronic effect of inflammation, which causes airway re-
modelling and the development of irreversible chronic obstructive airway disease at 
an early stage. 
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It is recommended in the guidelines that compliance and inhalation technique are 
checked before making changes to a patient’s therapeutic management. 
 
Acute asthma  
Goals of therapy 
The primary goal is prevention of life-threatening asthma by early recognition of 
signs of deterioration and early intervention. As such, the principal goals of treatment 
include 
- Correction of significant hypoxemia 
- Rapid reversal of airflow obstruction 
- Reduction of the likelihood of recurrence of severe airflow obstruction 
- Development of a written action plan in case of a further exacerbation 
These goals are best achieved by early initiation of treatment  
 
 
- SIGNS 
Signs include expiratory and inspiratory wheezing, dry hacking cough, tachypnea, 
tachycardia, pale or cyanotic skin, hyperinflated chest. 
- Laboratory:  FEV1 less than 50% of normal predicted values. FACTORS 
CONTRIBUTING TO ASTHMA SEVERITY 
- Viral Infections 
Viral upper respiratory tract infections are a major precipitant of acute asthma in 
children, being involved in up to 20% to 40% of acute episodes 2.  
 
 Treatment of acute asthma 
Patients with acute severe asthma usually are hypoxaemic, therefore they should be 
given high flow oxygen. β2-agonist is the first-line agent in acute asthma and should 
be administered as early as possible. 
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Combination of nebulised ipratropium bromide and β2-agonist produce significantly 
better bronchodilation than a β2 agonist alone.  
Steroids decrease mortality, relapses, hospital admissions and β2-agonist therapy 
requirement. Usually the infection which exacerbates asthma is viral, therefore there 
is no role for antibiotics (BTS, 2008).  
In this study, the drugs under investigation are: Terbutaline sulphate, salbutamol, 
formoterol, salmeterol xinafoate and fluticasone propionate.  Terbutaline sulphate is 
a synthetic derivative β2-adrenergic agonist that is used as a bronchodilator. It was 
specifically developed to relax the trachea without affecting the cardiac muscle. The 
terbutaline concentration in plasma or serum is generally low as the inhaled dose is 
small and the volume of distribution can be very large, hence which can result in it 
being cleared from blood to urine at a fast rate (Chrystyn, 1994 -b). Previous 
pharmacokinetic studies have shown that Terbutaline has poor oral absorption. As 
19% of lung deposition occurs when a 250µg dose of terbutaline is delivered by a 
dry powder device (Lipworth, 1996).  
Salbutamol has a rapid onset and short duration of action (Lotvall, 2001). Following 
oral administration the onset of action is around 30 minutes. The onset of 
bronchodilation after the inhalation occurs within 5 minutes, peaks after 30 minutes 
and lasts for up to 4 to 6 hours (Lipworth, 1992).  Salbutamol has a high volume of 
distribution (2.5l/kg) consequently leading to low plasma concentrations (Morgan, 
1986). Salbutamol has a low protein binding of approximately 8%.  
Formoterol is a long-acting β2 -agonist, with an extended duration of action (up to 12 
hrs) compared to short-acting β2 -agonists such as salbutamol, which are effective for 
4–6 hrs. It is used in the treatment of asthma and COPD.  
Formoterol is extensively metabolised in the liver (Brunton et al., 2006) and the 
percentage of renal excretion is 60%, (RK, 2005c).  
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Salmeterol xinafoate (SX) is generally only prescribed for severe persistent asthma 
and COPD following previous treatment with a short-acting β2-agonist such as 
salbutamol and is concurrently prescribed with a corticosteroid, such as budesonide 
(Johnson et al., 1993). The main difference between salmeterol and salbutamol is the 
duration of action which lasts approximately 12 hours (D’Alonzo and Tolep, 1997).  
As the therapeutic dose of SX is small, systemic levels are low or undetectable after 
inhalation of recommended doses. However, the plasma protein binding is 
considerably higher (96%). 
Fluticasone propionate (FP) is a medium-potency synthetic corticosteroid, is used 
topically to relieve inflammatory pain and also orally for the treatment of asthma 
(Crim et al., 2001).  
Less than 5% of a radiolabelled oral dose is excreted in the urine as metabolites. The 
volume of distribution averages 4.2 L/kg. The percentage of FP which is bound to 
human plasma proteins averages 91%.  
A combination inhaler of SX and FP has been shown to be more effective than 
doubling the steroid dose to improve the control treatment of asthma (Dahl et al. , 
1997, Weersink et al., 1997). These two drugs are formulated both as dry powder 
inhalers and as pressurized metered dose inhalers both individually and as a 
combination formulation. 
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2.1.2. Lung deposition 
2.1.2.1. Introduction  
For treatment of respiratory disorder different types of inhaler are used. Drug 
particles are deposited in the respiratory system depending on the drugs physical 
and chemical properties and the hosts’ physiology.  
2.1.2.2. Mechanism of particle deposition in the airways: 
There are  three important principal mechanisms for lung deposition: inertial 
impaction, gravitational sedimentation, and Brownian diffusion  (Bisgaard et al, 
2002, Newman et al, 1982) Figure (2.7).  
- Inertial Impaction. 
When the particles are heavy (larger than a few μm) or travelling at high speed 
this may lead to the particles being unable to follow if it changes its direction and 
as a result they will impact on the airway wall (Bisgaard et al, 2002, Newman et 
al, 1982).  
 
 
Figure 2.7 : Illustration of particle transport onto airway surfaces [Source:   (Bisgaard et al, 
2002)] 
- Gravitational sedimentation 
Particle sedimentation is driven by the gravitational force which is balanced by 
air resistance. Particle sizes range from 0.5 µm to 5 µm and may travel to 
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peripheral parts of the lung where they can settle onto smaller airways. This 
happens during quiet breathing or breath holding (Bisgaard et al, 2002, Newman 
et al, 1982). 
- Brownian Diffusion  
For particles smaller than 0.5 µm, Brownian Diffusion is the most important 
mechanism of deposition. Where  particles inside the airways may be displaced 
by the random bombardment of gas molecules and impact with the airway walls 
(Bisgaard et al, 2002, Newman et al, 1982). 
2.1.2.3. The methods of studying deposition 
There are two main methods to identify drug deposition in the lung:  in-vivo 
methods and in-vitro methods.    
- In-vivo methods 
Although they do not generally provide information on the distribution of drug 
into different regions of the lungs, Pharmacokinetic methods are used to evaluate 
the whole lung deposition (Derendorf et al, 2001). 
- In-vitro methods 
In-vitro methods are a major component of the quality control and in drug 
development as used by the pharmaceutical industry. Alongside this, researchers 
use in-vitro methods to predict  the drug deposition in the lung (Bisgaard et al, 
2002). The reason is that the pharmacological effects of an inhaled drug has a 
good relation with the amount of drug depositing in the lower airways and the 
deposition pattern as shown in Figure (2.8). In addition, in-vitro methods are 
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used to determine the difference between different inhaled formulations (Van 
oort, 1995).  
 
Figure 2.8: Relation between Andersen 8-stage CI cut size at 28.3L/min and likely deposition in 
lung. [Source: Adapted from (Mitchell & Nagel, 2000)] 
 
ACI (Andersen Cascade Impactor) 
The ACI is one of the most commonly used impactors within the pharmaceutical 
industry for the evaluating of inhaled products. It was originally developed as a 
bacteriological air sampler and then adopted by the pharmaceutical industry for 
characterising size distributions of aerosol products. The ACI is listed as 
apparatus for testing MDI and DPI products in the US and EU Pharmacopoeia. 
The ACI consists of 8 stages together with a final filter. The stages are clamped 
together and sealed with O-rings. It is normally manufactured from aluminium, 
316 stainless steel and also titanium ( Figure 2.9). 
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Figure 2.9: A- ACI (Aluminium, 316 Stainless Steel and Titanium) and B- Schematic of ACI ) 
[Source: adapted from (COPLEY, 2007a)] 
 
In order to prevent overloading stages in the case of DPI testing, it is  necessary 
to add a preseparator; which will trap the non-inhalable aerosols as shown in 
Figure 2.10 (Mitchell & Nagel, 2003). 
 
Figure 2.10: Pre-separator for Andersen Cascade Impactor. [Source: adapted from (Copley, 
2007a)] 
2.1.3. Pulmonary delivery devices 
2.1.3.1. Introduction 
Inhaled drug products are becoming increasingly popular as a method of drug 
delivery through nasal mucosa or the lung for systemic or local therapy. 
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Successful management of asthma and other lung diseases relies on achieving 
adequate delivery of inhaled drug to the lungs (Selroos et al, 1996). 
Although there are several new treatments for asthma, which may be given orally 
(more specific drugs) or via injection (monoclonal antibodies), it is unlikely that 
these will be as effective as the inhaled drug.(Barnes, 2004a). 
Inhaled bronchodilators and corticosteroids are the mainstay of treatment for 
asthma and COPD. The inhaled drug devices are classified into three main 
categories of a nebuliser pressurised metered dose inhaler (pMDI) or dry powder 
inhaler (DPI). Most clinical evidence shows that any of these devices will work 
for most situations, including the exacerbated and the stable outpatient (Celli et 
al, 2004). 
The type of drug and device used are very important factors in targeting drug to 
the respiratory tract (Barnes, 2004a, Bisgaard et al, 2002). 
2.1.3.2. Pressurised metered dose inhale (pMDI)  
The pMDI has been introduced for more than 50 years. It has become the most 
popular dosage form for the delivery of therapeutics to the respiratory tract. The 
MDIs aim to deliver liquid propellant loaded drugs to the lungs. The pMDI 
consist of propellants e.g. chlorofluorocarbons (CFC) and more recently 
hydrofluoroalkanes (HFA) , drug formulation, metering valve and actuator. 
pMDIs have several advantages and disadvantages. Table 2.1, lists the 
advantages and the disadvantages of pMDIs 
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   Table 2. 1:Advantages and disadvantages of conventional pMDIs 
 
Advantages  Disadvantages 
Convenient, Availability to use Drug delivery is significantly effected 
by inhalation technique.   Cost  
Number of doses may reach 100 Needs propellants   
High pressure protect its contents 
against bacteria and moisture.  
High velocity of particles lead to high 
oropharyngeal deposition 
 
2.1.3.3. Nebulisers 
Nebulisers are devices which can generate an aerosol droplet from a liquid to 
produce a  respirable cloud for inhalation.  
Nebulisers, are the oldest group of delivery of liquids to the lungs, which are 
usually restricted in administration to children, hospitalised patients and those 
who for any reason are unable to use MDIs or DPI (Fink, 2000). But generally, 
as nebulisers are bulky, costly and more complex. The indications for nebulised 
treatment in asthma have declined, especially in community settings (BTS, 
2007).  
2.1.3.4. Dry powder inhaler (DPIs ) 
DPIs are used for the delivery of dry powders and usually require an inert carrier 
excipient such as lactose for their efficient delivery (Islam & Gladki, 2008). Dry 
powder inhalers basically contain four functional elements: the powder container, 
the metering system, the disintegration principle and a mouthpiece. Many 
different disintegration principles exist which may vary from a simple screen 
(Rotahaler, Diskhaler), to twisted powder channels (Turbuhaler) (Figure 2.11).  
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At the end of the 1960s, the first DPI was introduced. The major reason was 
linked to the need for an increased dose of sodium cromoglycate ( 20 mg ) and 
the pMDI system was not capable of delivering such a dose, and the Spinhaler® 
(Aventis) was developed (Chrystyn, 2007a). 
The DPIs have some particular advantages as they require minimum or no 
coordination of actuation and inhalation as DPIs are only activated while the 
patient inhales. Also, because the formulation for DPIs is one-phase, as solid 
particle mixtures, they are more stable than pMDIs. But, the emitted dose 
depends on the patient’s inspiratory airflow (Chrystyn, 2007a). 
  
    
 
                               
 Figure 2.11: A schematic diagram of different types of inhalers available in the market. 
[Reproduced from (De Boer et al, 1996) 
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                                Table 2.2: Dry powder inhalers available in the market 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3.4.1. Types of DPI delivery devices 
DPI devices can be classified by dose type into three groups: single-unit dose, 
multi-unit dose and multi-dose reservoirs (Table2.2).  
- Single-unit dose devices 
The single-unit dose system is a breath activated dry powder inhaler device with 
a capsule, which when loaded into the inhaler provides a single dose such as the 
Rotahaler
®
, Aerolizer
®
.  
 
- Multi-unit dose devices 
The multi-unit dose dispensing system was developed to overcome the main 
disadvantage of single unit doses. This can hold multiple doses without the need 
to reload. The multi-unit dose device system has the advantage of the doses being 
Inhaler device (manufacturer) 
Single dose inhalers 
Spinhaler (Aventis) 
Cyclohaler (Pharmachemie) 
Rotahaler (GlaxoWellcome) 
Aerolizer (Novartis Pharma) 
Inhalator (Boehringer Ingelheim) 
Handihaler (Boehringer Ingelheim) 
Multi-dose inhalers 
Multiple unit-dose inhalers 
Diskhaler (GlaxoWellcome) 
Aerohaler (Boehringer Ingelheim) 
Diskus / Accuhaler (GlaxoWellcome) 
Reservoir systems 
Turbuhaler (AstraZeneca) 
Clickhaler (Innovata Biomed/ML labs celltech) 
Easyhaler (Orion Pharma) 
Pulvinal (Chiesi) 
Novolizer (Viatris) 
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protected from the environment condition and the dose uniformity is enhanced. 
Inhalers of this type include devices such as the Accuhaler
®
, Diskhaler
®
. 
 
- Multi-dose reservoir devices 
The multi-dose reservoir device stores the bulk supply of drug. The multi-dose 
dispensing system is a DPI device containing doses (200 doses) in a reservoir 
and has a built in meter to measure each single dose with each actuation. Inhalers 
of this type include devices such as Turbuhaler
®
, Easy haler
®
and Clickhaler
®
. 
(Tarsin, 2006) have studied the emitted dose estimates from Seretide Diskus® 
and Symbicort Turbuhaler® following inhalation by severe asthmatics.  
 
Summary  
The main disadvantage of inhaler devices is they are only delivered ≤ 30% of 
total emitted dose to the lung (Pauwels et al,, 1997). Table (2.3) illustrated the 
characteristics of aerosol inhaler for all three types of devices.    
Table 2.3: Characteristics of aerosol inhaler. [Source: (Khilnani & Banga, 2008)] 
 
 pMDI DPI Nebuliser 
Technique of generation 
of aerosol 
Propellant 
based 
Patient 
driven 
Bernoulli’s principle 
piezoelectric crystal 
Particle size 1-10 μ 1-10 μ Variable 
Drug deposition  5-10% 9-30% 2-10% 
Oro-pharyngeal deposition Significant Variable Insignificant 
Patient coordination Required Not 
applicable 
Not required 
Breath hold Required Not required Not required 
Patient generation of flow Not required Required Not required 
Amount of drug Small doses  Small doses Large doses possible 
Contamination No No Possible 
Use for chronic therapy Yes Yes Rarely 
Use for emergency 
management 
No No Yes 
Use for intubated patients Preferred No Second choice 
Cost Cheap Cheap Expensive 
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Patients are known to prefer DPI devices to pMDIs because they are easer to use. 
However, DPIs are flow-dependent and therefore it is difficult for patients with 
severe airway disease, or frequent pulmonary exacerbations or for children to use 
them. 
Many clinical studies have examined the performance of inhaler devices. These 
concluded that none of the devices shows any clinically superiority. Therefore 
the selection of a device should be guided by other factors, including patient 
preference, cost and patient age (Telko & Hickey, 2005).    
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2.2. Nanoemulsion 
2.2.1. Nanoemulsion – A historical overview 
 
   Microemulsions were not really known until the work of Hoar and Schulman 
in 1943, who reported a spontaneous emulsion of water and oil on addition of a 
strong surface-active agent (Sjöblom et al, 1996). The term “microemulsion” was 
first used by Schulman et al. in 1959 to explain a multiphase system consisting of 
water, oil, surfactant and alcohol, which forms a transparent solution. There has 
been much argument about the word “microemulsion” to explain such systems 
(Shinoda & Friberg, 1975). It was then defined in 1981 as “a system of water, 
oil, and amphiphile which is a single optically isotropic and thermodynamically 
stable liquid solution” (Danielsson & Lindman, 1981). A few years later, the 
term “nanoemulsion” was employed for the first time to name an optically clear 
complex system with a droplet particle size of 20-25nm (Shaw et al, 1998). Four 
years later, a “nanoemulsion” was classified into a different category and 
described as forming from homogenizing a “lamellar liquid-crystalline structure 
in the aqueous phase” with the particle size <200nm (Weder & Mutsch, 1992). 
Since then, other definitions have been proposed for nanoemulsions. For 
example, Tadros (Tadros, 2004) used the word “nanoemulsion” for all kinetically 
stable emulsions with the size range 50-200 nm. More recently however, particle 
size has been used as the key parameter for distinguishing nanoemulsions from 
microemulsions. Resulting from this a new definition, was proposed where 
nanoemulsions are generally considered to have a particle size of less than or 
equal to 100nm. Thus, from this definition, a nanoemulsion can be 
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thermodynamically or kinetically stable and formed spontaneously or with the 
help of applying energy (Sarker, 2005, Sarker, 2007, Shafiq-un-Nabi et al, 2007).  
Nanoemulsions have a broad range of physical stability with literature reports of 
prepared nanoemulsions being physically stable from a few days to more than 2 
years, because the energetic barrier to revert into cloudy mixture is high 
(Tenjarla, 1999).  
Two methods have been widely used in the literature to assess the stability of the 
nanoemulsions, monitoring the growth in the particle size of nanoemulsions and 
visual examination of the preparation for any phase separation (Aboofazeli et al, 
2000b, Kahlweit et al, 1987, Tenjarla, 1999). 
2.2.2. Surfactant solutions  
Surfactant molecules are water-soluble and create solutions with unique 
properties, due to the amphilic nature of the solubilised molecules. The two 
major properties of surfactant solutions are the adsorption at any interface and 
the micelle formation. These are the consequences of polar and non-polar 
interaction with the surfactant molecules. When a small amount of surfactant is 
added to the bulk of a system, the water will solubilize and disperse it. As more 
surfactant is added to the system, the system will become saturated with 
surfactant. When the surfactant concentration is above a specific value of the 
critical micelle concentration (CMC), the surfactant solution becomes a micellar 
solution (Figure 2.12)  
Micelles are dynamic structures with an aggregate rapid exchange of surfactant 
monomers with the aqueous phase. The relaxation time of this fast equilibrium 
was in the µs range; and the entire aggregate lifetime was around 1 ms to 1 s 
(Bridi, 1997). Micelle shapes depend on the surfactant concentration around the 
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CMC value; they are spherical with an average diameter of 2 nm. As the 
surfactant concentration increases the micelles size changes. Figure 2.13 shows 
the series of transitions which are observed when the concentration of surfactant 
is increased. When the concentration of surfactant is below the CMC, surfactant 
molecules are free monomers. At the CMC concentration the micelles are 
spherical and evolve to a cylindrical aggregate. For an additional increase of the 
surfactant concentration, a lamellar network is created which evolves to reverse 
micelles. A very high concentration of surfactant solution will form an inverted 
hexagonal structure. The CMC can be determined by measuring any micelle-
influenced physical function of surfactant concentration. In practice, surface 
tension, electrical conductivity and solubilization measurements are the most 
popular (Moroi, 1992) .  
 
Figure 2. 12: Micelles and Critical Micelle Concentration (CMC) (Adapted from (Moroi, 1992) ) 
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Figure 2.13: Formation of Micellar Aggregates (Adapted from (Moroi, 1992) ) 
2.2.3. Theory of Nanoemulsions 
The surface tension is the most essential characteristic of liquid interfaces. When 
two immiscible liquids are mixed together they tend to contract to the smallest 
surface area in order to achieve the lowest free energy (Bridi, 1997). 
There have been several theories on the explanation of nanoemulsion formation 
and stability. These include (i) Interfacial or mixed film theories (Berthod et al, 
1990), (ii) Solubilisation theories (Khaledi, 1997) and (iii) Thermodynamic 
theories (Berthod et al, 2000). One simplistic thermodynamic theory is based on 
the Gibbs free energy equation where the free energy of the nanoemulsion 
depends on how much the surfactant lowers the surface tension of the 
nanoemulsion interface and changes the entropy of the system. The free energy, 
∆Gf, of the formation of a nanoemulsion system is described in equation 2.1. The 
surface tension of the o/w interface γ, the change in interfacial area ∆A, the 
change in system entropy ∆S and the temperature T. 
                             ∆Gf  = γ∆A - T∆S   ……………………..Eq.  2.1 
When a nanoemulsion is formed, ∆A (change in interfacial area) is very large 
due to the large number of very tiny droplets formed. The entropic contribution is 
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also very big, due to dispersion entropy arising from the mixing of large numbers 
of tiny droplets and other entropic contributions arising from dynamic processes. 
Consequently a negative free energy is achieved by large reductions in surface 
tension accompanied by large favorable entropic change. Nanoemulsion is 
spontaneous and the resulting dispersion is thermodynamically stable (El-
Sherbiny et al, 2003) .   
2.2.4. Phase Diagrams 
The relationship between the phase behavior of a mixture and its composition 
can be determined with the aid of phase diagram. The phase behavior of simple 
microemulsion system composed of oil, water and surfactant in any given 
proportions can thus be determined.  
Different compositions of the three components form different phase formations 
shows a number of phase formations, determined from a ternary phase diagram 
(Figure 2.14). 
 
Figure 2.14: A comprehensive ternary phase diagram showing probable internal structures: (a) 
o/w microemulsion; (b) w/o microemulsion; (c) bicontinuous dispersion; (d) isolated and 
aggregated o/w dispersion; and (e) isolated and aggregated w/o dispersion  (Adapted from 
[(Kumar & Mittal, 1999)] 
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2.2.5. Formation of Nanoemulsions 
Nanoemulsions are based on a specific mixture of surfactants and a specific 
interaction with the water and oil phases. The systems are formed spontaneously 
at optimum composition or energy input, generally from the chemical potential 
or from mechanical devices of the components. Nanoemulsion formation by the 
so-called dispersion methods is generally achieved by using high shear stirring 
and ultrasound generators. Ultrasonic emulsification is also very efficient in 
reducing droplet size (Walstra & Becher, 1996). 
The driving force for nanoemulsion formation is the low interfacial energy, 
which is overcompensated by the negative contribution entropy of dispersion 
term. The low interfacial tension is produced in most cases by a combination of 
two molecules, referred to as surfactants and co-surfactants (medium-chain 
alcohol).        
The interfacial area is reduced by the presence of surfactants and co-surfactants 
because they consist of molecules containing both polar and non-polar parts 
(Ruckenstein, 1998). It has the tendency to pack into an interface that favours the 
expansion of the interface; this must therefore be balanced against the tendency 
for the interface to contract under normal surface tension. The interfacial tension 
plays an important role in the formation of nanoemulsion. The nanoemulsions 
usually occur when the interfacial tension approaches zero (Ruckenstein, 1998). 
With most single ionic surfactants and single non-ionic surfactants, this is not 
possible, since the interfacial tension is still sizeable when it is above CMC. To 
reach the required lowering of the interfacial tension a co-surfactant has to be 
included.  Studies illustrate that in nanoemulsion systems the interfacial tension 
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between water and oil is too low to be measured. This is undoubtedly the 
explanation for the high stability of such systems since they are 
thermodynamically stable. This means that during long-term storage, 
nanoemulsions display no demulsification and cannot be stratified by a 
centrifuge. Ruckenstein (1998) clearly explained that centrifugation can be used 
to differentiate between nanoemulsions and emulsions.   
2.2.6. Factors affecting the formation of nanoemulsions and separation 
in HPLC 
 
2.2.6.1. Effect of surfactant  
  The formation of a nanoemulsion is strongly contingent on the chemical nature 
of both the surfactant and the oil [(Bastogne & David, 1998, Eastoe et al, 1997, 
Li & Wang, 1999)]. The surfactant type used by Marsh et al. was SDS (sodium 
dodecyl sulphate), which is an anionic surfactant. Changing the type of surfactant 
to a cationic cetyltrimethylammonium bromide (CTAB) changed the retention of 
the polar analytes because the partitioning mechanism between the solute and the 
stationary phase (as there is a different adsorbed layer) was changed.  Li and 
Wang studied the solubilization of w/o microemulsions formed with mixed 
surfactants containing one anionic (sodium dodecyl sulphate [SDS] and one 
cationic surfactant acetyl trunethyl ammonium bromide [CTAB]) and a low 
chain alcohol, as a function of the alkyl chain length of oil. They found that the 
solubilization of water in microemulsion systems increases considerably with the 
mixed surfactants. This is due to the synergistic effect resulting from the strong 
columbic interactions between cationic and anionic surfactants (Li & Wang, 
1999). On the other hand, solutes are classified as droplet binding or droplet non-
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binding. Non-binding solutes are forced into the stationary phase by electrostatic 
repulsion which increases the retention time with an increasing concentration of 
surfactant. It was reported that the solutes in their test mixture were droplet 
binding as the retention decreased with increasing SDS concentration. (Marsh et 
al, 2004b). 
2.2.6.2. Effect of HLB  
The Hydrophilic-Lipophilic Balance (HLB) refers to a term describing relative 
attraction of the surfactant to oil and water which depends mainly on chemical 
structure and is used to determine the type of micelle produced (Aulton, 2007).  
The hydrophilic lipophilic balance (HLB) is a pointer to the relative affinity of a 
surfactant to divide itself between water and oil phases; higher HLB values show 
a sign of surfactant attraction for the water phase while lower values of HLB 
indicate favouritism to the oil phase.  
Two different dissimilar approaches of surfactant selection can be considered in 
order to obtain a high level of water solubilization in w/o nanoemulsions. The 
first approach is to maximise the amount of surfactant in the HLB 9-13 region, 
where it is intermediate between high oil solubility and high water solubility. The 
second approach is to use mixtures of highly oil soluble surfactants and highly 
water-soluble surfactants. The latter mixture has been found to reach the 
maximum water solubilization, obviously overcoming the expected partitioning 
of the two surfactant components into the water and oil phases and enhancing 
their partitioning to the interface (Huibers & Shah, 1997, Leon, 1977). 
2.2.6.3. Effect of oil type    
The stability of w/o nanoemulsions seems to be reliant on the molecular weight 
of the oil that could either increase or decrease with Mwt (Castro Dantas et al, 
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2001, Warisnoicharoen et al, 2000). In o/w nanoemulsion raising the length of 
the oil chain, the solubilization in water decreases, and the chain length is 
compatible when the system contains a medium-chain alcohol (Li & Wang, 
1999). It was also observed that the microemulsion phase diagram for 
triglyceride oils of high molecular weight gives smaller homogeneous regions of 
w/o microemulsions than of esters and hydrocarbons of low molecular weight. 
The effects of varying oil concentration and type (Berthod & De carvalho, 1992a, 
El-Sherbiny et al, 2007, Marsh et al, 2004b), are dependent on the nature of the 
solutes in the separation. For some hydrophobic solutes an increase in oil 
concentration in the microemulsion leads to a decrease in retention time. This 
arises because the retention time in RP-HPLC is determined mainly by the 
interaction between stationary phase and the solute. An increase in oil leads to an 
increase in the number of oil droplets for the hydrophobic analyte to partition 
into and, therefore, causes a decrease in retention time. (Marsh et al, 2004b) 
2.2.6.4. Effect of co-surfactant  
Co-surfactant can be used to speed up the formation of nanoemulsion. Co-
surfactant connects surfactant aggregates and reduces their interfacial free 
energy, accordingly, increasing the solubility of oil and water nanoemulsion 
(Friberg et al, 1999, Jihu & Laurence, 1997). The hydrocarbon part of the 
molecule is responsible for its solubility in oil, while the polar -OH or -COOH 
group has adequate sympathy to water to pull a short-length non-polar 
hydrocarbon chain into aqueous solution with it. If these molecules become 
located at the oil- water interface, they are able to locate their hydrophilic head 
groups in the aqueous phase and allow the lipophile hydrocarbon chains to 
escape into the oil phase. The distribution of alcohols between the aggregates, oil 
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and water of nanoemulsions, depends on the chain length of the alcohols and in 
general, the longer the hydrocarbon chain, the larger is the tendency for the 
alcohol molecules to adsorb on the air- water surface and, thus, lower the surface 
tension (Herrera et al, 2003, Jihu & Laurence, 1997, Puig et al, 2003). 
Nevertheless, in a study conducted (Nave et al, 2000) it was found, that some 
nanoemulsion systems could be formed without the presence of a co-surfactant.  
The addition of co-surfactant (alcohol) can increase the total interfacial area at 
low alcohol concentration, thereby increasing solubilization (Bastogne & David, 
1998). On the other hand, at higher alcohol concentrations, phase separation 
occurs at a small droplet size due to the increase in attractive inter-droplet 
interaction. To illustrate the point Leung & Shah (1987) has studied the effect of 
pentanol concentration on solubilization in a microemulsion containing 
hexadecane, octane, dodecane and benzene. The solubilization showed a 
maximum as a function of pentanol concentration. The maximum was most 
pronounced for the dodecane system due to the chain-length compatibility effect. 
Increasing the alcohol concentration can increase the alcohol partitioning at the 
interface, and consequently increase the total interfacial area available for 
solubilisation (Leung & Shah 1987). However, at adequately high 
concentrations, the fluidity of the interface increases, and consequently 
solubilization decreases .  
Kumar and Singh (1990) studied the influence of alkyl chain branching of the co-
surfactant on the solubilizing capacity of a w/o microemulsion formed from fatty 
acid soaps. They found that branching in the co-surfactant chain decreased the 
water solubilization capacity. The solubilization behaviour was interpreted in 
terms of the partitioning of the alcohol among the oil, water and interface, 
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depending on the chain length of the oil and surfactant. The molar ratio of the 
alcohol to surfactant at the droplet interface was found to increase with the length 
of the oil chain.  
2.2.6.5. Nanoemulsion pH  
El-Sherbiny et al. (2007) reported that the retention time increases with raising 
pH in intervals from 3–7 for the simultaneous determination of loratadine and 
desloratadine using o/w microemulsion. The separation was performed on a 
column packed with cyanopropyl bonded stationary phase adopting UV detection 
at 247 nm using a flow rate of 1 ml/min. Loratadine had a log P of 5.2 and a pKa 
of 5.0 while desloratadine had a log P of 3.2 and two pKa values of 4.2 and 9.7. 
As the pH increases both drugs become less ionised and the retention is 
dominated more by the differences in hydrophobicity. So, while both drugs were 
more retained for increasing pH values it was seen that desloratadine was more 
weakly retained than loratadine and the optimum separation was achieved at a 
pH of 3.  
2.2.6.6. Effect of ionic strength  
 
The solubilization of water in a microemulsion is strongly dependent on the ionic 
strength.  (Hamada et al, 2001, Hamid & Vera, 1996) reported that the water 
uptake of w/o microemulsions decreases as the salt concentration increases. This 
is due to the increase in the ionic strength which increases the charge density 
inside the reverse micelles. Hence, a reduction of the repulsive forces between 
surfactant –charged heads decreasing the reverse micelles (w/o) microemulsion.  
Thereby, reduces water uptake.  
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2.2.7. Methods of measuring particle size 
 The particle size of nanoemulsions is one of the most crucial factors in 
determining their quality and is usually measured by Photon Correlation 
Spectroscopy (PCS) or known as Dynamic Light Scattering (DLS) (Bagwe et al, 
2001) . This technique works on the basis of the difference between fluctuations 
in scattered light intensity of large and small particles due to variation in their 
diffusion properties (Brownian movement) (Malvern Instruments 1993). Thus, 
Brownian motion (or Brownian movement) can be defined as "the random 
movement of microscopic particles suspended in a fluid." 
The Principle Behind PCS is the molecules or particles are illuminated with a 
laser, the intensity of the scattered light fluctuates at a rate that is dependent upon 
the size of the particles as smaller particles are “kicked” further by the solvent 
molecules and move more rapidly.  
 The main advantage of PCS is its straightforward and easy process which 
enables the particle size measurement to be done in a few minutes and other 
advantages of this technology are reliable, accurate and repeatable particle size 
analysis in one or two minutes (Bagwe et al,, 2001). 
 
More recently, a new technique has been developed that allows visualisation (not 
imaging) of nanoscale particles in liquids. The Halo technology comprises a 
metallised optical element illuminated by a laser beam and nanoparticles in 
dispersion can be directly sized, visualised and counted in real time using an 
integrated optical microscope. depending on material of composition of the 
particles this system works on particle sizes of 10– 1000nm (Nanosight, 2008). 
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2.2.8. Methods of characterising nanoemulsions 
Elucidation of the structure of particles in the nanoemulsions is very complex 
and advanced analytical techniques are often used to determine their internal 
structure. Successful use of photon correlation spectroscopy (PCS), nuclear 
magnetic resonance (NMR), small angle neutron scattering (SANS), small angle 
X-ray scattering (SAXS), transmission electron microscopy (TEM), and time-
resolved fluorescence quenching (TRFQ) have been reported (Bagwe et al, 
2001).   
Techniques like (SAXS), (SANS), (PCS) allows to accesss structural information 
on the subject of nanoemulsion system (Prince, 1977a, Watarai, 1997). These can 
include an account of shape, size and the elucidation of the structural units as 
well as their mutual interactions.   
When using SANS technique, it is possible to highlight the location of a specific 
component by deuterating the component. In addition the location of each of the 
components (i.e. surfactant, co-surfactant and drug) in the system can be 
obtained. Using SANS there are also reports of surfactant effects on the 
morphology of the final particle (Magid, 1986). 
Also NMR experiments can be used to investigate the self-diffusion coefficient 
(i.e. the diffusion coefficient of a molecule in the absence of a chemical potential 
gradient) and chemical structure of the ingredients in a nanoemulsion 
formulation (Currie et al, 2001, Soderman & Nyden, 1999). Parameters such as 
aggregation number (number of a certain molecule that is available in a single 
micelle) and particle size of the nanoemulsion droplets can be investigated using 
TRFQ (Hayter & Penfold, 1983, Howe et al, 1987).  
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TEM has also been used to study the size and shape of nanoemulsion particles 
(Kahlweit et al, 1987), (Regev et al, 1996) (Shafiq-un-Nabi et al, 2007). By using 
these TEM, studies it has been shown that nanoemulsion particles are not perfect 
spheres. For example, the nanoemulsion particles reported by (Shafiq-un-Nabi et 
al, 2007) were incomplete spherical particles with particle size of 45-55nm and 
the particle size was close to that obtained from the PCS results (i.e. 34.5nm).  
 
2.2.9. Use of nanoemulsions as a mobile phase for high 
performance liquid chromatography (NELC) 
  
NELC is an extension of micellar liquid chromatography (MLC). In MLC a 
surfactant is added in excess of the (CMC) with the result that the mobile phase 
contains a large amount of micelles. But the micelles affect the chromatography 
as the analytes rather than adsorbing onto the stationary phase partition with the 
micelles. 
 Different types of microemulsions can be formed, but only two of these; o/w and 
w/o, have been used as mobile phases for separation by HPLC. Beside, there is a 
type which can be considered as a stage between o/w and w/o nanoemulsions 
called bicontinuous, in which approximately equal amounts of water and oil are 
available ( Figure 2.15) which have a particle size larger than few hundred 
nanometers (Lawrence & Rees, 2000).  
W/O microemulsions have been used for normal-phase chromatography while 
o/w microemulsions are employed as eluents for reversed phases HPLC. Recent 
reports have found that separations can be achieved with superior speed and 
efficiency to conventional HPLC modes. While also offering a unique selectivity 
with excellent resolution and the capability for quantitative and stability-
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indicating analysis (El-Sherbiny et al, 2003, El-Sherbiny et al, 2005, Malenović et al, 
2004).   
 
Figure 2.15: Most common microemulsion structures: (a) oil-in-water, (b) bicontinuous and (c) 
water-in-oil (Lawrence & Rees, 2000). 
 
As separation in HPLC is controlled by the partition of molecules to different 
degrees between the mobile and stationary phases the use of a microemulsion 
mobile phase alters these partitioning characteristics due to the layer of surfactant 
molecules which adsorbs onto the stationary phase surface. A secondary 
partitioning mechanism also exists in MELC where solutes partition with both 
the stationary and mobile phases and into the oil droplets (Momenbeik et al, 
2010). Hence, similar separation mechanism is applied when nanoemulsion is 
used as mobile phase. For an oil-in-water nanoemulsion, water-insoluble 
compounds favor inclusion in the oil droplet, the surface of which is not rigid, 
unlike that of a micelle, where solutes can penetrate easily and their retention is 
predominantly influenced by partitioning into the nanoemulsion droplets. Water-
soluble analytes can reside mainly in the aqueous phase and their retention is 
largely controlled by stationary phase interactions. The hydrophobic organic 
solvents used to create the droplets are also distributed to some extent on the 
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surface of the column which increases the amount of stationary phase and also 
affects solute selectivity and retention (El-Sherbiny et al, 2003). All of these 
partitioning mechanisms can control the retention and separation of solutes in a 
NELC separation. 
Generic conditions for rapid method development 
When developing analytical methods it is regularly the case that the analyst will 
look for methods where similar work has been carried out. However in newly 
developed procedures of which microemulsion HPLC is one, there are obviously 
not many publications available. However Marsh has indicated in capillary 
electrophoresis and HPLC (Marsh et al. 2004b) that a starting point could be to 
use a generic set of microemulsion operating parameters The proposed generic 
parameters of microemulsion consists are  33 g SDS, 8 g n-octane, 66 g butan-1-
ol in 1 L 0.05% trifluoroacetic acid (TFA). The sample for analysis is dissolved 
in the microemulsion and separation is performed on a C18 RP column, at 
ambient temperature, UV detection 254 nm and a flow-rate of 1 mL/min  
To mixtures containing a wide range of solute polarities standard MELC 
conditions can be applied because of the ability of the microemulsions to 
solubilize both water-soluble and insoluble compounds.  
2.2.10. Use of nanoemulsion liquid chromatography for 
pharmaceutical analysis  
 
Like in microemulsion systems, particles in nanoemulsion can exist as water-in-
oil and oil-in-water form, where the core phase is either water or oil, 
respectively.  
 Literature review                                                                                              Chapter 2  
 
 
48 
2.2.10.1.   O/W MELC  
An oil-in-water microemulsion, is made up of oil droplets enclosed in a 
surfactant and co-surfactant layer, and dispersed all through water. In recent 
years microemulsions have been reported for Capillary Electrophoresis CE 
separation electrolytes (Watarai, 1997) but applications of microemulsions as 
HPLC mobile phases is an area where there appears to be growing interest where 
the application uses a conventional reversed phase column.  
The first studies using oil-in-water microemulsions was reported in 1992 
(Berthod & De carvalho, 1992a, Berthod et al, 1992b) where pentanol, heptane, 
SDS and water were used for the reversed-phase chromatographic separation of a 
series of alkyl benzenes (Berthod & De carvalho, 1992a) from toluene to 
decylbenzene was studied. The study looked at the effect of increasing the 
proportion of organic phase (heptane and pentanol). By increasing the organic 
volume of the microemulsion it reduced the retention factors of the alkyl 
benzenes and this effect was more pronounced for compounds with longer alkyl 
chains. During this study, the unique solubilising power of the microemulsion for 
hydrophobic compounds was noted. Separation efficiency was found to be 
equivalent to conventional HPLC methods due to the competition between SDS 
and pentanol for adsorption onto the stationary phase. In another method  the 
rapid screening of 11 drugs used illegally in sports was reported  (Berthod et al, 
1992b).  Additionally Torres Cartas, et al (1995) studied the separation of 14 
anabolic steroids in pharmaceutical formulations used SDS-pentanol-water 
microemulsion method (Torres Cartas et al, 1995). In this work the unique 
selectivity and solubilising properties of the microemulsion enabled easy sample 
preparation and prevented the interference of excipients in the chromatogram 
 Literature review                                                                                              Chapter 2  
 
 
49 
commonly encountered with conventional HPLC. The method was shown to give 
accurate and reproducible quantitative results. The separation of a number of   
anti-hypertensive’s and non-steroidal anti-inflammatory drugs using an SDS, 
butanol, octanol, water microemulsion was reported by D El-Sherbiny  et al; 
(2003). 
As the microemulsion components used are relatively large in number structured 
experimental design techniques have been employed  to optimise the 
composition. In one example the SDS, butanol, diisopropyl ether, water 
microemulsion used to separate the cholesterol-lowering drug simvastatin from 
six of its impurities in drug substance and pharmaceutical formulation 
(Malenović et al, 2004). Earlier, a number of different analytical techniques were 
required to carryout this analysis.  
The measurement of the stability of drug substance and formulated products is an 
important aspect of pharmaceutical analysis, and methods need to be capable of 
resolving synthetic and degradative impurity peaks from the main component 
peak and excipient peaks. In relation to this the stability indicating nature of 
MELC separations has been demonstrated on a number of compounds and their 
related impurities covering a wide range of polarities and solubilities. For 
instance Authors reported the separation by isocratic oil-in-water MELC of 
simvastatin and six impurities (Malenović et al, 2004) and flunarizine and 
degradation products (El-Sherbiny et al, 2005).  
Another area which has been studied is the ability of a method to accurately 
quantify the amount of an analyte present in a sample is equally important for 
pharmaceutical analysis. Preliminary demonstrations of the potential of MELC 
for quantitative analysis has been performed which suggest that following a 
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suitable validation procedure (Lim et al, 1998) MELC methods are well suited to 
routine use.  
2.2.10.2. W/O MELC  
 Water-in-oil microemulsions, consists of surfactant-coated water droplets 
dispersed in an oil phase. It has been reported that the droplets can be stabilized 
by adding a short-chain alcohol co-surfactant (Altria et al, 2005). W/O 
microemulsions have also been shown to work for normal phase chromatography 
when using silica columns and the first report appeared in 1986, where 
Hernandez-Torres and co-workers experimented with reversed-micellar mobile 
phases of 50 mM Aearesol-OT (AOT) + 1 % v/v water in hexane and found that 
the microemulsion mobile phase provided a much more robust methodology than 
the traditional non-polar eluents. In 1990, the retention factors of 4-nitrobenzoic 
acid and 4-nitrophenol were measured for 50 different AOT-water-heptane 
microemulsion compositions (Berthod et al, 1990).  Recently, a more detailed 
study (Altria et al, 2005) on the use of water-in-oil microemulsion eluents for 
HPLC has been performed. Whereas Hernandez-Torres (Berthod et al, 1990, 
Hernandez-Torres et al, 1986) examined the effect of water and surfactant 
content on the retention of a test solute, (Altria and co-workers, 2005) have 
assessed the effect on the separation of a 4-component test-mixture of varying oil 
type, co-surfactant, surfactant, water concentration, temperature and flow-rate.   
 Using an optimised water-in-oil microemulsion composition of 5 % w/w water 
containing 70 mM sodium acetate, 8.33 % w/w SDS and 16.6 % w/w pentanol in 
heptane, the method was used to separate a range of acidic, basic and neutral 
compounds, and used these conditions to determine quantitatively the drug 
content in bumetanide tablets (Altria et al, 2005). In this work Altria indicated 
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the importance of solute solubility and correlates this with the water-in-oil 
MELC retention time, and the results indicate that retention is largely dependent 
on analyte log P value, with water-insoluble salutes such as naphthalene eluting 
first. Altria and co-workers also found that selectivity for water-in-oil MELC 
separations is very different from that obtained using oil-in-water MELC 
methods.   
In addition previous studies using microemulsion as mobile phase for HPLC 
have used an ionic surfactant, but it was found that such a mobile phase was not 
able to separate highly hydrophilic compounds that have very similar chemical 
properties (Marsh et al, 2005). Because the knowledge in this area is limited and 
therefore it is proposed during this research work to examine non-ionic surfactant 
as well as ionic surfactants would be used in the formation of nanoparticle 
mobile phase for the assay of inhaled drugs in their formulation.        
2.2.11. Use of nanoemulsion liquid chromatography (NELC) for 
bioanalysis 
 
Analysis of drugs and their metabolites in the biological fluids are essential to 
provide the necessary information that are required for the evaluation and 
interpretation of bioavailability, bioequivalence, pharmacokinetic, and 
toxicology study data. But thruogh conventional isocratic mobile phases there are 
usually difficulties in separation of the drugs in the biological fluid. As a result 
gradient MELC would be examined for the separation of different ranges of 
pharmaceutical compounds (Bryant and Altria, 2004) (Marsh et al,, 2005) and for 
quantification of drugs in their pharmaceutical preparation  (McEvoy et al,, 
2007). Although gradient MELC has been reported to be very powerful to 
separate analytes with different polarity, McEvoy et al, (2007) found that the 
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peak retention times and resolution were irreproducible. These authors attributed 
this to the fact that equilibration of the column with the gradient MELC mobile 
phase is not possible because of dynamic nature of the surfactant adsorped onto 
the column. Also, they concluded that reproducible separations could only 
achieved using isocratic MELC. Overall when examining the literatures the use 
of microemulsion as HPLC mobile phase has mainly been applied to 
pharmaceutical analysis (Berthod et al, 1992b, El-Sherbiny et al, 2005, 
Malenović et al, 2004, Torres Cartas et al, 1995, Watarai, 1997). But there are 
limited reports to show the application of this technique for bioanalysis with 
work on serum and plasma. 
However bioanalysis was the original application of o/w MELC when Berthod 
and co-workers, (1992b) reported its use for the separation of a series of alkyl 
benzenes and the screening of 11 drugs illegally used in sport which is discussed 
above. The proposed advantage of this technique is that the presences of oil 
droplets in the mobile phase have the advantage of being able to solubilize 
proteins in complex matrices and eliminate lengthy pre-treatment steps thus 
speeding up analysis time and saving money.  
Another examples of bioanalysis is by El-Sherbiny et al, (2003) who 
demonstrated the use of MELC for the analysis of bumetanide and acebutolol in 
plasma. Although the author has claimed the analysis of these drugs in a urine 
matrix, no results or chromatograms were shown. Moreover, the method was not 
validated. More recently, Walash et al, (2007) have developed and validated a 
method for the determination of nicardipine in pharmaceutical preparation and 
human plasma.  Therefore taking into account the comments on El-Sherbiny`s 
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work no work to date has reported using microemulsion or nanoemulsion mobile 
phases for the bioanalysis of drugs in a urine matrix.  
2.2.12. Analytical method validation     
All methods developed in this study were validated according to ICH 
(International Committee on Hormonisation, 1996) and FDA guidelines (2001). 
The validation of the analytical methods is demonstrated to illustrate the 
reliability and performance in different conditions.  
In this work the fundamental parameters for an analytical method validation 
included of the evaluation of the linearity, selectivity, precision, accuracy, 
recovery, sensitivity, robustness and stability. 
 
Analytical reference standard 
 
In the experimental programme before validation can be contemplated, an 
authenticated analytical reference standard was required and these were prepared 
with solutions of known concentrations.  
 
2.2.12.1. Linearity  
A calibration curve is the relationship between the instrument response and 
known concentrations of the analyte. According to ICH (1996) and FDA (2001) 
guidelines and the linearity is defined as the ability of the assay to produce 
results that are directly proportional to the known concentrations of the analyte. 
The linearity should be determined by at least a series of five different 
concentrations with at least replicate measurement  
The following equation represents the regression line: y= mx + c. 
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The point of interception with the y-axis is given by c, and m is the slope of 
regression line. The correlation coefficient (R
2
) expresses the relationship 
between the results and the analyte concentrations. When R
2
 = 1, this indicates a 
complete linear relationship, while this value decreases with decreasing the 
linearity relationship. 
2.2.12.2. Accuracy 
The accuracy of an analytical method describes the degree of agreement between 
the test result generated to the true value of the analyte. According to ICH (1996) 
and FDA (2001) guidelines, it should be measured using a minimum of five 
determinations per concentration. A minimum of three concentrations in the 
range of expected concentrations is recommended. 
2.2.12.3. Precision 
The precision is “the closeness of agreement (degree of scatter) between a series 
of measurements obtained from multiple sampling of the same homogeneous 
sample under the prescribed conditions”. It should be measured using a 
minimum of five determinations for each concentration. A minimum of three 
concentrations in the range of expected concentrations is recommended. 
Precision can be subdivided into intra-day precision (within-day or repeatability) 
and inter-day precision (between-days or reproducibility). The degree of 
precision is expressed as the relative standard deviation as a percent (RSD%) 
which is also known as coefficient variation (CV).  
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2.2.12.4. Recovery 
Recovery should be performed by comparing the analytical results for extracted 
samples at three concentrations (low, medium, high), with unextracted standards 
that represent 100% recovery. 
2.2.12.5. Selectivity  
 Selectivity or specificity is the ability of an analytical method to differentiate 
and quantify the analyte in the presence of other components in the sample which 
may include impurities, degradation or any substance which may interfere with 
the analyte.  
2.2.12.6. Sensitivity  
The sensitivity is regularly expressed as the limit of detection (LOD) and limit of 
quantitation (LOQ). The limit of detection (LOD) of the assay is defined as the 
lowest concentration of the analyte which can be detected but not necessarily 
quantified. There are two methods to express the LOD. One of the simple ways 
to obtained this is by measuring the response against the noise and 3 to 1 (signal 
to noise) is regularly used. An alternative is to use  the standard deviation to 
determine the Limit of Detection (ICH guideline, 1996).  
LOD= 
S
3.3
 ………………………..Eq 2.2  
  = the standard deviation of Y-intercept Where  
            S= the slope of calibration curve.  
The limit of quantitation (LOQ) of the assay is defined as the lowest 
concentration of the analyte which can be quantified with an acceptable level of 
precision and accuracy. The simplest method is to find the concentration which 
give 10 time the signal to the noise. The other method is represented by the 
following equation.  
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LOQ= 
S
10
 ……………………….Eq 2.3  
   = the standard deviation of Y-intercept Where  
            S= the slope of calibration curve. 
2.2.12.7. Robustness  
The robustness examines the reliability of the analytical procedure when small 
changes in the method parameters are carried out such as, pH, variation in mobile 
phase composition, column temperature, and flow rate.  
 
2.2.12.8. Stability 
The stability test is important in the validation procedure of a bioanalytical 
method to evaluate the storage conditions, the chemical properties of the drug, 
the matrix and the container system. Stability procedures should evaluate the 
stability of the analytes during sample collection and handling, after long-term 
(frozen at the intended storage temperature) and short-term storage (24 hr at 
room temperature), and after going through freeze and at least three thaw cycles 
(FDA guidelines, 2001).  
 
2.2.13. Summary    
Nanoemulsions have been shown to have excellent solubilisation capabilities for 
both hydrophobic and hydrophilic analytes due to their unique two-phase 
composition which affords rapid separations and also enables their use for 
sample extraction and preparation. It has been claimed that for oil-in-water 
mobile phase separations, highly lipophilic compounds can be eluted quickly 
without resorting to organic solvent gradients as is necessary with conventional 
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HPLC methods (El-Sherbiny et al, 2003).  Surfactants play an important role on 
the formation of nanoemulsion and in the separation of compounds by NELC. 
Ionic surfactants were mainly used in the previous studies. However, these 
surfactants have shown limited capacity in separation of compounds that have 
very similar chemical structure. Therefore, the alternative is to use non-ionic 
surfactant which would help in the separation of compounds that have very close 
structural similarities.  
 NELC offers alternative separation selectivity to other HPLC and an equivalent 
or greater separation efficiency and peak resolution. Moreover, separations using 
nano-particles eluents have been shown to be faster than if performed by 
conventional HPLC modes (Altria et al, 2005, El-Sherbiny et al, 2003, El-
Sherbiny et al, 2005, Torres Cartas et al, 1995). Shorter separation time can also 
be achieved by increasing surfactant (El-Sherbiny et al, 2003, El-Sherbiny et al, 
2005, Malenović et al, 2004) and co-surfactant concentration (Malenović et al, 
2004), but such changes can also affect peak-peak resolution. The most difficult 
issue associated with bioanalysis arises in having to resolve the compound of 
interest from interfering substances in complex biological fluid. The presence of 
oil droplet in the mobile phase of NELC provides increased selectivity compared 
with the conventional HPLC methods. Hence, allowing a better manipulation for 
the separation of the samples from biological origin. 
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3.1. Instruments and Apparatus 
3.1.1. High Performance Liquid Chromatography instrument 
3.1.1.1. HPLC System 
 The HPLC System was a 1050 Hewlett Packard series instrument 
which consisted of a HP 1050 UV-detector, HP 1050 auto sampler 
and HP 1050 pumping system (Hewlett Packard, Waldbronn, 
Germany). 
3.1.1.2. Detectors 
 A spectrofluorometric detector RF-551 (Shimadzu, Columbia, 
MD). 
 Variable wavelength UV/Visible detector HP 1050 series. 
3.1.1.3. Integrators  
 Prime software was used (HPLC Technology Ltd., Welwyn 
Garden City, UK). 
3.1.1.4. HPLC Columns and Guard Columns 
 A Hichrom ODS1-C18 Reversed-phase 250mm X 4.6mm i.d.  X 
5µm (Hichrom Ltd., UK). 
 Phenomenex C18 Columbus, 150mm X 4.6mm i.d. X 5µm 
(Phenomenex, Macclesfield, Cheshire, UK). 
 The analytical column was protected with a C18 (4 X 3mm i.d.) 
security cartridge system (Phenomenex, Torrance, USA). 
3.1.2. UV Spectrometers and Spectrofluorimeters 
 The UV spectrophotometer was a Hewlett Packard diode-array 
spectrophotometer 8452A. Solutions were placed in a 1cm path 
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length quartz cuvette (Hewlett Packard, Palo Alto, California, 
USA). 
 Perkin Elmer variable spectrofluorimetry LS45 Luminescence 
Spectrometer (Bucks, UK). 
3.1.3. Solid Phase Extraction (SPE) System 
3.1.3.1. Solid Phase Extraction Cartridges 
 Water Oasis® (1cc/30mg) HLB (hydrophilic–lipophilic balance) 
(Milford, USA). 
 Isolute HCX, 100mg, 1ml (Hengoed, Wales). 
3.1.3.2. SPE Vacuum Manifolds 
 Vacmaster International Sorbent Technology, Ltd. 
 Vac-Elut Analytichem International (Harbour City, CA, USA). 
3.1.4. Apparatus used to determine dose emission and particle size 
from dry powder inhalers 
 GAST 1023 Pump, 0-100l/min (GAST, Brook Hampton, 
Doncaster, UK). 
 Electronic digital flow meter Model DFM (Copley Scientific Ltd., 
Nottingham, UK). 
 Critical Flow Controller Model TPK (Copley Scientific Ltd.). 
 Sampling Apparatus for DPI (content uniformity) (Copley). 
 Glass fibre filter, 47mm (Pall Gelman Sciences, Michigan, USA). 
 Anderson Cascade Impactor (Copley Scientific, Nottingham, 
UK). 
3.1.5. General Laboratory Instruments 
 Malvern Zetamaster® (UK). 
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 Ultrasonic bath (Telsonic, Basel, Switzerland). 
 Syringe filters 0.2m pore size (Scientific Resources Inc., NJ, 
USA). For filtration of the samples after solid phase extraction 
before injection in HPLC instruments. 
 Nylon membrane filters, 0.45µm pore size (Millipore, Ireland). 
For filtering nanoemulsion mobile phases. 
 Filters for Anderson Cascade Impactor (Copley Scientific, 
Nottingham, UK). 
 Vortex mixture (Jencons Scientific, UK). 
 Mettler AE240 electronic balance (Mettler Toledo Ltd., 
Switzerland). 
 Accumet® AB10 pH meter (Fisher Scientific, Pittsburgh, PA, 
USA). 
 Mobile phases were degassed using membrane degasser (Thermo 
Separation Product, USA). 
 ELGA ultrapure water dispensing system (High Wycombe, UK). 
 Nitrogen gas cylinder (BOC, Manchester, UK). 
 
 3.2. Materials 
 3.2.1. Solvents    
 1-Butanol (Sigma, St.Louis, MO, USA). 
 Ethanol (Fisher Scientific, UK). 
 Acetonitrile HPLC Grade (Fisher Chemical, UK). 
 Polyoxyethylene 23-lauryl ether [Brij 35] (Sigma, St.Louis, MO, 
USA). 
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 Polysorbate 80 surfactant [Tween 80] (Sigma–Aldrich, USA). 
 Ethyl acetate (Fisher Chemical, UK). 
 1-Octane sulfonic acid sodium salt 0.1M solution (Fisher 
Chemical, UK). 
 1-Heptane sulfonic acid sodium salt 0.1M solution (Fisher 
Chemical). 
 Hexane 95% (Aldrich, Germany). 
 Octane 98% (Aldrich, Germany). 
 Hexyl acetate 99% (Aldrich, Germany). 
 Butyl acetate 99.7% (Aldrich, Germany). 
 Methanol  (Fisher Scientific, Leicestershire, UK ) 
3.2.1.2. Buffer salts and additives 
 Potassium dihydrogen phosphate (BDH Laboratories, Poole, UK). 
 Ortho phosphoric acid (Fisher Scientific, Leicestershire, UK). 
 Trifluoroacetic acid (TFA) (Fisons, UK). 
 Glacial acetic acid (BDH, UK). 
 Sodium hydroxide (BDH Laboratories). 
3.2.2. Analytes and general chemicals used   
 Salmeterol (Sigma, UK). 
 Feneterol (Sigma, UK). 
 Salbutamol (Sigma, UK). 
 Clenbuterol (Sigma, UK). 
 Reproterol (Sigma, UK). 
 Terbutaline sulphate (Sigma, UK). 
 Sodium dodecyl sulphate 
[SDS] 99% (Park Scientific 
Limited, Northampton, UK).  
 
 Pindalol (Sigma, UK). 
 
 Fluticasone propionate (Sigma, 
UK). 
 
 Bamethane (Sigma, UK). 
 Formoterol (Sigma-Aldrich, 
USA).
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3.2.3. Derivatisation studies 
 9-Fluorenylmethylchloroformate [FMOC-Cl] (Sigma-Aldrich, USA). 
 Fluorescein isothiocyanate [FITC] (Sigma, UK). 
 Glycine (BDH, UK). 
 Triethylamine (BDH, UK). 
3.2.4. Solid Phase Extraction Solvent 
 Methanol (Fisher Scientific, UK). 
 Potassium dihydrogen Phosphate (BDH, UK). 
 Hydrochloric acid (Sigma, UK). 
 Ammonia (Fluka, Switzerland). 
 Boric acid (Sigma, UK). 
 Acetonitrile (Fisher Scientific, UK). 
 Ethyl acetate (Fisher Scientific, UK). 
 Tetrahydrofuran (Fisher Scientific, UK). 
 Glacial acetic acid (BDH, UK). 
3.2.5. Pharmaceutical preparations 
 Formoterol fumarate dihydrate (Sigma–Aldrich, USA). 
 Easyhaler® Salbutamol Sulphate (Ranbaxy, UK). 
 Oxis Turbohaler® (Astra Zeneca, Gloucestershire, UK). 
 Bricanyl Turbohaler® (Astra Zeneca, UK). 
 Seretide 100 Accuhaler® (Glaxo Wellcome, UK). 
 Carbomix activated charcoal (Penn Pharmaceuticals, Tredegar, Gwent, UK). 
 
Instruments and apparatus                                                                    Chapter 3  
 
 
64 
3.3. Methods 
3.3.1. Preparation of buffers for mobile phase 
Suitable buffer salts were weighed out and transferred to volumetric flasks. Then 
ELGA deionised water was added and the solutions were made up to the volume, 
leave 1 or 2 ml before made up to the volume. The exact pH was accomplished by 
adding a minimal volume of acid or alkali using a pasture pipette. The pH meter was 
calibrated at pH 4.0, 7.0 and 10.0 using commercially available buffer solutions. 
3.3.2. Preparation of microemulsion (MELC) mobile phases 
The standard microemulsion system was prepared by weighing (% w/w) surfactant, 
(% w/w) oil, (% w/w) co-surfactant, and (% w/w) of phosphate buffer mM or 
trifluoroacetic acid (TFA) to a volumetric flask. This mixture was sonicated for 15 
minutes to aid dissolution. The solution was an optically transparent microemulsion, 
which was stable for several months. Specific microemulsions were prepared for 
each experimental section by following the same protocol and when the effects of 
surfactant, co-surfactant, and ion-pair reagents were studied, the suitable amount of 
additive was dissolved into the standard microemulsion. The mobile phase was 
filtered under vacuum through a 0.45µm nylon filter to remove any particulate that 
might block the HPLC system. The mobile phase was then degassed by sonication 
under vacuum for 10 minutes.  
3.3.3. Collection of blank urine 
Blank urine samples were collected from healthy volunteers (male and female) and 
mixed together.  
3.3.4. General method for SPE 
Solid phase extraction techniques were used to isolate the drugs from the urine 
samples. This extraction method also enables the concentration of some drugs to be 
increased by multi folds making detection easier. This also enables the use of less 
solvent for extraction. 
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3.3.4.1. SPE Particular method  
A solid-phase extraction method using an Oasis HLB cartridge (Sorbent Technology, 
UK) was developed by Mazhar and Chrystyn (2009) to extract terbutaline and 
bamethane from urine. The SPE cartridges were connected to the vacuum manifold 
(Figure 3.1). A pretreated sample was prepared by adding 1ml of an aqueous solution 
of 600μg/l bamethane to 1ml of urine as an internal standard. This was adjusted (if 
necessary) to pH 6.5 -7.2 and mixed well for 30 seconds. Each Oasis HLB cartridge 
was conditioned with 2ml methanol followed by 2ml of 45mM potassium 
dihydrogen phosphate (pH 7). The pretreated sample was then applied to the 
cartridges followed by the addition of 2ml of 15mM potassium dihydrogen phosphate 
(pH 7) followed by a full vacuum drying for 2 min. The cartridge was then washed 
with 1ml of MeOH: H2O (05:95) followed by a full vacuum drying for 1 min, then 
1ml of ACN:H2O (02:98) followed by a full vacuum drying for 1 min, then 1ml of 
THF:H2O (0.25:99.75) followed by 2 min full vacuum drying. The analyte was then 
eluted from the cartridge into a sample tube using 2ml of CH3COOH:H2O (02:98) at 
low vacuum (less than 3 bar) for 2-3 min. After evaporation to dryness using a 
nitrogen stream at 120
O
C for 35 min, the residue was reconstituted in 1ml mobile 
phase and 100μml was injected into the HPLC system.  
 
Figure 3.1: Solid Phase Extraction (SPE) vacuum manifold. 
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3.3.5. Formoterol/FMOC-CL Derivatisation Analysis 
3.3.5.1. FMOC-CL Solution 
A FMOC-CL solution was freshly prepared by dissolving an appropriate amount of 
FMOC-CL reagent in acetonitrile (HPLC grade). The solution was prepared with 
ultrapure Milli-Q water and filtered through a nylon membrane filter of 0.45µm 
pores.  
3.3.5.2. Formoterol/FMOC-CL Derivatisation Procedure  
The following procedure for formoterol/FMOC-CL derivatisation was applied for 
determination of formoterol in aqueous solutions. In a 4ml screw-capped glass vial, 
a 1000µl formoterol solution was mixed with 1000µl acetonitrile (HPLC grade), 
then derivatised with 2500µl FMOC-CL (2.5mM). The mixture was vortexed for 40 
seconds and kept in the dark at room temperature for 30 minutes. After completion 
of the reaction, 125µl of 0.1M glycine (BDH) was added to react with an excess 
amount of FMOC-CL reagent. After 3 minutes, the reaction mixture was neutralised 
by adding 25µl glacial acetic acid (HPLC grade) to prevent further reaction. The 
reaction mixture solution was diluted by 500µl of ethanol (HPLC grade) to minimise 
the interfering peaks. Then 100µl was injected into the HPLC. 
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Determination of the boundaries of the microemulsion domain 
with the aid of a phase diagram 
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4. Determination of the boundaries of the microemulsion domain 
with the aid of a phase diagram  
4.1. Introduction 
     One of the main advantages of the microemulsion system is its stability. In addition, 
the presence of oil droplets in the aqueous phase is an important feature of this 
system that has allowed it to be used as a potential mobile phase for HPLC due to its 
superior selectivity and speed of analysis compared to conventional HPLC. The 
limited work on oil-in-water microemulsion has usually been used as a mobile phase 
for reversed phase HPLC. In this system, the fat soluble analytes favour the 
inclusion in the oil droplets while water-soluble analytes will reside mainly in the 
aqueous phase (see section 2.2.11). The shape and size of microemulsion regions are 
greatly affected by the concentration and type of surfactant, oil, and co-surfactant 
(Wen-Teng  et al, 2005). However, it has been reported that the phase behaviour of 
long and short-chain surfactants is similar (Kahlweit and Strey, 1985). In this 
research program a ternary phase diagram was used to examine the phase behaviour 
of different microemulsion systems. Microemulsion phase behaviour was 
determined by visual observation of an optically transparent single phase. The phase 
diagram was constructed for each of the sodium dodecyl sulphate (SDS), Brij35, and 
tween80 surfactants and then the effect of the concentration of the other components 
including the oil and co-surfactant was examined. The aim of this study was to 
determine the phase diagram for different microemulsion systems and the phase 
boundary of these systems, and to identify the clear stable microemulsion phase that 
can be considered as mobile phase for HPLC, and then exclude the non-stable 
phases.                                    
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4.2. Method  
4.2.1. Construction of the pseudo ternary phase diagram 
A mixture of components A, B, C can be represented with an equilateral triangle 
called a “ternary diagram” (Ekwall., 1975); (Hellweg et al, 2001). The total of A, B 
and C equals 100%. Figure 4.1 shows a phase diagram, with three inputs, A, B, C, 
where A is the ratio of co-surfactant to surfactant, B the water and C the oil. The 
ratio of surfactant and co-surfactant is constant for each phase diagram.  
 
 
Figure 4.1: Triangular grid from www.asminternational.com.   
 
 
The following procedure explains how the triangular diagrams can be used: 
- Each side of the triangle represents two components.  
- Each apex represents 100% of that component.  
- The apex directly opposite the side of the triangle represents 0% of the apex 
component.  
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- Any point lying inside the triangle is determined using the triangular net method. 
The lines for each side represent 10% of the components, and from these lines which 
pass through this point in place the percentage of each component of the point is 
determined. 
- After several experiments regions start to emerge, and these regions correspond to 
a specific structure, which can be an emulsion or a more organised structure such as 
a microemulsion.  
 
Selection of co-surfactant   
A co-surfactant has the capability to locate itself at the oil-water interface. It acts to 
further reduce the interfacial tension and therefore lower the interfacial free energy  
which is an energetically favourable situation (Prince, 1977b). The effect of co-
surfactant structure on formation of microemulsions was previously studied using 
heptanol and butanol as co-surfactants. Figure 4.2(a) illustrates a microemulsion 
prepared with butanol as a co-surfactant, while Figure 4.2(b) is the phase diagram of 
a microemulsion prepared with heptanol as a co-surfactant. The area called N2 
corresponded to the microemulsion domain. It was shown that area N2 using butanol 
in Figure 4.2(a) is wider, indicating the considerable influence of the co-surfactant 
structure. The surface tension at the boundary was lower for a microemulsion 
prepared with butanol than one prepared with heptanol, and consequently the 
butanol mixes more efficiently (Rosano and Clausse, 1987). Therefore, butanol was 
selected in our study. Also, the ratio of SDS to butanol was selected to be 1:2 (see 
section 4.3.1).   
  Phase diagram                                                                                           Chapter 4  
 
 
71 
   
 
Figure 4.2: a) Microemulsion prepared with butanol as a co-surfactant. b) Microemulsion prepared 
with heptanol as a co-surfactant. Adapted from  (Rosano and Clausse, 1987).   
 
4.2.2. Preparation of microemulsion 
A certain amount w/w of a mixture of surfactant:co-surfactant was weighted, and 
then mixed with oil in a phosphate buffer. Afterward the mobile phase was sonicated 
in a water bath for 10 minutes, then it was monitored and examined for the 
formation of microemulsion.  
4.2.3. Method of particle size measurement  
The experiment on the particle size of microemulsions was performed based on 
photon correlation spectroscopy (PCS) using a Malvern Zetasizer Nano ZS® 
(Malvern, UK) (Bagwe et al, 2001). This technique works on the basis of the 
difference between fluctuations in scattered light intensity of large and small 
particles due to variations in their diffusion properties (Brownian movement) 
(Malvern instruments, 1993). The main advantage of PCS is its straightforward and 
easy process which enables the particle size measurement to be done in a few 
minutes.  
 
It has been reported that the Malvern Zetasizer Nano ZS is the preferred instrument 
for particle sizing of microemulsion systems, providing reproducible particle size 
determinations (Amani. A., 2008). 
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4.3. Results and discussion 
4.3.1. Preparation of microemulsion using sodium dodecyl sulphate (SDS) 
surfactant 
The ternary phase diagram of the microemulsion using the SDS surfactant is shown 
in Figure 4.3. It illustrates the phase boundary between clear phase and opaque or 
turbid multiphase microemulsion. The apices of the phase diagram are octane, 
phosphate buffer and SDS/butanol. Each vertex of the triangle represents 100% 
(w/w). The translucent area is represents as microemulsion. The rest of the regions 
in the phase diagram represent conventional emulsion, gel area and turbidity based 
on visual identification. 
 
Previous studies of the surfactant to co-surfactant ratio have shown that the optimum 
ratio of SDS to butanol that forms microemulsion is 1:2. The addition of butanol 
reduces the interfacial tension by incorporation between the surfactant molecules 
(Marsh et al, 2005). Also, it was reported by (Wen-Ting  et al, 2005) that some co-
surfactant modifies the HLB value of the surfactant to an optimal value that is 
suitable for microemulsion formulation. This shows that butanol has an important 
role in promoting the formation of the microemulsion.  
 
The effect of addition of SDS/butanol in the microemulsion was examined in the 
range 5–90% w/w. Table 4.1 shows the composition of both microemulsion and 
non-microemulsion regions of different % of SDS/butanol (1:2 ratio). The turbid 
solutions were kept for several days to ensure the turbidity was permanent. It was 
found that increasing the SDS/butanol to 70% facilitated the formation of the 
microemulsion (Figure 4.3). Also, it was noticed that increasing SDS/butanol 
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increases the amount of oil that could be incorporated into the microemulsion. This 
is due to fact that the addition of surfactant and co-surfactant caused a reduction in 
the oil-water interfacial tension to very low values that promote the formation of 
microemulsion, as found by (Wen-Ting  et al, 2005). An unstable biphasic system 
was formed when SDS/butanol was above 80%w/w. 
 
Figure 4.3: Phase diagram of SDS/butanol (1:2), octane and phosphate buffer pH3. 
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Table 4.1: System composition for microemulsion and non-microemulsion regions at various 
percentages of SDS/butanol (1:2). 
 
 
 
 
 
             1:2 
SDS:butanol  % 
Oil (octane)  % Buffer pH3  % Description 
5 0.8 94.2 Turbid 
10 0.8 89.2 Nanoemulsion 
10 1.5 88.5 Turbid 
15 3 82 Nanoemulsion 
20 5 75 Microemulsion 
20 8 72 Turbid 
20 10 70 Turbid 
30 10 60 Microemulsion 
30 15 55 Microemulsion 
30 20 50 Turbid 
30 30 40 Turbid 
35 25 40 Microemulsion 
35 35 30 Microemulsion 
35 50 15 Microemulsion 
35 60 5 Turbid 
40 25 35 Microemulsion 
40 30 30 Microemulsion 
40 40 20 Microemulsion 
40 55 5 Microemulsion 
50 40 10 Microemulsion 
60 30 10 Microemulsion 
70 10 20 Microemulsion 
80 10 10 Turbid 
90 5 5 Turbid 
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 4.3.1.1. Using Zetasize Nano to examine the phase boundary of the 
microemulsion region with SDS 
 
The particle size of several microemulsion systems that cover different locations in 
the microemulsion region was measured by Malvern Zetasizer Nano ZS® (Malvern 
Instruments., 1993). Figure 4.4 presents a few points (five) which cover both o/w 
and w/o microemulsions. 
 
   Figure 4.4: Diagram showing the selected points for particle size measurement. 
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The data analysis for particle size of the solution at point 1 using the Malvern 
Zetasizer Nano for (SDS:butanol) 12%,  octane 1.8%  nanoemulsion is illustrated in 
Figure 4.5. 
 
 
Figure 4.5: Size distribution (by intensity) at point 1 of SDS:butanol 12%, octane 1.8%, measured by 
Malvern Zetasizer Nano analysis. 
 
The results from the Malvern Zetasizer Nano for particle size of solution at point 1 
that consists of SDS:butanol 12%, octane 1.8% are summarised in Table 4.2. The 
PCS analysis was repeated three times (n=3). 
Table 4.2: Zetasizer Nano results for SDS:butanol 12%, octane 1.8%. 
 
 Particle size (nm) 
Analysis1 42.3 
Analysis2 41.2 
Analysis3 41.4 
Mean 41.6 
SD 0.6 
 
 
It was found that the mean particle size (n=3) for solution at point 1 was 41.6nm 
with SD = 0.6 which shows that this solution was a nanoemulsion. Similarly the 
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particle size for microemulsion systems at points 2, 3, 4 and 5 was measured by 
Malvern Zetasizer Nano (Figures 4.6 to 4.9 and Tables 4.3 to 4.6). Figure 4.6 
illustrates the data analysis for microemulsion at point 2 using the Malvern Zetasizer 
Nano. The microemulsion at point 2 consists of SDS:butanol 40%,  octane 10%.   
 
 
Figure 4.6: Size distribution (by intensity) at point 2 of SDS:butanol 40%, octane 10%, measured by 
Malvern Zetasizer Nano analysis. 
 
The results from the Malvern Zetasizer Nano for particle size at point 2 are shown in 
Table 4.3. The PCS analysis was repeated three times. The mean particle size (n=3) 
of microemulsion at point 2 is 287nm. 
Table 4.3: Zetasizer Nano results for SDS:butanol 40%, octane 10%. 
 
 Particle size (nm) 
Analysis1 318 
Analysis2 258 
Analysis3 285 
Mean 287 
SD 30 
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Figure 4.7 shows the data analysis for microemulsion at point 3 using the Malvern 
Zetasizer Nano. The microemulsion consists of SDS:butanol 40%, octane 40%.   
 
Figure 4.7: Size distribution (by intensity) at point 3 of SDS:butanol) 40%, octane 40% measured by 
Malvern Zetasizer Nano analysis. 
 
 The results from the Malvern Zetasizer Nano for particle size at point 3 are 
summarised in Table 4.4. The PCS analysis was repeated three times. The particle 
size at point 3 has increased tremendously compared to point 1 and 2.  
 
                                 Table 4.4: Zetasizer Nano results for SDS :butanol  40%,  octane 40%. 
 
 Particle size (nm) 
Analysis1 1127 
Analysis2 1244 
Analysis3 963 
Mean 1111.3 
SD 141 
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Figure 4.8 shows the size distribution for microemulsion at point 4 using the 
Malvern Zetasizer Nano. The microemulsion consists of SDS:butanol 35%, octane  
45%.   
 
Figure 4.8: Size distribution (by intensity) at point 4 of  SDS:butanol 35%, octane  45%, measured by 
Malvern Zetasizer Nano analysis. 
 
The results from the Malvern Zetasizer Nano for particle size at point 4 are 
summarised in Table 4.5. The PCS analysis was repeated three times. 
                        
Table 4.5: Zetasizer Nano results for SDS:butanol 35%, Octane 45%. 
 
 Particle size (nm) 
Analysis1 1026 
Analysis2 1024 
Analysis3 1021 
Mean 1023.7 
SD 2.5 
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Figure 4.9 shows the size distribution for microemulsion at point 5 using the 
Malvern Zetasizer Nano. The microemulsion consists of SDS:butanol 55%, octane  
30%.  
  
Figure 4.9: Size distribution (by intensity) at point 5 of SDS:butanol 55%, octane 30%, reported by 
Malvern Zetasizer Nano analysis. 
 
The results from the Malvern Zetasizer Nano for particle size at point 5 are 
summarised in Table 4.6. The PCS analysis was repeated three times on the sample 
formulation.  
Table 4.6: Zetasizer Nano results for SDS:butanol  55%, octane 30%. 
 
 Particle size (nm) 
Analysis1 878 
Analysis2 981 
Analysis3 848 
Mean 873 
SD 26.63 
                   
 
In summary the results in Figures 4.5–4.9 and Tables 4.2–4.6 show that the particle 
droplet size of the microemulsion increased with increasing the volume fraction of 
oil. These results are in agreement with those of (aboofazeli et al, 2000a), who 
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reported that the changes in droplet size of a microemulsion for a fixed ratio of 
surfactant/co-surfactant increases with increasing the volume fraction of the 
dispersed phase. The preferred nanoemulsion system was chosen using the minimum 
quantity of surfactant:co-surfactant and oil, to keep the back pressure of the column 
to a minimum. This was 10% SDS:butanol, 0.8% octane and 89.2% phosphate 
buffer pH3. 
4.3.2. Preparation of microemulsion using Tween 80 surfactant 
 
Pseudo-ternary phase diagram studies were performed using different proportions of 
oil to the mixture of surfactant/co-surfactant. The ternary phase diagram of the 
microemulsion using the Tween80 surfactant is shown in Figure 4.10. The apices of 
the phase diagram are octane, phosphate buffer, and mixture of Tween80/sorbitol. 
Each vertex of the triangle represents 100% (w/w).The solution region of 10–20% of 
Tween80/sorbitol and 0–2% octane formed a stable oil in water nanoemulsion 
system.  
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Figure 4.10: Phase diagram of Tween8:Sorbitol (8:2), octane and phosphate buffer pH3. 
 
4.3.2.1. Using Zetasize Nano to examine the phase boundary of the 
microemulsion region with Tween80 
 
Figure 4.11 gives some illustrative data from the analysis of the nanoemulsion using 
the Malvern Zetasizer Nano for Tween80 10%.  
 
Figure 4.11: Size distribution (by intensity) of 10% Tween80 nanoemulsion reported by Malvern 
Zetasizer Nano  analysis.  
 
  Phase diagram                                                                                           Chapter 4  
 
 
83 
Table 4.7 is a summary of the results from the Malvern Zetasizer Nano for particle 
size of 10% Tween80. The PCS analysis was repeated three times. 
Table 4.7: Zetasizer Nano results for Tween80 (10%). 
 
 Particle size (nm) 
Analysis1 22.4 
Analysis2 21.9 
Analysis3 23.3 
Mean 22.5 
SD 0.7 
 
 
The Malvern Zetasizer Nano ZS provided reproducible particle size determinations. 
The mean particle size (n=3) of the solution droplets is 22.5nm and this was 
reproducible with SD = 0.7. However, the nanoemulsion formed a narrow line 
region and therefore was not considered for further studies as mobile phase for 
HPLC. (Figure 4.10). 
 
4.3.3. Preparation of microemulsion using Brij35 surfactant 
 
The phase diagram of the microemulsion using Brij35 surfactant is shown in Figure 
4.12. The figure shows the boundary of the microemulsion system which consists of 
ethylacetate-Brij35/butanol-phosphate buffer. Although the region of microemulsion 
was small, it was slightly bigger than the nanoemulsion system that was prepared 
with Tween80.  
 
The nanoemulsion with 2–5% w/w of Brij35/butanol and 0.5–2.9% w/w ethylacetate 
formed a stable oil in water nanoemulsion system. However, outside this region 
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turbid solutions were noticed. Again the turbid solutions were kept for few days to 
be sure that the turbidity was permanent. 
 
   Figure 4.12: Phase diagram of Brij35:butanol (1:1.5), ethyl acetate and phosphate buffer pH3. 
 
        
4.3.3.1. Using Zetasize Nano to examine the phase boundary of the 
microemulsion region with Brij35 
 
The particle size of the solution at point x (see Figure 4.12) was measured using the 
Malvern Zetasizer Nano. Figure 4.13 shows the size distribution of the selected 
solution.    
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Figure 4.13: Size distribution (by intensity) of Brij35 (1.6%), reported by Malvern Zetasizer Nano 
analysis. 
  
The results from the Malvern Zetasizer Nano for particle size of the selected solution 
are shown in Table 4.8. The PCS analysis was repeated three times. The mean 
particle size of the solution droplets was 8.89nm (SD = 0.2) which shows that this 
solution is a nanoemulsion. This nanoemulsion system has been selected to be used 
as a mobile phase for reversed phase HPLC (see section 5.1.3.1.1). 
Table 4.8: Zetasizer Nano results for undiluted Brij35 (1.6%). 
 
 Particle size (nm) 
Analysis1 9.12 
Analysis2 8.74 
Analysis3 8.82 
Mean 8.89 
SD 0.2 
 
 
4.4. Conclusions 
In this study the preparation and design of three types of microemulsions / 
nanoemulsions containing SDS, Brij35 and Tween 80 (as surfactants), butanol, 
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sorbitol (as co-surfactants), ethyl acetate and octane (as oils) in a phosphate buffer 
solution were demonstrated. The size and stability of the microemulsion particles 
were investigated. It was found that increasing the SDS/butanol to 70% facilitated 
the formation of a microemulsion. Turbid solutions were formed when SDS/butanol 
was above 80%w/w. On the other hand, when the amount of oil was above 55% 
w/w, no microemulsion formed. Also, it was found that the solution of SDS:butanol 
12%, octane 1.8% (point 1) formed a nanoemulsion while other solutions at points 2, 
3, 4, and 5 formed microemulsions. 
 The area of nanoemulsion with Tween80 was extremely small and consequently 
was not considered for further studies. The solution with 0.5–2.9% ethylacetate and 
2–5% of Brij35/butanol produced a stable oil-in-water nanoemulsion system. 
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Chapter  5 
Nanoemulsion high performance liquid chromatography (NELC) 
analysis for hydrophilic drugs such as terbutaline and salbutamol 
in dosage form and urine 
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5.1. Nanoemulsion high performance liquid chromatography (NELC) 
method development for the analysis of terbutaline in aqueous samples 
5.1.1. Terbutaline sulphate 
Even though the treatment of asthma is based on the regular use of corticosteroids as 
preventatives, the treatment still relies heavily on the use of β2-agonists such as 
terbutaline and salbutamol as reliever therapy. Terbutaline sulphate is a selective β2-
adrenoceptor agonist that is used as a prophylactic and for treatment of diseases 
associated with airways obstruction (bronchodilator) and in patients with COPD. It 
was first introduced in the 1970s  (Waldeck, 2002, Sears, 2005b). Its chemical name 
is [(1RS)-1-(3,5-dihydroxypheynyl)-2-(tert-butylamino)-ethanol] sulphate 
(Martindale, 2006). The compound has the molecular formula (C12H19NO3).H2SO4. 
Figure 5.1 shows the molecular structure of terbutaline sulphate. The molecular 
mass of terbutaline is 225.3 and that of terbutaline sulphate is 274.3, thus, terbutaline 
sulphate 500µg is equivalent to terbutaline base 410.6µg. 
 
Figure 5.1: Molecular structure of terbutaline sulphate. (Sweetman, Martindale (Eds) 2009) 
 
Terbutaline is a hydrophilic white to grey-white crystalline powder, odourless or 
with a faint odour of acetic acid, soluble in 0.1N-hydrochloric (HCl) acid and water, 
slightly soluble in methanol, and insoluble in chloroform (United States 
Pharmacopeia, 2002). Terbutaline sulphate is present in many dosage forms 
(inhalation, oral solution, injection, and tablet). In regular use it should be inhaled as 
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one or two doses of 250μg terbutaline sulphate, every 4 to 6 hours up to a maximum 
of 8 inhalations in 24 hours (Martindale, 2002). 
 
Pharmacokinetics 
After inhalation, the bronchodilating effect of terbutaline usually begins within 5 
minutes and lasts about 3 to 4 hours (Florey, 1990). Terbutaline concentrations in 
plasma or serum are low as the inhaled dose is small and the volume of distribution 
is very large, therefore it clears from blood to urine at a fast rate (Chrystyn, 1994a). 
Orally administered terbutaline sulphate is usually absorbed from the gastrointestinal 
tract (Sears, 2005a, Florey, 1990). About 60% of the absorbed dose undergoes first 
pass effect metabolism to the sulphate ester (Sweetman, 2002). Also, terbutaline 
plasma protein binding is low, 14 to 25% (Analytical Profiles, 1990).  
 
In this part of the program it is proposed to assess the potential of NELC for the 
analysis of terbutaline in aqueous solutions and pharmaceutical preparation, and also 
to investigate the effects of operating parameters on the assay of terbutaline.   
5.1.2. Experimental method  
5.1.2.1. Chromatographic conditions 
Chromatographic separation was performed using a 250mm×4.6mm i.d. (5m 
particle size) Spherisorb C18 column (Waters, UK). The mobile phase was 95.5% 
aqueous orthophosphate buffer (adjusted to pH3 with ortho phosphoric acid), 1.5% 
Brij35, 2.5% 1-butanole, 0.5% ethyl acetate, all w/w. The mobile phase was filtered 
under vacuum through a 0.45m filter and degassed in an ultrasonic bath under 
vacuum for 10min. The HPLC system consisted of a Hewlett-Packard (HP) 1050 
pump and auto-sampler connected to an on-line membrane degasser. The Shimadzu 
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fluorescence detector model RF-551 was set at an excitation wavelength of 267nm 
and an emission wavelength of 313nm, and the detector was linked to Prime Multi-
channel Data Station Software Version 4.2.0. (HPLC Technology Ltd, Herts, UK) 
(see section 3.1.1). Terbutaline samples and bamethane (internal standard) were 
injected into the system and separated at 25
o
C. The mobile phase was delivered at a 
flow rate of 1.0ml/min and the injection volume was 20l. 
5.1.2.2. Particle size measurement of the mobile phase 
 
The particle size of the filtered mobile phase was measured. The reported size was 
the Z-average size of five replicates determined at 25
◦
C based on PCS using a 
Zetasizer Nano ZS® (Malvern, UK). The accuracy of the instrument had been 
confirmed using a Nanosphere
TM
 size standard, 60nm. No dilution was performed on 
the samples prior to measurement.  
5.1.2.3. Preparation of standard terbutaline sulphate in mobile phase 
A stock solution containing 100µg/ml of terbutaline was prepared using the internal 
standard. The internal standard was prepared beforehand at a concentration of 
400g/l in the mobile phase. Ten millilitres of stock solution were pipetted into a 
100ml volumetric flask and made up to volume using the internal standard to 
produce a terbutaline sulphate of 10µg/ml (sub-stock). Calibration standards in the 
concentration range of 25, 50, 100, 200, 300, 400 and 500ng/ml were prepared in the 
appropriate volumetric flasks using an internal standard. All standards/samples were 
filtered through a 0.45m filter prior injection. 
5.1.3. Results and discussion 
5.1.3.1. Method development 
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5.1.3.1.1. Mobile phase 
Initial experiments were carried out with a typical microemulsion mobile phase, 
using octane as the oil droplet. This type of mobile phase was reported to be 
successful for separation of different type of drugs in test mixtures (Mahuzier, 2001, 
Altria, 1999, Miola, 1998). Thus initially, 0.8% w/w n-octane was used as the oil 
droplet phase and 6.6% w/w butan-1-ol as co-surfactant, as well as 3.3% w/w SDS 
as surfactant, all mixed in 89.3% w/w of 5mM phosphate buffer, but this mobile 
phase gave poor separation of terbutaline and bamethane. The mobile phase was 
optimised further for the concentration of oil, surfactant and co-surfactant. 
The effect of SDS concentration was examined using a range of 1.5–4% w/w. The 
increase in the concentration of SDS from 1.5–4% w/w had a very small effect on 
retention time and on separation resolution (Figure 5.2). Decreasing the 
concentration of SDS below 1.5% w/w did not form a nanoemulsion. On the other 
hand, increasing the SDS concentration above 4% w/w was maximum amount the 
back pressure of the column which led to stopping the system. 
 
Figure 5.2: Effect of concentration of SDS on separation of terbutaline and bamethane.  
Microemulsion consists of: SDS 2-4%, octane 1.25%, butanol 8%, phosphate 87.5% pH3.  
 
The effect of oil concentration was examined over the range 0.5–1.25% w/w, where 
no more oil was solubilised above 1.25% w/w by the microemulsion system. 
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Increasing the concentration of oil produced a small effect on the retention time and 
separation resolution (Figure 5.3). Increasing the concentration of oil should increase 
the mobile phase hydrophobicity. However, both terbutaline and bamethane are 
hydrophilic and therefore their retention was not affected by increasing the oil 
concentration. 
 
Figure 5.3: Effect of octane concentration on separation of terbutaline and bamethane. 
 
The concentration of butanol was varied from 0–9 %. At 0% w/w of butanol, it was 
difficult to separate terbutaline and bamethane. Separation was improved by adding 
the co-surfactant to the microemulsion mobile phase. However, increasing the 
concentration of butanol from 2–9 % had a very small effect on retention time and 
on separation resolution (Table 5.1). These results are consistent with the report of 
Alex et al. (2005). 
Table 5.1: Retention time of terbutaline and bamethane. Microemulsion consists of: SDS 1.6%, 
octane 1.25%, butanol 2.9%, phosphate pH 3 87.5% w/w. 
 
 Terbutaline      
 
Bamethane 
 
Flow Rate : 
0.85 ml/min 
Butanol    2 % 3.97 4.43 235 bar 
Butanol    4.5 % 4.01 4.38 235 bar 
Butanol    6 % 3.70 4.50 255bar 
Butanol     9 % 3.76 4.55 305 bar 
 
  NELC to determine hydrophilic drugs                                                      Chapter 5  
 
 
93 
The optimum mobile phase of the nanoemulsion was SDS 2%, octane 1.25%, 
butanol 6%, phosphate 90.75% pH 3. However, this mobile phase was not able to 
provide a baseline resolution between terbutaline and bamethane (I.S.), as shown in 
Figure 5.4. Subsequently nanoemulsion mobile phase using a non-ionic surfactant 
such as Brij 35 was employed.  
 
 
Figure 5.4: Effect of ionic surfactant on solute retention in terbutaline and bamethane in aqueous 
solution. The conditions were as follows: nanoemulsion consists of: SDS 2%, octane 1.25%, butanol 
6%, phosphate 90.75% pH3. 
 
5.1.3.1.2. Concentration of surfactant (Brij35) 
The presence of a surfactant in the mobile phase can affect the separation selectivity. 
The surfactant molecules have the tendency to adsorb on the surface of the porous 
stationary phase and modify their surfaces (Berthod, 1992a). The adsorbed 
surfactant molecules fill up part of the silica pore volume, hence they reduce 
stationary phase surface area and increase the thickness of the stationary organic 
layer, which changes the efficiency of the ODS column (Berthod, 1992a, Berthod. 
A., 1997, Garti, 2001). The adsorbed surfactant on the stationary phase could have a 
direct impact on the retention of solutes and their partition with the stationary phase. 
Using different concentrations of Brij35 (0.5–2%) showed that retention of 
bamethane decreases with increases in the concentration of Brij35 between 0.5% and 
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1%. This indicates that Brij35 may have modified the stationary surface and 
therefore reduced the retention time of bamethane. However further increases in 
Brij35 concentration have a very small effect on the retention time of both 
bamethane and terbutaline (Figure 5.5).  
 
Figure 5.5: Effect of Brij35 concentrations on the separation of terbutaline and bamethane. 
                 
5.1.3.1.3. Concentration of the co-surfactant (butanol) 
Co-surfactants such as alcohol are used to enhance and stabilise the microemulsion 
system. The nature of the co-surfactant affects the phase behaviour in the 
microemulsion system (Garti, 2001). Figure 5.6 shows the effect of changing the 
concentration of the co-surfactant butanol in the range of 0.5-3.5% w/w. It was 
found that retention time of both terbutaline and bamethane decreases on increasing 
the concentration of butanol from 0.5-2.5%w/w. Nevertheless, a further increase in 
butanol concentration had no marked effect on retention time (Figure 5.6). The 
decrease in retention time on increasing the concentration of co-surfactant could be 
attributed to the increase in the solubilisation capacity of the microemulsion with the 
use of butanol. Garti et al. (2001) demonstrated the effect of alcohol chain on phase 
behaviour and they found that short chain alcohols increased the area of 
microemulsion in the phase diagram while long chain alcohols such as long chain 
pentanol and hexanol decreased the solubilisation capacity of the microemulsion. 
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Figure 5.6: Effect of co-surfactant concentrations on the separation of terbutaline and bamethane. 
 
5.1.3.1.4. Oil concentration 
The oil is dispersed into nano-droplets in the continuous water phase to form the 
microemulsion with the assistance of the surfactant/co-surfactant which resides on 
the oil-water interface (Mason, 2006). In microemulsion HPLC, the type and 
concentration of oil have a marked effect on the retention time of analytes. This 
effect depends on the nature of these analytes. Different concentrations of oil (ethyl 
acetate) were studied in the range 0–1 % w/w (Figure 5.7). At 0% the mobile phase 
contains micellar and it was found that the retention time of both terbutaline and 
bamethane were 5.2 and 7.3min respectively. The retention of both analytes 
decreased with the addition of oil. This is due to the fact that a microemulsion has a 
stronger elution capacity than a micellar solution (Liu, 2007). 
 
A slight decrease in retention of analytes was observed on increasing the oil content 
above 0.5%. Unlike lipophilic compounds, hydrophilic compounds such as 
terbutaline and bamethane have high affinity to the continuous phase of the 
microemulsion and therefore do not partition as fully as in the oil droplet (Ryan, 
2008 -b). 
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Figure 5.7: Effect of oil concentration on the separation of terbutaline and bamethane. 
 
5.1.3.1.5. Mobile phase pH  
The effect of the pH of the mobile on the retention time of both terbutaline and 
bamethane was measured at low pH (pH3) and high pH (pH6). It was found that 
there is no marked effect of change in pH on the retention of terbutaline and 
bamethane. The ionised terbutaline and bamethane have less affinity to the oil 
droplet and therefore their retention will mainly depend on the interaction with the 
stationary phase. Both terbutaline and bamethane are weak basic drugs and therefore 
they are fully protonated in the examined pH range. Hence they will have less 
interaction with ODS stationary phase, and changing the pH will have little effect on 
their retention. Then again, it was noticed that the peak efficiency of terbutaline was 
improved at pH 3. Lowering the pH of the mobile phase reduces the adsorption of 
the basic drugs to the silanol group of the stationary phase. Assi et al. (2006b) have 
used low pH mobile phase for the determination of formoterol and budesonide in a 
Symbicort Turbohaler to avoid the adsorption problem. They indicated that at the 
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very low pH, mobile phase eliminates the interaction between the ionised silanol 
group and the NH2 groups of the solutes.  
5.1.3.1.6. Buffer concentration 
The effect of phosphate buffer concentration on the retention behaviour of both 
terbutaline and bamethane was examined at different concentration levels. Four 
mobile phases were prepared with different concentrations of phosphate buffer 5, 10, 
20 and 25mM. Figure 5.8 shows that the retention time of both terbutaline and the 
internal standard decreased as the buffer concentration increased. These results 
corroborate with the findings reported by (Mao et al., 2001). However, Mao et al. 
studied the effect of buffer concentration using conventional mobile phase. The 
consistency in both studies shows that in reverse phase chromatography the retention 
time of positively charged analytes decreases with increasing buffer concentrations 
whether the mobile phase contains microemulsion or not. This shows that there is an 
electrostatic interaction between protonated analytes (terbutaline and bamethane) 
and silanol groups even with low pH mobile phase. The logarithm of the retention 
factor of a cationic analyte has a negative relationship with logarithm buffer 
concentration in a cationic exchange column. Mao et al. also reported that even with 
double end capping ODS there is still a considerable cation exchange between the 
positively charged analytes and stationary phase, which the authors attributed to 
electrostatic interactions between the charged analytes and residual silanol groups 
(Mao et al., 2001). 
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Figure 5.8: Effect of phosphate buffer concentrations on the separation of terbutaline and bamethane. 
 
5.1.3.1.7. Column temperature 
The column temperature affects the elution of basic drugs in reverse phase 
chromatography. Changing the temperature of the column alters the dissociation 
constant of the basic analytes. The aqueous pKa of basic analytes decreases 
significantly with increases in temperature, thus as temperature increases more of the 
neutral form and less of the protonated form will be present (McCalley, 2000). In 
reversed phase, the main factor that controls the retention of analytes is their 
interaction with the stationary phase. The neutral form interacts with the ODS phase 
much more strongly than does the charged form. Hence retention should increase 
upon increasing the temperature of the ODS column (Mao et al., 2001). However, 
the effect of temperature on retention of basic drugs in HPLC microemulsion 
systems can be more complicated than that described above. In reversed phase 
microemulsion there are two contradictory mechanisms. On the one hand as the 
basic drugs become more neutral they retain longer in the stationary phase. On the 
other hand their partition with the oil droplet will increase and therefore their 
retention should decrease.  
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The effect of temperature was examined at 6 different temperatures from 25-50 ˚C 
(Figure 5.9). It was found that increasing the temperature had no marked effect on 
the retention either of terbutaline or the internal standard. Peak efficiency and 
resolution were improved with increasing temperature. This result is consistent with 
findings reported by (Mrash et al., 2004a). 
 
Figure 5.9: Effect of temperature on the separation of terbutaline and bamethane. 
 
5.1.3.1.8. Effect of fluorescence spectra 
Fluorescence spectroscopy was used to recognize the emission spectra of 
nanoemulsion mobile phase. The optimum mobile phase consisting of 
1.5:0.5:2.5:95.5 Brij35:ethyl acetate:1-butanole:phosphate buffer was examined 
(Figure 5.10). The optimum emission wavelength was obtained by fixing the 
excitation wavelength of the fluorescence detector at 267nm, and detecting the 
repeated injections at different emission wavelengths ranging from 310–320nm. 
Furthermore, the optimum excitation wavelength was obtained by fixing the 
emission wavelength at 313nm, and detecting the repeated injections at different 
excitation wavelengths, ranging from 242–280nm. The maximum yield of the 
nanoemulsion mobile phase was obtained at excitation and emission wavelengths of 
267 and 313nm respectively. 
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Figure 5.10: Fluorescence spectra of the nanoemulsion mobile phase. The mobile phase consists of 
1.5:0.5:2.5:95.5 Brij35: ethyl acetate:1-butanole:phosphate buffer (adjusted to pH3 with 
ortho-phosphoric acid) (% w/w). 
 
5.1.3.1.9. Particle size of the mobile phase 
The preparation of the optimum mobile phase was repeated on five different 
occasions and five replicate measurements were performed for each mobile phase. 
The particle size obtained for all mobile phases was always less than 10nm. Figure 
5.11 shows a representative measurement of particle size of the mobile phase. 
Moreover, the mobile phase was stable for more than 3 months.  
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Figure 5.11: Size distribution (by intensity) of nanoemulsion mobile phase. The mobile phase consists 
of 1.5:0.5:2.5: 95.5 Brij35:ethyl acetate:1-butanole:phosphate buffer (adjusted to pH3 with 
ortho phosphoric acid) (% w/w ) measured by Malvern Zetasizer Nano analysis. 
 
5.1.4. Method validation    
The developed method was validated, and the validation procedure was based on  
(ICH  1996) guidelines. 
5.1.4.1. Selectivity 
The method was shown to be selective for terbutaline. Figure 5.12 shows a typical 
separation of terbutaline (200ng/ml) and the internal standard bamethane 
(400ng/ml), all dissolved in the mobile phase. The figure shows that terbutaline was 
eluted at 4.3 min. The analysis of mobile phase and blanks confirmed that there were 
no interfering peaks due to the blank. 
 
Figure 5.12: Chromatogram of terbutaline (200µg/l), and the internal standard, bamethane (400µg/l). 
Peak identities: terbutaline 4.3min, and bamethane 5.1min. 
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5.1.4.2. Linearity    
Six different concentrations were prepared ranging from 25 to 500ng/ml,
 
including 
the limit of quantification (LOQ) and covering the expected range. The linearity of 
the calibration standards was evaluated over this range. The calibration samples 
were injected in duplicates and also blank samples were analysed along with the 
calibration standards. The detector response was shown to be linear over the covered 
range and gave a regression coefficient (r
2
) of 0.998 (Figure 5.13). The standard 
deviations for the slope and intercepts were 0.0003 and 0.00814 respectively; y = 
0.003x - 0.024.  
 
Figure 5.13: Linearity curve. 
 
5.1.4.3. Sensitivity 
The sensitivity was expressed as the limit of quantitation (LOQ) and limit of 
detection (LOD). Limit of quantitation (LOQ) is the injected amount that results in a 
peak with a height at least ten times as high as the baseline noise level, and the limit 
of detection (LOD) corresponds to a peak height to base line ratio of 3:1 (ICH  
1996). Another approach to calculating LOQ and LOD is based on the standard 
deviation (SD) of the y intercept from the regression of the calibration curve 
(Apostol, 2009). In this approach the LOQ = 10s/m and LOD = 3.3s/m where s is the 
standard deviation of the y-intercept and m is the slope of the calibration. The limit 
of detection (DL = 3.3s/m) was 8.81ng/ml and the limit of quantitation (QL = 
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10s/m) was 26.7ng/ml. Three samples of both terbutaline and bamethane were 
prepared at the quantitation limits and were analysed (n=10), and the relative 
standard deviation (RSD) was 0.92.  
5.1.4.4. Precision 
Precision was assessed by five determinations at known concentrations 
corresponding to low (25ng/ml), medium (200ng/ml) and high (500ng/ml) levels in 
the calibration range. The same study was repeated for 5 days to determine the inter-
day variation. The intra- and inter-day variations were determined by calculating the 
relative standard deviations. The intra-day variations (RSD%) ranged from 0.76 to 
1.46% and inter-day RSD% ranged from 0.80 to 1.11% (Table 5.2).     
Table 5.2: a) Intra-day precision study using 25, 200, 500ng/ml aqueous terbutaline standard. 
 
Injection 
%RSD 
25ng/ml 200ng/ml 500ng/ml 
1 2.23 0.88 1.04 
2 1.39 1.47 0.82 
3 0.96 1.49 0.47 
4 1.51 1.32 0.58 
5 1.22 0.94 0.9 
Mean 1.46 1.22 0.76 
                     
                
   b) Inter-day precision study using 25, 200, 500ng/ml aqueous terbutaline standard.  
Days 
%RSD 
25ng/ml 200ng/ml 500ng/ml 
1 0.89 0.32 1.12 
2 1.09 0.96 0.28 
3 0.23 0.73 0.77 
4 1.41 0.98 0.30 
5 1.94 1.70 1.51 
Mean 1.11 0.93 0.80 
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5.1.4.5. Accuracy 
The accuracy of the method was determined by adding the analyte into blank 
matrices at different concentrations. Then it was assessed by comparing the 
calculated spike concentration with the true concentration of terbutaline. Three 
different concentrations levels corresponding to low (25ng/ml), medium (200ng/ml) 
and high (500ng/ml) were used (n=5 for each level). The accuracy of the method 
ranged from 99.82 to 101.02% (Table 5.3). 
 Table 5.3: Accuracy data for terbutaline. 
 
Actual  
  concentration 
(ng/ml) 
Observed 
concentration  
(ng/ml) 
Accuracy % 
25 25.25 101.03 
200 199.7 99.83 
500 498.9 99.79 
 
5.1.4.6. Recovery 
The recovery was assessed by extracting known amounts of terbutaline from control 
filters. The mean recoveries of terbutaline from the electrostatic filters were 
>98.04%. The details of the recovery study for terbutaline from control filters are 
shown in Table 5.4. 
Table 5.4: Recovery of terbutaline from control filters (n=5). 
 
Nominal  
concentration 
(ng/ml) 
Mean (SD) 
 calculated concentration 
(ng/ml) 
 
% Recovery 
25 25.38 101.53 
200 196.15 98.08 
500 490.19 98.04 
5.1.4.7. Stability 
Reference solutions were stored in the refrigerator at +4◦C for 6 weeks and re-
analysed in an injection sequence employing freshly prepared standard solutions. 
The concentration after such storage conditions and on comparison with a freshly 
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prepared standard was 99%. Longer storage periods may be possible but were not 
assessed in this study. 
5.1.4.8. Robustness 
The robustness of an analytical method is a measure of its capacity to resist changes 
due to small variations in method conditions. The method robustness was assessed 
as a function of changing the Brij35, buffer concentration, 1-butanole and pH. The 
changes ranged over ±5% of the target (experimental condition). The method system 
suitability criteria of a resolution greater than 2.0 between the peaks were 
maintained.  
 
5.1.5. Application of the method for determination of terbutaline in 
dosage form (Bricanyl
®
 Turbohaler)  
 
The pharmaceutical performance of inhaled products can be characterized by the 
total emitted dose and the aerodynamic particle size distribution including the fine 
particle dose. Reliable and consistent dosage emission from an inhaler is crucial for 
the management of asthma in patients (Tarsin et al, 2004a). Aerodynamic particle 
size distribution including the fine particle dose is useful to provide some indication 
of therapeutic use (Weda et al, 2004). The variation of the emitted dose is a very 
important factor that could affect the clinical response and have side effects.  
In this work, the assessment of nanoemulsion as eluent for HPLC using a non-ionic 
surfactant for the determination of terbutaline in Bricanyl
®
 Turbohaler was 
examined to assay the content uniformity of the emitted dose and the fine particle 
dose of terbutaline in the Bricanyl
®
 Turbohaler.  
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5.1.5.1. Dose content uniformity 
The method was useful to measure the emitted dose of terbutaline in the Bricanyl
®
 
Turbohaler (500µg). The emitted dose uniformity was measured using a dose 
sampling apparatus (Figure 5.14) that is described in pharmacopoeial methods 
(European Pharmacopoeia, 2008, United States Pharmacopeia, 2005). Ten individual 
doses (dose numbers 2, 3, 4, 49, 50, 51, 52, 98, 99 and 100) of the entire dose 
available (100 doses) were collected from the Bricanyl at a pressure drop of 4kPa 
across the inhaler. The flow duration was 4.5s; this was to allow a volume of 4 L to 
be drawn through the inhaler. The flow duration was calculated using the relation 
described in the USP (2005).  
Time T = (60 sec x V)/Q 
T = duration of inspiration consistent with withdrawal of air from the inhaler  
V = 4L to be drawn through the inhaler  
Q = inhalation rate 
The inhalation flow through the mouthpiece of the Bricanyl
® 
Turbohaler device was 
set at a flow corresponding to 4kPa. At each operation the absolute pressure ratio 
P3/P2 was adjusted to less than or equal to 0.5 thus ensuring critical sonic flow. The 
critical flow controller contains a two way solenoid valve which controls both the 
time and the pressure of the airflow. The two-way valve enables air to be drawn 
through the mouthpiece of the Bricanyl
® 
Turbohaler device at a set flow rate by a 
vacuum pump. The Bricanyl
® 
Turbohaler device was used according to the 
instructions in the patient information leaflet and inserted into the dose sampling 
tube.  
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The sampling tube and filter were rinsed with standard aqueous bamethane solution 
(internal standard). The resultant solution was placed in a sonic bath for three 
minutes. Studies (Yakubu, 2009) have shown that this procedure removes the entire 
entrained drug on the filter. All the solutions were collected and made up to a 
volume of 25ml. The amount of active drug collected on the filter and deposited on 
the wall of the tube was determined by the NELC method. 
 
The HPLC data were then compared with the label claim dose (500µg) of the 
Bricanyl inhaler (Table 5.5). Doses not required were discharged to waste using a 
flow of 90L/min
 
for a 16 second vacuum period to clean the Turbohaler. It was 
found that the RSD value was high because of the high inter-dose emission 
variability from a Turbohaler inhaler (Assi, 2006b, Tarsin, 2004c). 
 
Figure 5.14: Schematic design showing the method for measuring the dose emission from the 
Bricanyl ® Turbohaler device. 
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Table 5.5: Percentage of the nominal dose of terbutaline emitted from Bricanyl Turbohaler at a 
pressure drop of 4kPa across the inhaler. 
  
Dose no. 
%  Label       
dose 
2 65.2 
3 47.3 
4 63.6 
49 92.2 
50 76.7 
51 64.7 
52 67.0 
98 73.5 
99 84.5 
100 82.1 
Mean 71.7 
SD 12.8 
RSD 17.8 
 
5.1.5.2. Particle size distribution 
The particle size distribution and the fine particle mass from the Bricanyl
®
 
Turbohaler were measured using the Andersen MKII Cascade Impactor (ACI) 
[Figure 5.15]. The flow rate through the mouthpiece was set at a pressure drop of 
4kPa across the inhaler. Five separate determinations were made and for each 
determination one dose was discharged into the Andersen MKII Cascade Impactor. 
For each dose the pump was switched on for 4.5s (equivalent to an inhaled volume 
of 4L drawn through the inhaler) with the inhaler in situ ready to deliver each dose. 
The collection plates were then sprayed with silicone fluid (Releasil B silicone 
spray, Dow Corning Limited, Barry, Glamorgan, UK) and then allowed to dry for at 
least one hour prior to delivery of the dose into the ACI. The excellent sensitivity of 
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the method allowed the delivery of one dose to the ACI. High delivery doses to the 
ACI would overload the plates and cause a particle bounce effect (Dunbar, 2005).  
 
The fine particle size for terbutaline was 170.26µg. The probability of the 
cumulative percentage of mass being less than a stated particle size was plotted 
against the log of aerodynamic diameter (m) as shown in Figure 5.16. The mass 
median aerodynamic diameter (MMAD) was 2.76m and the geometric standard 
deviation (G.S.D.) was 1.79m. 
 
 
Figure 5.15: A - Andersen Cascade Impactor (ACI) (Aluminium, 316 Stainless Steel and Titanium) 
and  B - Schematic of ACI ) [Source: adapted from (Copley, 2007b)]. 
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Figure 5.16: The cumulative drug distribution. 
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5.2. Development of the nanoemulsion high performance liquid 
chromatography (NELC) method for determination of salbutamol in 
aqueous solutions 
 
5.2.1. Introduction                                                                  
Β2-adrenoreceptors are located in many tissues including the airways. Salbutamol 
and terbutaline are short acting β2-adrenoreceptor agonists. They stimulate β2-
receptors located in the cell membrane of smooth muscles present in the airways 
resulting in bronchodilation, thereby providing relief for sufferers of asthma and 
other conditions associated with airways obstruction. 
 
 
  
  
 
 
 
 
 Figure 5.17: Molecular structure of Salbutamol  (Sweetman & Martindale (Eds) 2009). 
 
 
Salbutamol was introduced by Allen and Hanburys (Glaxo Group) in 1969. 
Salbutamol is a white, crystalline odourless powder and its chemical name is α1-
[(tert-butylamino) methyl]-4-hydroxy-1,3-benzenedimethanol. It has a relative 
molecular mass of 239.31 (Figure 5.17) and is a hydrophilic compound, relatively 
polar with basic properties. It has 2 ionisable groups: a secondary amine (pKa 10.3) 
and phenol (pKa 9.4). Salbutamol is sparingly soluble in water (1 in 70 of water), 
slightly soluble in ether and soluble in ethanol (96%). Salbutamol is used as base or 
as salt in aerosol inhalers. 100µg of salbutamol base is equivalent to 120.5µg of 
salbutamol sulphate. In its capacity as a short acting β2-agonist, salbutamol can be 
delivered to its site of action in a variety of ways such as oral and aerosol-inhaler 
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(e.g. inhaler). Inhaled salbutamol is the most commonly used quick-relief 
medication. The pharmacological activity is usually in the (R)-enantiomer; so far 
there is no evidence that (S)-enantiomer is risky to the patient (Waldeck, 2002). 
 
Pharmacokinetics  
Salbutamol has a rapid onset and short duration of action (Lotvall, 2001). Following 
oral administration the onset of action is around 30 minutes. The onset of 
bronchodilation after the inhalation occurs within 5 minutes, peaks after 30 minutes 
and lasts for up to 4 to 6 hours (Lipworth, 1992). Salbutamol is readily absorbed 
from the gastro-intestinal tract following administration by the oral route (Evans, 
1973). Studies have found peak plasma concentrations occur approximately 3 to 4 
hours after inhalation from a MDI (Evans, 1973) and within 1.8 to 3 hours after oral 
administration (Evans, 1973, Goldstein, 1987, Martin, 1971). The peak excretion of 
the unchanged drug is seen at 30 minutes post dose which is due to the rapid renal 
elimination of the fraction of drug absorbed through the lung (Hindle, 1992). 
 
Salbutamol is eliminated either renally as the unchanged drug in the urine or 
following metabolism to the sulphate ester. The sulphate ester metabolite has been 
found to be pharmacologically inactive (Evans, 1973, Martin, 1971). After direct 
bronchial instillation of the radio labelled drug, salbutamol was eliminated mainly as 
an unchanged drug (62%) (Shenfield, 1976). Salbutamol has a high volume of 
distribution (2.5l/kg) consequently leading to low plasma concentrations (Morgan, 
1986). Salbutamol has a low protein binding of approximately 8%.  
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In this section it is proposed to examine the application of NELC for the analysis of 
salbutamol in aqueous solution and to study the effects of experimental parameters 
on the assay of salbutamol. 
5.2.2. Method development 
The mobile phase of 1.5:0.5:2.5:95.5 Brij35:ethyl acetate:1-butanole:phosphate 
buffer 20mM (adjust pH with orthophosphoric acid) (%w/w) was delivered at a 
constant flow rate of 1ml/min. The samples were injected onto a C18 Spherisorb 
(250mm X 4.6mm X 5mm) column at 25°C. The salbutamol peak was detected by 
fluorescence using excitation and emission wavelengths of 267 and 313nm 
respectively.  
5.2.2.1. Concentration of surfactant 
Following the application of different concentrations of Brij35 (0.5% to 2%) it was 
found that increasing the concentration of Brij35 from 0.5% to 1% decreased the 
retention of bamethane. This shows that Brij35 may have modified the stationary 
surface (see section 5.1.3.1.2) and therefore reduced the retention time of 
bamethane. However further increases in Brij35 concentration had a very small 
effect on the retention time of both bamethane and salbutamol (Figure 5.18).  
 
 
Figure 5.18: Effect of Brij35 concentration on the separation of salbutamol and bamethane. 
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5.2.2.2. Concentration of the co-surfactant  
Different concentrations of co-surfactant were studied. Figure 5.19 shows the effect 
of changing the concentration of co-surfactant butanol across the range 0.5-3.5% 
w/w. It was found that the retention time of both salbutamol and bamethane 
decreased on increasing the concentration of butanol from 0.5-2.5% w/w, which is 
due to the increase in the solubilisation capacity of the microemulsion with the use 
of a co-surfactant (see section 5.1.3.1.3). Nevertheless, a further increase in butanol 
concentration showed no marked effect on the retention time (Figure 5.19).   
 
Figure 5.19: Effect of co-surfactant concentration on the separation of salbutamol and bamethane. 
 
5.2.2.3. Oil concentration 
Different concentrations of oil (ethyl acetate) were investigated in the range 0.5-
1.0% w/w (Figure 5.20). A slight decrease in retention of analytes was observed on 
increasing the oil content above 0.5%. In contrast to lipophilic compounds, 
hydrophilic compounds such as salbutamol and bamethane have a high affinity to 
the continuous phase of the microemulsion and therefore do not partition as fully as 
in the oil droplet  (Ryan, 2008 -b). 
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Figure 5.20: Effect of oil concentration on the separation of salbutamol and bamethane. 
 
5.2.2.4. Buffer concentration 
The effect of phosphate buffer concentration on retention behaviour of both 
salbutamol and bamethane was studied at different concentrations levels. Four 
mobile phases were prepared with different concentrations of phosphate buffer 5, 10, 
20 and 25mM. Figure 5.21 shows that retention time of both salbutamol and the 
internal standard decreased as the buffer concentration increased. These results are 
in accordance with the findings reported by Mao et al. (2001) [ see section 
5.1.3.1.6].  
 
Figure 5.21: Effect of buffer concentration on the separation of salbutamol and bamethane. 
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5.2.2.5. Column temperature 
The effect of temperature was examined at 6 different temperatures from 25-50˚C 
(Figure 5.22). It was found that increasing the temperature had no marked effect on 
the retention both of salbutamol and of the internal standard. Peak efficiency and 
resolution were improved with increasing temperature. This result is consistent with 
findings reported by Marsh et al. (2004a). 
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Figure 5.22: Effect of temperature on the separation of salbutamol and bamethane. 
 
5.2.3. Method validation  
The developed method was validated according to ICH ( 1996) guidelines. 
5.2.3.1. Selectivity 
The method was shown to be selective for salbutamol. Figure 5.23 shows a typical 
separation of salbutamol (200ng/ml) and the internal standard bamethane 
(400ng/ml), all dissolved in the mobile phase. The figure shows that salbutamol was 
eluted at 3.2 min. The analysis of mobile phase and blanks confirmed that there were 
no interfering peaks due to the blank. 
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Figure 5.23: Selectivity of salbutamol. 
 
5.2.3.2. Linearity 
Six different concentrations were prepared ranging from 25 to 500ng/ml,
 
including 
the limit of quantification (LOQ), and covering the expected range. The linearity of 
the calibration standards was evaluated over this range. The calibration samples 
were injected in duplicates and also blank samples were analysed along with the 
calibration standards. The detector response was shown to be linear over the covered 
range and gave a regression coefficient (r
2
) of 0.9995 and y = 0.0013x + 0.0467 
(Figure 5.24). 
 
 
Figure 5.24: Linearity of salbutamol. 
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5.2.3.3. Sensitivity 
The measurements of LOQ and LOD were based on the standard deviation (SD) of 
the y intercept from the regression of the calibration curve [see section 5.1.4.3]. The 
limit of detection (DL = 3.3s/m) was 9.61ng/ml and the limit of quantitation (QL = 
10s/m) was 29.13ng/ml.  
5.2.3.4. Precision 
Precision was assessed by five determinations at known concentrations 
corresponding to low (30ng/ml), medium (120ng/ml) and high (250ng/ml) levels in 
the calibration range. The same study was repeated for 5 days to determine the inter-
day variation. The intra- and inter-day variations were determined by calculating the 
relative standard deviation. The intra-day variations (RSD %) and inter-day (RSD 
%) are shown in Table 5.6.  
      Table 5.6: Precision of salbutamol intra-day and inter-day. 
    
 
 
 
 
 
 
5.2.3.5. Accuracy 
The accuracy of the method was determined by adding the analyte into blank 
matrices at different concentrations, then comparing the measured spiked 
concentration with the true concentration of salbutamol. Three different 
concentrations levels corresponding to low (30ng/ml), medium (120ng/ml) and high 
(250ng/ml) were used (n=5 for each level). The accuracy of the method ranged from 
97.78 to 99.74% (Table 5.7). 
 
Nominal  
concentration  
(ng/ml) 
Intra-day coefficient 
of variation (%) 
Inter-day coefficient 
of variation (%) 
30 0.2 1.8 
120 1.6 1.2 
250 0.9 0.7 
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 Table 5.7: Accuracy of salbutamol. 
 
5.2.3.6. Stability 
Reference solutions were stored in the refrigerator at +4
◦
C for 6 weeks and re-
analysed in an injection sequence employing freshly prepared standard solutions. 
The concentration after such storage conditions and on comparison with a freshly 
prepared standard was 99%. Longer storage periods may be possible but were not 
assessed in this study. 
5.2.3.7. Robustness 
As mentioned earlier, the robustness of an analytical method is a measure of its 
capacity to resist changes due to small variations in method conditions. The method 
robustness was assessed as a function of changing the Brij35, buffer concentration, 
1-butanole and pH. The changes ranged over ±5% of the target (experimental 
condition). The method system suitability criteria of a resolution grater than 2.0 
between the peaks were maintained.  
 
Actual       
concentration 
(ng/ml) 
Observed 
concentration  
(ng/ml) 
Accuracy % 
30 29.33 97.78 
120 119.69 99.74 
250 246.29 98.51 
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5.3. Simultaneous nanoemulsion high performance liquid chromatography   
(NELC) analysis of terbutaline and salbutamol in aqueous solution 
 
5.3.1. Introduction                                                                                                      
Salbutamol and terbutaline (short acting β2-agonists) are commonly used in the 
treatment of human asthma (see section 5.1.1 and 5.2.1). They are available in the 
form of dry powder inhalers (DPIs), metered dose inhalers (MDIs) and nebulizer. 
Salbutamol α1-[(tert-butylamino) methyl]-4-hydroxy-1,3-benzenedimethanol (see 
section 5.2.1) and terbutaline 1-(3,5-dihydroxyphynyl)-2-(tert-butylamino)-ethanol 
(see section 5.1.1) possess similar physiochemical properties and have very similar 
chemical structures. The only difference between them is the substituent’s on the 
phenyl ring: terbutaline has two hydroxyl groups on the phenyl ring while 
salbutamol has one hydroxyl group and an additional –CH2OH substituent on the 
phenyl ring. These hydroxyl groups on both salbutamol and terbutaline (Figure 5. 
25) increase their hydrophilicity (Yamini et al., 2006) and hence it is very difficult to 
separate these analytes by conventional isocratic HPLC. The objective of this current 
work is to demonstrate the ability of the microemulsion mobile phase to separate 
hydrophilic analytes with very similar chemical structures and similar 
physiochemical properties.  
 
  pKa1= 9.22 ± 0.47. pKa2= 9.83 ± 0.47.                               pKa1= 9.12 ± 0.1. pKa2= 9.33 ± 0.47. 
Figure 5.25: Structure of salbutamol and terbutaline and their pka (from Yamini et al., 2006). 
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5.3.2. Method development 
5.3.2.1. Effect of surfactant 
Different concentrations of Brij35 were investigated (see Figure 5.26). It was found 
that the retention time of salbutamol decreased with increases in the concentration of 
Brij35 from 0.5% to 1%. However, further increases in Brij35 concentration have a 
very small effect on the retention time of both terbutaline and salbutamol.  
 
 
Figure 5.26: Effect of Brij35 concentration on salbutamol and terbutaline. 
 
5.3.2.2. Effect of co-surfactant 
Different concentrations of co-surfactant were studied. Figure 5.27 shows the effect 
of changing the concentration of the co-surfactant butanol over the range 0.5-3.5% 
w/w. It was found that the retention time of both salbutamol and terbutaline 
decreased with increases in the concentration of butanol from 0.5-2.5% w/w. This is 
because butanol enhances the solubility of salbutamol and terbutaline in the 
microemulsion (see section 5.1.3.1.3). However, further increases in butanol 
concentration showed no marked effect on the retention time (Figure 5.27).   
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Figure 5.27: Effect of butanol concentration on the separation of salbutamol and terbutaline. 
 
5.3.2.3. Effect of buffer concentration 
The effect of phosphate buffer concentration on retention behaviour of both 
salbutamol and terbutaline was studied at different concentrations levels. Four 
mobile phases were prepared with different concentrations of phosphate buffer 5, 10, 
20 and 25mM. Figure 5.8 shows that the retention time of both salbutamol and 
terbutaline decreased as the buffer concentration increased. Similar results were 
demonstrated for the effect of buffer concentrations on terbutaline and bamethane 
retention time (see section 5.1.3.1.6).  
 
Figure 5.28: Effect of phosphate buffer concentration on the separation of salbutamol and terbutaline. 
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5.3.3. Method validation  
The developed method was validated according to ICH ( 1996) guidelines. In the 
method validation terbutaline was employed as internal standard. 
5.3.3.1. Specificity 
The method was shown to be selective for both salbutamol and terbutaline. Figure 
5.29 shows a typical separation of salbutamol (200ng/ml) and the internal standard 
terbutaline (200ng/ml), all dissolved in the mobile phase. The figure shows that 
salbutamol was eluted at 2.8 min. The analysis of mobile phase and blanks 
confirmed that there were no interfering peaks due to the blank. 
 
 
 
 
Figure 5.29: Chromatogram of salbutamol (200ng/ml) and the internal standard, terbutaline 
(200ng/ml) against the blank including I.S. 
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5.3.3.2. Linearity 
Seven different concentrations of salbutamol were prepared, ranging from 25 to 
500ng/ml
 
including the limit of quantification (LOQ) and covering the expected 
range. All solutions of salbutamol were prepared using the internal standard 
(terbutaline). The linearity of the calibration standards was evaluated over this range. 
The calibration samples were injected in duplicates and also blank samples were 
analysed along with the calibration standards. The detector response was shown to 
be linear over the covered range and gave a regression coefficient (r
2
) = 0.998 and y 
= 0.0029 X + 0.0215 (Figure 5.30). 
 
Figure 5.30: Linearity curve. 
 
5.3.3.3. Sensitivity 
The limit of detection (DL = 3.3s/m) was 8.51ng/ml and the limit of quantitation 
(QL = 10s/m) was 25.79ng/ml.  
5.3.3.4. Precision 
Precision was assessed by five determinations at known concentrations 
corresponding to low (25ng/ml), medium (200ng/ml) and high (500ng/ml) levels in 
the calibration range. The same study was repeated for 5 days to determine the inter-
day variation. The intra- and inter-day variations were determined by calculating the 
relative standard deviation. The intra-day variations (RSD %) and inter-day (RSD 
%) are shown in Table 5.8.  
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Table 5.8: Precision of salbutamol intra-day and inter-day. 
 
5.3.3.5. Accuracy 
The accuracy of the method was calculated by adding the analyte into blank matrices 
at different concentrations, then comparing the calculated spiked concentration with 
the true concentration of salbutamol. Three different concentrations levels 
corresponding to low (25ng/ml), medium (200ng/ml) and high (500ng/ml) were used 
(n=5 for each level). The accuracy of the method ranged from 99.82 to 101.6% 
(Table 5.9). 
 
Table 5.9: Accuracy of salbutamol. 
 
5.3.3.6. Stability 
Reference solutions were stored at room temperature for 24 hours and in a 
refrigerator at 2-8 ˚C for two weeks and re-analysed in a comparison with a freshly 
prepared standard (Table 5.10).  
 
 
Nominal concentration  
(ng/ml) 
Intra-day coefficient 
of variation (%) 
Inter-day coefficient of 
variation (%) 
25 0.73 1.60 
200 0.41 0.34 
500 0.62 0.56 
Actual   
concentration 
(ng/ml) 
Observed 
concentration 
 (ng/ml) 
Accuracy % 
25 24.96 100.44 
200 203.20 101.60 
500 499.34 99.82 
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Table 5.10: Stability of salbutamol. 
 
Actual salbutamol 
concentration (ng/ml) 
Stored at room 
temperature for 24hr 
Stored in refrigerator at  
2-8 ˚C for 15 days 
Recovery % Recovery % 
Low = 25 98.8 98.21 
Medium = 200 99.7 99.04 
High = 500 100.23 99.37 
 
5.3.3.7. Robustness 
As explained earlier, the robustness of an analytical method is a measure of its 
capacity to resist changes due to small variations in method conditions. The method 
robustness was assessed as a function of changing the Brij35, buffer concentration, 
1-butanole and pH; the changes ranged over ±5% of the target (experimental 
condition). The method system suitability criteria of a good resolution between the 
peaks were maintained.  
 
5.3.4. Application of the assay method for assessing the dose content 
uniformity of salbutamol in dosage form Easyhaler
®
                                    
   
In vitro measurement of the total emitted dose is one of the quality control 
procedures used to assess inhaled products and demonstrate the accuracy and 
consistency of dose delivery (see section 5.1.5). The method was used to measure 
the dose emission uniformity of salbutamol form Easyhaler
® 
(200µg) using Dose 
Sampling Apparatus described in USP 2005 (see Figure 5.14). 
 
The emitted dose uniformity was assessed by collecting ten individual doses. Dose 
numbers 2, 3, 4, 99, 100, 101, 196, 197, 198 and 199 of the entire dose available 
(200 doses) were collected from the Easyhaler at a pressure drop of 4kPa across the 
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inhaler which gives a flow rate of 43L/min. The flow duration was 4.5s; this was to 
allow a volume of 4 L to be drawn through the inhaler (Table 5.11). Each dose was 
collected and then transferred to a 25ml volumetric flask (for details of the 
procedure see section 5.1.5.1). The mean for the dose emission was 76.56% with 
RSD 11.43. The high value of RSD shows that Easyhaler has high inter-dose 
emission variability.  
 
 
Table 5.11: Dose emission of Easyhaler salbutamol sulphate 200µg at inhalation rate of 43 L /minute. 
 
Dose no. 
%  Label 
      dose 
2 66.2 
3 78.1 
4 83.9 
99 83.2 
100 90.6 
101 73.9 
196 74.1 
197 75.2 
198 60.6 
199 80.0 
Mean 76.56 
SD 8.75 
RSD 11.43 
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5.4. Nanoemulsion high performance liquid chromatography (NELC) 
for determination of terbutaline in urine samples 
 
5.4.1. Introduction 
Analysis of hydrophilic compounds in urine samples by reversed-phase HPLC can 
be very difficult and challenging because of the presence of proteins, acidic and 
basic compounds, and other organic compounds that have a similar chemistry to the 
analyte of interest. Also, the presence of silanol groups on the surface of the column 
can affect the peak shape and hence reduce resolution between the analyte and urine 
matrix components. 
 
Sample preparation can be useful for the isolation of the compound of interest from 
urine matrix components such as proteins and from some other small molecules. On 
the other hand it may be difficult to extract the analyte from those organic 
compounds that have similar chemical properties to the analyte of interest, as this 
can reduce the total recovery of the analyte. The most commonly used sample 
preparation techniques include liquid-liquid extraction and solid-phase extraction 
(SPE). Solid-phase extraction was chosen because in liquid-liquid extraction the 
total recovery of the analyte of interest is usually low and results in an increased 
volume of solvent waste (Fritz, 1999). Also the concentration of the analyte using 
SPE is often superior (Fritz, 1999). In SPE the solutes are extracted from the sample 
matrix onto a pre-conditioned solid phase extraction column contained within a 
disposable cartridge.  
 
Polettini et al. (1995) have reported a coupled-column liquid chromatography for the 
analysis of β-agonists (terbutaline) in urine by a direct sample injection method. In 
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this method a reversed-phase column was used to concentrate the analyte. After that 
the analyte is automatically back-washed from the concentration column onto a 
second reversed-phase column where final separation of β-agonists from urine 
constituents occurs. When automated by computer control this method is simple to 
perform and manual pre-treatment of urine samples is not necessary. However, the 
direct injection of urine, a large injection volume, a very high flow-rate and length of 
the columns used will cause a very high operating backpressure and short column 
life. 
 
Several methods were reported for the analysis of terbutaline in urine samples using 
SPE and conventional HPLC. However, the main drawback of this reported method 
is the lengthy analysis run-time. The main objective of the current work was to apply 
NELC for the analysis of terbutaline in urine samples and explore the potential of 
NELC to separate terbutaline from urine matrix components. 
5.4.2. Experimental method 
5.4.2.1. Solid Phase Extraction (SPE)  
Recently, Mazhara and Chrystyn (2009) reported a reversed-phase HPLC assay for 
salbutamol in the urine, where terbutaline was used as the internal standard. A solid-
phase extraction method using an Oasis Hydrophilic-Lipophilic-Balance (HLB) 
cartridge (Sorbent Technology, UK) was used to extract salbutamol and an internal 
standard from urine. This method was developed and validated for the extraction of 
terbutaline, salbutamol and bamethane by Mazhara and Chrystyn (2009). A 
pretreated sample is prepared by adding 1ml of an aqueous solution of 600μg/l (w/v) 
bamethane to 1ml of urine as an internal standard. This was adjusted (if necessary) 
to pH 6.5-7.2 and mixed well for 30 seconds. Each Oasis HLB cartridge was 
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conditioned with 2ml methanol followed by 2ml of 45mM potassium dihydrogen 
phosphate (pH 7). The pretreated sample was then applied to the cartridges followed 
by the addition of 2ml of 15mM potassium dihydrogen phosphate (pH 7) continued 
by full vacuum drying for 2 min. The cartridge was then washed with 1ml of 
MeOH:H2O (05:95) followed by full vacuum drying for 1 min, then 1ml of 
ACN:H2O (02:98) continued by full vacuum drying for 1 min, then 1ml of THF:H2O 
(0.25:99.75) followed full vacuum drying for 2 min. The analyte was then eluted 
from the cartridge into a sample tube using 2ml of CH3COOH:H2O (02:98) at low 
vacuum (less than 3 bar) for 2-3 min when all was eluted. After evaporation to 
dryness using a nitrogen stream at 120
O
C for 35 min, the residue was reconstituted 
in 1ml mobile phase and 100μml was injected into the HPLC system.  
5.4.2.2. General method for preparation of buffer 
2.72g of potassium dihydrogen orthophosphate was dissolved into 1 litre of Milli-Q 
water to get a concentration of 20mM. The pH of this solution was adjusted with 
ortho phosphoric acid and checked with a pH meter (pH 3). 
5.4.2.3. Preparation of mobile phase   
The standard nanoemulsion system was prepared by weighing 1.5g Brij35, 0.5g 
ethyl acetate, 2.5g butanol, 1.1g octane sulfonic acid (OSA) and 94.4g of phosphate 
buffer 20mM to a 100ml flask. This mixture was sonicated for 15 minutes to 
complete dissolution. The solution was an optically transparent nanoemulsion, 
which was stable for several months.  
5.4.2.4. Standard terbutaline urine solutions 
A stock solution containing 50mg/L of terbutaline was prepared using an internal 
standard (bamethane). The internal standard was prepared beforehand at a 
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concentration of 400µg/L in blank urine. The urine blank was collected from six 
different human sources, including male and female subjects. Calibration standards 
of terbutaline in the concentration range 60–1000ng/ml were prepared using internal 
standard urine solutions.  
5.4.3. Method development 
5.4.3.1. The concentration of the surfactant 
 
A blank urine sample from human subjects was extracted (see section 5.4.2.1) and 
afterwards was spiked with terbutaline and bamethane. The effect of Brij35 was then 
examined using the range 1–2% w/w and it was found that it has a small effect on 
retention time and on separation resolution (Table 5.12). The nanoemulsion 
consisted of: Brij35 1-2%, ethyl acetate 0.5%, butanol 0.75%, phosphate 95.5% 
pH3. 
Table 5.12: Effect of Brij35 concentration on retention time of terbutaline and bamethane.  
 
Brij35 (% w/w) Terbutaline Bamethane 
0.5 4.2 6 
1 4.3 5.1 
1.5 4.3 5.1 
2 3.9 4.9 
 
5.4.3.2. The concentration of the co-surfactant 
As mentioned before (see section 5.1.3.1.3), co-surfactants are usually used to assist 
the formation of the microemulsion and this is considered an important factor in 
stabilizing the microemulsion system. The effect of co-surfactant on the retention 
behaviour of spiked urine samples with terbutaline and bamethane was studied. It 
was found that retention time of both terbutaline and bamethane decreased on 
increasing the concentration of the co-surfactant (Table 5.13). Similar results were 
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found for effect of co-surfactant on retention of terbutaline and bamethane in 
aqueous samples (see section 5.1.3.1.3).   
Table 5.13: Effect of co-surfactant concentration on retention time profile of terbutaline and 
bamethane. 
 
Butanol (% w/w) Terbutaline Bamethane 
0.5 6.7 8.2 
1.5 5.2 7.1 
2.5 4.3 5.1 
3.5 4.3 5.1 
 
5.4.3.3. Effect of Oil 
The effect of oil (ethyl acetate) concentrations on the separation of terbutaline spiked 
urine samples containing internal standard was examined. It was found that 
increasing the oil concentration had no marked effect on the retention time of either 
terbutaline or bamethane (Table 5.14). The nanoemulsion mobile phase consisted of: 
SDS 1.6%, Brij35 1.6%, octane 1.25%, butanol 8%, phosphate pH 3 87.5%. 
Table 5.14:  Effect of oil on the solute retention time of terbutaline and bamethane. 
Ethyl acetate 
(% w/w)  
Terbutaline Bamethane 
0.5 4.3 5.1 
0.75 4.3 5.0 
1 4.1 4.9 
 
5.4.3.4. Effect of ion pair 
The effect of the addition of different types of ion pair on separation selectivity was 
examined using heptane sulfonic acid (HSA) and octane sulfonic acid (OSA).  Table 
5.15 shows the concentration of the examined ion pairs that managed to give the best 
separation of both terbutaline and bamethane from the urine matrix. It was found 
that OSA has a more significant effect both on retention time and separation 
resolution as compared to HSA. The optimum nanoemulsion was found to be 1.5% 
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Brij35, 0.5% ethyl acetate, 2.5% butanol, 1.1% OSA in 0.02M phosphate buffer pH 
3. This mobile phase gave a separation of the terbutaline and the internal standard 
(bamethane) from the urine matrix in a reasonable analysis time (less than 15 min). 
Table 5.15:  Effect of addition of different types of ion pair on solute retention. 
 
Factors Terbutaline Bamethane 
HSA (ion pair) 4 % 7.0 9.0 
OSA (ion pair) 1% 9.8 13.6 
5.4.4. Method validation  
The method was validated to determine the terbutaline in the urine samples, ethical 
approval was obtained from the University of Bradford. and the validation procedure 
was based on ICH (1995) guidelines for bioanalytical methods in human studies.  
  5.4.4.1. Specificity 
Specificity is the ability of the method to quantify the analyte in the existence of 
other components in the urine matrix. The blank urine samples collected from six (3 
females, 3 males) volunteers were individually spiked with terbutaline. Both the 
blank and spiked urine samples were extracted by HLB-SPE (see section 5.4.2.1) 
from the urine matrix and then assayed by HPLC. 
The NELC mobile phase was compared with other conventional mobile phases, i.e. 
methanol:OSA:phoshate buffer [20:1.1:78.9] in urine and micellar which consists of  
[brij35,1.5%:butanol 2.5%:OSA 1.1%:buffer 94.9%] in urine (Figure 5.33). The 
specificity of the method (NELC) shows that there were no interferences from 
components of endogenous material. Peaks of terbutaline and internal standard were 
well resolved and were separated from the urine components.  On the other hand, the 
conventional mobile phase and micellar failed to separate terbutaline and bamethane 
from urine matrix components (Figure 5.31 and Figure 5.32).  
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Figure 5.31: Chromatogram obtained from blank urine after the extraction. Nanoemulsion consists of: 
Brij35 1.5%, ethyl acetate 0.5%, butanol 2.5%, OSA 1.1%, phosphate pH3 94.4%, at 
25C˚, 1.0 ml/min flow rate and C18 column ODS1. 
  
 
 
Figure 5.32: Chromatogram obtained from terbutaline spiked urine (400ng/ml) after the extraction. 
Nanoemulsion consists of: Brij35 1.5%, ethyl acetate 0.5%, butanol 2.5%, OSA 1.1%, 
phosphate pH3 94.4%, at 25C˚, 1.0 ml/min flow rate and C18 column ODS1. 
. 
 
Figure 5.33: Comparison of NELC with other mobile phase i.e. A) methanol:OSA:phosphate buffer  
[20:1.1:78.9] in urine. B) Micellar [Brij35 1.5%:butanol 2.5%:OSA 1.1%:buffer  
94.9%] in urine. 
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5.4.4.2. Linearity       
Twenty microlitre aliquots of a calibration solution of terbutaline were injected (in 
duplicate). The calibration curve was constructed by plotting the peak height ratios 
against the final concentrations of the drug (ng/ml). Different concentrations ranging 
from 60 to 1000ng/ml including the lower limit of quantification (LOQ) and 
covering the predicted range were prepared in a urine matrix. Terbutaline was 
extracted with HLB-SPE (see section 5.4.2.1). Blank samples were also analyzed 
along with the calibration standards. The extracted terbutaline samples including 
internal standard were injected in duplicates. The calibration curve (Figure 5.34) 
showed a linear response and gave a regression coefficient (r
2
) of 0.9981 (y = 
0.0088x + 0.2358). 
 
 
Figure 5.34: Calibration curve of terbutaline spiked urine. 
 
5.4.4.3. Sensitivity 
As stated before, sensitivity is expressed as the limit of quantitation (LOQ), a peak 
height to baseline ratio of 10:1, and as the limit of detection (LOD), a peak height to 
base line ratio of 3:1. The LOQ is accepted if the analyte peak response is 
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identifiable and reproducible with a precision of 20% and an accuracy of 80-120% 
(ICH 1995). The LOD and LOQ of the method for terbutaline spiked urine samples 
were calculated from the mean of the intercept of five urine calibration curves. The 
LOD and LOQ were 20.21 and 61.24ng/ml respectively. Terbutaline in urine at a 
concentration of 60ng/ml was extracted then injected on five separate days to 
determine the precision of the terbutaline peak 
5.4.4.4. Precision  
The precision was examined by five determinations at known concentrations 
corresponding to low (200ng/ml), medium (600ng/ml) and high (1000ng/ml) levels 
in the calibration range. This study was repeated for five days to determine the inter-
day variation. Inter-day assay CVs ranged from 2.87% to 4.28% at concentrations 
ranging from 200 to 1000ng/ml (Table 5.16).                 
 
Table 5.16: Intra-day and inter-day precision for terbutaline urine extraction method. 
 
Nominal  concentration  
(ng/ml) 
Intra-day coefficient of 
variation (%) 
Inter-day coefficient of 
variation (%) 
200 4.21 2.89 
600 3.56 4.28 
1000 5.13 2.87 
 
5.4.4.5. Recovery and accuracy  
The recovery was calculated by comparing the detector response of the extracted 
terbutaline urine standard at three concentrations levels: low (200ng/ml), medium 
(600ng/ml) and high (1000ng/ml), with the detector response of the terbutaline 
standards spiked in the extracted blank urine matrix. The measurements were 
performed using five determinations per concentration. Recovery was determined by 
comparing the peak height of the extracted terbutaline urine standard with the peak 
height of the terbutaline standard externally spiked with the extracted blank urine 
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matrix. The method showed excellent and consistent recoveries, and the mean 
recoveries for the studied concentrations ranged from 87.64 to 94.02 (Table 5.17).  
 
The accuracy of the method was assessed by replicate analysis (n=5) of the extracted 
terbutaline urine standards at known concentrations that included low (200ng/ml), 
medium (600ng/ml) and high (1000ng/ml), and then compared with the true 
concentration of terbutaline. The accuracy was assessed by comparing the calculated 
concentration of the extracted terbutaline urine standard with the true concentration 
of terbutaline. The accuracy of the bioanalytical method was greater than 99.4% 
(Table 5.17). 
 
Table 5.17: Recovery and accuracy data for terbutaline spiked urine samples. 
 
Actual 
concentration 
(ng/ml) 
Observed 
concentration (ng/ml) 
 
Recovery % 
 
Accuracy % 
 
200 201.7 94.02 100.8 
600 596.4 87.64 99.4 
1000 996.1 92.20 99.6 
 
5.4.4.6. Stability 
Stability studies should evaluate situations likely to be encountered during the 
sample processing, from collection to final analysis. The stability of the urine 
standards was evaluated by assaying the analyte during sample collection, handling, 
after short-term storage and after going through freeze-and-thaw cycles. The 
stability of terbutaline in the urine matrix was examined by repeated injections (n=3) 
of the terbutaline urine samples that were stored at different temperatures, and by 
comparing them with a freshly prepared standard. 
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A short-term stability test performed at room temperature showed that the samples 
were stable for 24 hr, and the mean recoveries were higher than 88.53. Similarly, the 
long term stability study showed that terbutaline urine samples were stable for 1 
month when stored at -20°C, with an average recovery >92.71%. No decrease in 
terbutaline concentration in urine was detected after exposing samples to three 
freeze/thaw cycles, and mean recovery ranged from 90.23 to 98.62% (Table 5.18). 
 
Table 5.18:  Stability data of terbutaline spiked urine method. 
 
Actual 
terbutaline 
concentration 
(ng/ml) 
Stored at room 
temperature 
for 24hr 
Stored at -20°C 
for 1 month 
Three freeze/thaw 
cycle 
RSD  
% 
Recovery % 
RSD
% 
Recovery% 
RSD 
% 
Recovery% 
200 3.49 96.57 4.83 92.71 3.97 91.4 
600 4.35 88.53 6.74 94.75 2.63 90.23 
1000 2.99 100.49 1.83 99.16 1.16 98.62 
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5.5. Validation of salbutamol in urine using bamethane as I.S. in existence 
of terbutaline 
5.5.1. Introduction  
Salbutamol and terbutaline are widely prescribed β2-agonists drugs in the treatment 
of asthma (see sections 5.1.1 and 5.2.1). Several methods have been reported for the 
determination of terbutaline or salbutamol in urine matrix. However, these methods 
have been developed specifically for the determination either of salbutamol or 
terbutaline but not both simultaneously (Mazhara and Chrystyn, 2009). 
 
Terbutaline has a similar chemical structure and possesses very similar 
physicochemical properties to salbutamol (see section 5.3.1). Occasionally when 
assessing and comparing an inhalation delivery system of salbutamol with patients, 
if those patients are taking terbutaline medication, it is necessary to have a method 
that can separate salbutamol from terbutaline in patient urine samples. 
 
Recently Mazhara and Chrystyn (2009) have reported a conventional HPLC method 
for the determination of salbutamol using terbutaline as internal standard, and in 
another study (an unpublished PhD) bamethane was used as an internal standard due 
to co-administration of terbutaline with salbutamol study doses. However, the 
method was very sensitive to variations in mobile phase components and it was 
indicated that any slight variation in the mobile phase constituents can cause 
significant changes to the peak width and retention time. This may be due to the 
complex nature of mobile phase ingredients interacting very differently with 
analytes. The mobile phase was 10:8:14:68% (v/v) acetonitrile: 
tetrahydrofuran:methanol:buffer. The buffer was 5mM KH2PO4 adjusted to pH 2.5 
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(with H3PO4) that contained 25mM of the ion-pairing agent SDS. In addition, the 
analysis time was relatively long (about 30min) (Mazhara & Chrystyn, 2009). 
 
The aim of the present study is to use NELC to develop a much simpler and more 
reliable method with a shorter run time compared with the conventional HPLC 
method for the simultaneous determination of salbutamol and terbutaline in urine 
samples. The other aim was to exercise the potential of the nanoemulsion mobile 
phase for analysis of complex samples (i.e. analytes that have very similar chemical 
structures, like salbutamol and terbutaline in a urine matrix) (Mazhar and Chrystyn, 
2009).  
5.5.2. Method development  
5.5.2.1. Buffer concentration 
The effect of phosphate buffer concentration on retention behaviour of salbutamol, 
terbutaline and bamethane was studied at different concentrations levels. Four 
mobile phases were prepared with different concentrations of phosphate buffer 5, 10, 
20 and 25mM. Figure 5.35 shows that the retention time of salbutamol, terbutaline 
and the internal standard decreased as the buffer concentration increased. These 
results are in accordance with the findings reported by Mao et al. (2001).  
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Figure 5.35: Effect of buffer concentration before addition of ion-pair. 
 
5.5.2.2. Effect of ion pair 
   
The selectivity of the method for separation of terbutaline, salbutamol and 
bamethane in a urine matrix was assessed with respect to ion pair addition. Different 
concentrations of OSA were added to the nanoemulsion mobile phase and their 
effect on the separation was monitored. It was found that 2% of OSA gave the best 
separation (Table 5.19 and Figure 5.37). The nanoemulsion consisted of: Brij35 
1.6%, ethyl acetate 0.5%, butanol 2.5%, OSA 2%, phosphate pH3 93.4%.   
Table 5.19: Effect of ion pair addition on solute retention.  
 
Factors  (ion pair)   
Salbutamol 
400ng/ml 
Terbutaline 
500ng/ml 
Bamethane 
500ng/ml 
OSA     1% 5.9 9.8 13.6 
OSA     1.5% 7.5 13.8 18.1 
OSA     2% 8.96 17.4 21.51 
 
5.5.3. Method validation  
 
  5.5.3.1. Specificity 
The specificity of the method was examined to ensure that there was no interference 
from components of endogenous material. Peaks of salbutamol, terbutaline and 
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internal standard were well resolved and were separated from the urine components 
(Figure 5.36 and Figure 5.37). 
 
 
Figure 5.36: Chromatogram obtained from blank urine after the extraction. Nanoemulsion consists of: 
Brij35 1.6%, ethyl acetate 0.5%, butanol 2.5%, OSA 2%, phosphate (pH3) 93.4%, at 
25C˚, 1.0 ml/min flow rate and C18 column ODS1. 
  
 
 
Figure 5.37: Chromatogram obtained from salbutamol spiked urine (800ng/ml) after the extraction. 
Nanoemulsion consists of: Brij35 1.6%, ethyl acetate 0.5%, butanol 2.5%, OSA 2%, 
phosphate (pH3) 93.4%, at 25˚C, 1.0ml/min flow rate and C18 column ODS1. 
Terbutaline (500ng/ml), Bamethane (200ng/ml).  
 
5.5.3.2. Linearity       
Different concentrations were prepared ranging from 100 to 1000ng/ml including the 
lower limit of quantification (LOQ) and covering the predicted range. The standards 
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were prepared in a urine matrix and then salbutamol was extracted with HLB SPE. 
Blank samples were also analyzed along with the calibration standards. The linearity 
of the calibration standards was evaluated over the range 100 to 1000ng/ml. The 
extracted salbutamol samples including internal standard (see section 5.4.2.1) were 
injected in duplicates. The calibration curve (Figure 5.38) showed a linear response 
and gave a regression coefficient (r
2
) of 0.9988 (y = 0.0025x + 0.0435). 
 
 
Figure 5.38: Calibration curve of salbutamol spiked urine. 
 
 
5.5.3.3. Sensitivity 
The LOD and LOQ of the method for salbutamol spiked urine samples were 
calculated from the mean of the intercept of five urine calibration curves. The LOD 
and LOQ were 34.33 and 104.03ng/ml respectively. 
5.5.3.4. Precision  
Precision was examined by five determinations at known concentrations 
corresponding to low (100ng/ml), medium (600ng/ml) and high (1000ng/ml) levels 
in the calibration range. This study was repeated for five days to determine the inter-
day variation. Inter-day assay RSD values ranged from 1.81% to 6.88% at 
concentrations ranging from 100 to 1000ng/ml (Table 5.20).        
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Table 5.20: Intra and inter-day precision for salbutamol urine extraction. 
  
Nominal  
concentration  
(ng/ml) 
Intra-day 
coefficient of 
variation (%) 
Inter-day 
coefficient of 
variation (%) 
100 8.7 6.88 
400 4.8 3.34 
1000 6.5 1.81 
 
5.5.3.5. Recovery and accuracy  
The recovery was studied by comparing the detector response of the extracted 
salbutamol urine standard at three concentrations levels: low (100ng/ml), medium 
(400ng/ml) and high (1000ng/ml), with the detector response of the salbutamol 
standards spiked in the extracted blank urine matrix. The measurements were 
performed using five determinations per concentration. Recovery was determined by 
comparing the peak height of the extracted salbutamol urine standard with the peak 
height of the salbutamol standard externally spiked with extracted blank urine 
matrix. The method showed excellent and consistent recoveries, and the mean 
recoveries for the studied concentrations ranged from 84.5 to 95.40 (Table 5.21).  
The accuracy of the method was assessed by replicate analysis (n=5) of the extracted 
salbutamol urine standards at known concentrations that included low (100ng/ml), 
medium (400ng/ml) and high (1000ng/ml), and by comparing them with the true 
concentration of salbutamol. The accuracy of the bioanalytical method was greater 
than 98.06% (Table 5.21). 
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Table 5.21: Recovery and accuracy data for salbutamol spiked urine method. 
 
Actual 
concentration 
(ng/ml) 
Observed 
concentration 
(ng/ml) 
 
Recovery % 
 
Accuracy % 
 
100 102.79 84.5 102.79 
400 392.25 95.8 98.06 
1000 1022.6 90.42 100.26 
5.5.3.6. Stability 
The short-term stability of salbutamol in the urine matrix assessed at room 
temperature confirmed that the samples were stable for 24 hr, and the mean 
recoveries were higher than 86.2%. Similarly, the long term stability study showed 
that salbutamol urine samples were stable for 1 month when stored at -20°C, with an 
average recovery >91.8%. No decrease in salbutamol concentration in urine was 
detected after exposing samples to three freeze/thaw cycles, and mean recovery 
ranged from 88.32 to 96.49% (Table 5.22). 
 
Table 5.22:  Stability data of salbutamol spiked urine method 
 
Actual 
salbutamol 
concentration 
(ng/ml) 
Stored at room 
temperature 
for 24hr 
Stored at -20°C 
for 1 month 
Three freeze/thaw 
cycle 
Recovery % Recovery % Recovery % 
100 94.31 91.80 88.32 
400 86.20 93.57 89.67 
1000 98.13 97.78 96.49 
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5.6. Validation of terbutaline in urine using bamethane as I.S. in existence 
of salbutamol 
      
5.6.1. Specificity 
As mentioned earlier, specificity is the capability of the method to quantify the 
analyte in the proportion of other components in the urine matrix. The blank urine 
samples collected from six (3 females, 3 males) volunteers were individually spiked 
with terbutaline and salbutamol. Ethical approval was obtained from the University 
of Bradford.  Both the blank and spiked urine samples were assayed by HPLC. The 
specificity of the method was examined to ensure that there was no interference 
from components of endogenous material and salbutamol. Peaks of terbutaline, 
salbutamol and internal standard were well resolved from the urine components 
(Figure 5.39 and Figure 5.40). 
 
 
 
Figure 5.39: Chromatogram from obtained blank urine after the extraction. Nanoemulsion consists of: 
Brij35 1.5%, ethyl acetate 0.5%, butanol 2.5%, OSA 2%, phosphate (pH3) 93.4%, at 
25C˚, 1.0 ml/min flow rate and C18 column ODS1. 
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Figure 5.40: Chromatogram obtained from terbutaline spiked urine (400ng/ml) after the extraction. 
Nanoemulsion consists of: Brij35 1.5%, ethyl acetate 0.5%, butanol 2.5%, OSA 2%, 
phosphate pH3 93.4%, at 25C˚, 1.0 ml/min flow rate and C18 column 
ODS1.Salbutamol (600ng/ml), Bamethane (200ng/ml). 
 
5.6.2. Linearity       
The linearity of the calibration standards was evaluated over the range 100 to 
1000ng/ml. The extracted terbutaline samples were injected in duplicates. The 
calibration curve (Figure 5.41) showed a linear response and gave a regression 
coefficient (r
2
) of 0.9979 (y = 0.0016x + 0.0531). 
 
Figure 5.41: Calibration curve of terbutaline spiked urine. 
 
5.6.3. Sensitivity 
The LOD and LOQ of the method for terbutaline spiked urine samples were 
calculated from the mean of the intercept of five urine calibration curves. The LOD 
and LOQ were 28.71 and 87.02ng/ml respectively. 
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5.6.4. Precision  
The precision was examined by five determinations at known concentrations 
corresponding to low (150ng/ml), medium (600ng/ml) and high (1500ng/ml) levels 
in the calibration range. This study was repeated for five days to determine the inter-
day variation. Inter-day assay RSD ranged from 2.23% to 7.93% at concentrations 
ranging from 150 to 1500ng/ml (Table 5.23).     
 
Table 5.23: Inter-day and intra-day precision for terbutaline urine samples. 
 
Nominal  
concentration  
(ng/ml) 
Intra-day 
coefficient of 
variation (%) 
Inter-day  
coefficient of 
variation (%) 
150 9.12 7.93 
600 8.24 5.82 
1500 6.26 2.23 
 
5.6.5. Recovery and accuracy  
Recovery was determined by comparing the peak height of the extracted terbutaline 
urine standard with the peak height of the terbutaline standard externally spiked with 
extracted blank urine matrix. The method showed excellent and consistent 
recoveries, and the mean recoveries for the studied concentrations ranged from 
87.27 to 94.06 (Table 5.24).  
 
The accuracy of the method was assessed by replicate analysis (n=5) of the extracted 
terbutaline urine standards at known concentrations that included low (150ng/ml), 
medium (600ng/ml) and high (1500ng/ml), and by comparing them with the true 
concentration of terbutaline. The accuracy of the NELC bioanalytical method was 
greater than 97.35% (Table 5.24). 
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Table 5.24: Recovery and accuracy data for terbutaline spiked urine samples. 
 
Actual 
concentration 
(ng/ml) 
Observed 
concentration  
(ng/ml) 
 
Recovery % 
 
Accuracy % 
 
150 156.56 87.27 104.37 
600 587.19 94.06 97.86 
1500 1460.31 87.82 97.35 
 
5.6.6. Stability 
The short-term stability test of terbutaline in the biological fluid performed at room 
temperature showed that the samples were stable for 24 hr, and the mean recoveries 
were higher than 87.4%. Similarly, the long term stability study showed that 
terbutaline urine samples were stable for 1 month when stored at -20°C, with an 
average recovery >92.6%. No decrease in terbutaline concentration in urine was 
detected after exposing samples to three freeze/thaw cycles, and mean recovery 
ranged from 89.4 to 97.6% (Table 5.25). 
 
Table 5.25:  Stability data of terbutaline spiked urine method. 
 
Actual 
terbutaline 
concentration 
(ng/ml) 
Stored at room 
temperature 
for 24hr 
Stored at -20°C 
for 1 month 
Three freeze/thaw 
cycle 
Recovery % Recovery% Recovery% 
150 93.7 90.8 89.4 
600 87.4 92.6 90.7 
1500 97.9 98.8 97.6 
 
 
5.7. Clinical volunteer studies 
In vivo pharmacokinetic methods (using plasma or urine samples) can be used to 
assess relative lung deposition for drugs. The difficulty with the use of plasma  
pharmacokinetics is that plasma or serum drug concentrations are low because the  
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inhaled doses are small and the volume of distribution is large, especially for polar 
and basic (β-agonist) drugs which have a high renal clearance. The urinary 
pharmacokinetic had been introduced to overcome the problem associated with low 
plasma concentrations (Chrystyn, 1994a). Drugs which are excreted in the urine are 
found in more concentrated levels in the urine than in the serum. This means that the 
absorption of relatively low doses of inhaled drug may be detected. The analysis of 
urine specimens has been successfully employed in the determination of the relative 
lung bioavailability of salbutamol to lungs following inhalation (Hindle and 
Chrystyn, 1992). 
 
After the NELC method was developed and validated for spiked urine samples of 
terbutaline, it was applied clinically for the determination of terbutaline in urine 
samples of healthy volunteers following Bricanyl® Turbohaler (dose 500µg per 
actuation). Ethical approval was obtained from the University of Bradford. One dose 
was inhaled per study. The volunteers were given urine collection containers and 
asked to collect and pour their urine into the container. Each volunteer provided a 
urine sample 15 minutes before the administration of the dose (a blank) and charcool 
and then at 24 hours following the dose. Their urine samples were collected at 24 
hours post-inhalation on each study day and the volume of each urine sample was 
recorded. Samples were then extracted by the established methods (see section 
5.4.2.1). The prepared samples were injected onto the chromatographic system 
connected to a fluorescence detector, and the excitation and emission wavelengths 
were 267 and 313nm respectively. The results achieved from this method (Figure 
5.43) indicated that in spite of the presence of a large number of interfering peaks 
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the NELC method gives a good and baseline separation of terbutaline peak from any 
endogenous interfering peak.  
 
Figure 5.42: Chromatogram obtained from blank urine after the extraction. Nanoemulsion consists of: 
Brij35 1.5%, ethyl acetate 0.5%, butanol 2.5%, OSA 2%, phosphate pH3 93.4%. 
 
 
 
Figure 5.43: Chromatogram obtained from terbutaline in urine after 24 hours post-inhalation 
Bricanyl
®
 Turbohaler (500µg). Nanoemulsion consists of: Brij35 1.5%, ethyl acetate 
0.5%, butanol 2.5%, OSA 2%, phosphate pH3 93.4%. 
  
In conclusion, the urinary pharmacokinetic method can be successfully employed 
using the NELC method in the determination of the relative lung bioavailability of 
terbutaline. The cumulative amounts of terbutaline excreted in the urine over the 24 
hrs reflect the lung bioavailability. 
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Conclusion 
This study has shown that nanoemulsion can be used as a mobile phase for the 
analysis of hydrophilic drugs in their pharmaceutical preparation and in urine 
samples. Oil-in-water nanoemulsion was applied as a mobile phase and the method 
was successfully developed and validated for the determination of terbutaline and 
salbutamol in aerosol formulations. The separation was highly robust to a wide 
range of changes in temperature. Furthermore, this method is precise, rapid, reliable 
and accurate.   
It was a challenge to separate salbutamol and terbutaline both in aqueous solution 
and in urine samples because they have very similar chemical structures. In 
conventional mobile phase, either partially or fully overlapping peaks of terbutaline 
and salbutamol were observed (Figure 5.33). However, the NELC mobile phase 
nicely separated salbutamol and terbutaline with a very short analysis time (Figure 
5.32). Also, the NELC method was successfully validated for individual and 
simultaneous determination of salbutamol and terbutaline in urine samples. 
Moreover, the NELC method that has been developed and validated for 
simultaneous determination of terbutaline and salbutamol is much simpler and more 
robust, and offered a much faster run time (Rt = 9 min and 17.7 min for salbutamol 
and terbutaline respectively) compared to the previously reported conventional 
HPLC method which has a complicated mobile phase, is less robust, and has a 
longer analysis run time (Rt = 24min and 27min for salbutamol and terbutaline 
respectively). The ability of NELC to separate compounds that are moderately and 
highly lipophilic is explored in Chapter 6 (formoterol) and chapter 7 (salmeterol and  
fluticasone propionate). 
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Chapter 6 
Development and validation of nanoemulsion liquid 
chromatography (NELC) for determination of formoterol in 
aqueous and urine specimens  
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6. Development and validation of nanoemulsion liquid 
chromatography (NELC) for determination of formoterol in 
aqueous and urine specimens 
6.1. Formoterol  
Formoterol is a long-acting β2 -agonist, with an extended duration of action (up to 12 
hrs) compared to short-acting β2 -agonists such as salbutamol, which are effective 
for 4–6 hrs. It is used in the treatment of asthma and COPD. Formoterol is used as a 
“symptom controller” to supplement prophylactic corticosteroid therapy.  
The pharmacologic effects 
The pharmacologic effect of formoterol as a B2 -adrenoceptor agonist drug is the 
stimulation of the enzyme intracellular adenyl cyclase, which catalyzes the 
conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine 
monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of 
bronchial smooth muscle and inhibition of the release of mediators of immediate 
hypersensitivity from cells, especially from mast cells (DeBellis and Ronald, 2005). 
In vitro trials illustrate that formoterol is an inhibitor of the release of mast cell 
mediators, for instance leukotrienes and histamine, from the lung.  
Pharmacokinetics  
The peak response of formoterol is 1-3 hours after inhalation and the initial response 
is after 1-3 minutes, while after oral administration the peak response is after 20 
minutes  (Product_Information, 2004).  It has a duration of 8-12 hrs for a single 
inhaled dose and  5-8 hours for an oral dose (RK, 2005c). Formoterol is extensively 
metabolised in the liver (Brunton et al., 2006). The percentage of renal excretion is 
60%, and 16%-28% of a dose is excreted as the unchanged drug (RK, 2005c). Its 
elimination half-life is 10 hours. The aim of this work is to explore the capabilities 
of the NELC for the quantitative determination of formoterol in aqueous and 
biological fluids focusing on urine samples. 
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6.2. Optimisation of the derivatisation method for the analysis of 
formoterol in aqueous solution 
Initial studies were carried out with a conventional column and mobile phase in 
order to develop and optimise the derivatisation method for formoterol in aqueous 
solution with good peak shape. These initial experiments assessed the development 
of the NELC method. However, further development and optimisation were 
required. 
6.2.1 Selection of detection technique 
Selection of the detection technique is one of the key factors in method 
development. A sensitive detection technique would assist the detection of low 
concentrations (ng/ml-µg/ml) of formoterol, such as formoterol samples in 
bioanalysis. A fluorescence detector was used because of its sensitivity and 
selectivity. The natural fluorescence of formoterol (Figure 6.2) is low because of the 
presence of two bulky groups (formanilide and methoxy phenyl) which give it a very 
flexible and less rigid structure (Figure 6.1). Moreover, the lack of a fluorophore 
makes it practically impossible for the use of fluorometric (Mashat, 2008).  
 
Figure 6.1: Formoterol structure. (Sweetman, Martindale (Eds) 2009) 
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On the other hand, the presence of a secondary amino group assists formoterol in 
reacting to derivatising agents like fluorescene isothiocyanate (FITC) and 9-
fluorenylmethyl chloroformate (FMOC). Therefore, derivatisation of formoterol 
with a suitable agent will lead to a highly detectable product.  
 
 
Figure 6.2: Chromatogram of formoterol in fluorescence detector conditions:  λex 265nm, λem 
320nm. Mobile phase: acetonitrile – water – glacial acetic acid (90:9.8:0.2 v/v) pH 3, A 
Hichrom ODS1- C18 Reversed-phase (250mm x 4.6mm x 5µm); flow rate 1.0 ml/min, 
column temperature 30C. 
 
6.2.2 Derivatisation method development with FITC 
6.2.2.1. Principle of Reaction 
FITC is used as the derivatising agent because it reacts selectively with secondary 
and tertiary amino groups present in amino phenols and amino alcohols (Cherkaoui 
et al., 1995). The derivatised formoterol-FITC complex is illustrated in Figure 6.3. 
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Figure 6.3: Formoterol and FITC complex. 
 
6.2.2.2. Preparation of FITC-formoterol derivatisation  
Mashat (2006) has reported a derivatisation method of FITC with tobramycin. This 
method was adapted for formoterol. In a HPLC glass vial, 400µl of formoterol was 
added to 400µl of FITC (0.3mM, in pyridine). The mixture was vortexed for 40 sec, 
and incubated at 80˚C in the oven for 20 min. After cooling, 100µl was injected into 
the HPLC system with fluorescence detector at λ excitation 490nm and λ emission 
518nm. This method was not useful for the derivatisation of formoterol due to the 
overlapping of the formoterol derivative peak with FITC hydrolysis reaction peaks, 
as shown in Figure 6.4 (a, b). One of the disadvantages of FITC as a derivatising 
agent is that sometimes it can lead to extensive fluorescence quenching which occurs 
in aqueous solutions (Peng et al., 1977). In addition, it was reported that 
derivatisation of fenoterol hydrobromide, which has similar properties to formoterol, 
has led to problems in maintaining reproducibility (Meineke et al., 2002). This can 
be a major factor limiting the use of the reagent.  
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Figure 6.4 (a): Chromatogram of FITC reagent only. 
 
 
 Figure 6.4(b): Chromatogram of FITC and Formoterol 2.5µg/L complex. Conditions: λEx 490nm, λEm 
518nm. Mobile phase: acetonitrile – water – glacial acetic acid (90:9.8:0.2 v/v) pH 3, 
A Hichrom ODS1- C18 Reversed-phase (250mm x 4.6mm x 5µm); flow rate 1.0 
ml/min, column temperature 30C. 
6.2.3. Derivatisation method development with 9-fluorenyl-methyl-
methanol chloride (FMOC-CL) using conventional mobile phase  
6.2.3.1. Principle of reaction 
FMOC-CL reacts with amino groups of formoterol under alkaline conditions to form 
an amino derivative. However, FMOC-CL undergoes hydrolysis to produce 
hydrolysis products such as FMOC-OH (9-fluorenylmethylmethanol) as shown in 
Figures 6.5 and 6.6 (Lopez et al., 1996).  
  NELC to determine formoterol drugs                                                      Chapter 6  
 
 
159 
 
Figure 6.5: Reaction of 9-fluorenylmethyl chloroformate (FMOC) with secondary amino group. 
 
 
Figure 6.6: Hydrolysis of FMOC-CL reagent. 
 
6.2.3.2. Preparation of solutions 
6.2.3.2.1. Stock solution 
The stock solution of formoterol was prepared by dissolving a suitable amount of the 
analyte in Ultrapure Milli-Q water (mg/ml). Various concentrations of formoterol 
solutions were prepared from the stock solution by dilution with the solvent.  
6.2.3.2.2. Conventional mobile phase  
The mobile phase consisted of acetonitrile (HPLC grade) – Ultrapure Milli-Q water 
– glacial acetic acid (90:9.8:0.2 v/v). The mobile phase was filtered through a nylon 
membrane filter of 0.45µm pores under vacuum for 10 minutes. In addition, it was 
passed through an on-line membrane degasser. 
6.2.3.2.3. Effect of florescent spectrum 
The optimum excitation wavelength was obtained by fixing the emission wavelength 
at 320nm, and detecting the repeated injections at different excitation wavelengths 
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ranging from 245-285nm. Moreover, the optimum emission wavelength was 
obtained by fixing the excitation wavelength at 265nm, and detecting the repeated 
injections of standard formoterol solution after derivatisation with FMOC-CL at 
different emission wavelengths ranging from 290-340nm. The maximum yield of 
FMOC-formoterol derivative was obtained at excitation and emission wavelengths 
of 265 and 320nm respectively. 
6.2.3.2.4. FMOC Solution 
A FMOC solution was freshly prepared by dissolving an appropriate amount of 
FMOC-CL reagent in acetonitrile (see section 3.3.5.1). Figure 6.7 shows the 
chromatogram of the FMOC-CL reagent in the fluorescence detector with 
conventional mobile phase, while Figure 6.8 shows the formoterol after the 
derivatisation with FMOC. All solutions were prepared with Ultrapure Milli-Q water 
and filtered through a nylon membrane filter of 0.45µm pores. All solutions were 
stored in a dark place at 2°C. 
 
Figure 6.7:  Chromatogram of FMOC only. Conditions: Ex 265nm, Em 320nm. Mobile phase: 
acetonitrile – water – glacial acetic acid (90:9.8:0.2 v/v) pH 3, A Hichrom ODS1- C18 
reversed-phase (250mm x 4.6mm x 5µm); flow rate 1.0ml/min, column temperature 30C. 
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Figure 6.8: Chromatogram of FMOC-formoterol derivative. Conditions: Ex 265nm, Em 320nm. 
Mobile phase: acetonitrile – water – glacial acetic acid (90:9.8:0.2 v/v) pH 3. A Hichrom 
ODS1- C18 reversed-phase (250mm x 4.6mm x 5µm); flow rate 1.0 ml/min, column 
temperature 30C. Peak order: FMOC-formoterol derivative (4.7 min), FMOC-CL reagent 
peak (5.6 min).  
 
6.2.4. Analysis of formoterol in aqueous solution using NELC as mobile 
phase  
6.2.4.1. Optimisation of FMOC-CL derivatisation method  
The derivatisation reaction of FMOC-CL with formoterol was optimised for a series 
of factors, such as reaction time, FMOC-CL concentration, and fluorescence 
spectrum.  
6.2.4.1.1. Effect of reaction time 
The reaction time was first examined by allowing the derivatisation to proceed for 
various times ranging from 5 to 60 min. The FMOC-formoterol derivative was 
formed within 5 min but the optimum yield was at 30 min. A small amount of 
precipitation was observed in the reaction mixture at 40 min of reaction. This could 
explain the decrease in the FMOC-formoterol yield at 40-60 min of reaction time, as 
shown in Figure 6.9. Furthermore, the reaction mixture was neutralised by adding 
5µl of glacial acetic acid (HPLC grade) to prevent further hydrolysis reaction.  
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Figure 6.9: Effect of reaction time. 
6.2.4.1.2. Effect of FMOC-CL concentration 
The influence of the concentration of the FMOC reagent on the reaction yield was 
examined in the range 0.1-3.0mM. The optimum formoterol peak was obtained at 
0.2mM FMOC, while further increments of FMOC concentration did not 
significantly improve the peak height of formoterol, as shown in Figure 6.10. 
 
Figure 6.10: Effect of FMOC-CL concentration. 
 
When the sample had a low concentration of formoterol, the excess of FMOC-CL 
was high. However the excess of FMOC-CL reagent was removed by adding a 
suitable amino acid such as glycine (Stead and Richrds, 1996, , 1997). Therefore no 
interference peaks were seen with the FMOC-formoterol peak.  
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6.2.4.1.3. Effect of pH 
The pH was varied from 2.5 to 9. Higher pHs resulted in reduction in the reaction 
yield with poor peak-peak resolution and multiple hydrolysis product peaks, most 
probably due to the hydrolysis of the FMOC reagent, so the optimum pH for the 
derivatisation method was 8. 
6.2.4.2. Optimising the operating parameters of NELC 
6.2.4.2.1. Preparation of NELC mobile phase 
Initially a nanoemulsion mobile phase of Brij35 (1.5% w/w), ethyl acetate (0.5% 
w/w), butan-1-ol (2.5% w/w) and phosphate buffer 5mM (95.5% w/w) (see Chapter 
5.1.3.1.1) was used but no results were obtained. Subsequently this mobile phase 
was replaced with the standard microemulsion system that contains SDS as 
surfactant,  which has been reported previously in many studies (Marsh et al., 2005); 
(McEvoy et al., 2007).  
6.2.4.2.2. Effect of surfactant concentration 
The SDS concentration of the microemulsion was studied and the condition ranged 
from 1.5 to 4%. When the concentration was below 1.5% w/w, the system could not 
solubilise the oil and the microemulsion did not form. Increasing the concentration 
of SDS above 2% caused an increase in column backpressure. Therefore, SDS 
concentration was kept to a minimum of 1.5 % w/w. 
6.2.4.2.3. Effect of co-surfactant concentration  
The concentration of co-surfactant butan-1-ol was varied from 1-10 % w/w. Outside 
this range the microemulsion did not form. Increasing the butan-1-ol concentration 
to 6 % w/w had little effect on the separation. 
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6.2.4.2.4. Effect of oil concentration  
The standard concentration of oil (octane) under normal conditions was 0.8% w/w. 
However, further concentration ranges were checked by varying the concentration 
from zero to 1.2% w/w, where no more oil could be solubilised by the surfactant 
system. At 1% w/w or more of oil poor reproducibility was shown, which indicates 
that the nanoemulsion system was unstable. The peak retention decreased with 
increasing microemulsion oil content, which was anticipated due to the increase in 
oil concentration that improves the solubilising power of the eluent; 0.7% w/w of 
octane gave a reasonable run time (<13 min) with good injection repeatability.  
6.2.4.2.5. Effect of fluorescent spectrum 
Fluorescence spectroscopy was used to identify emission spectra of the mixture 
(MELC mobile phase and formoterol solution). The excitation wavelength was set to 
270nm and scanned from 200-750nm using the emission monochromator. On the 
other hand, the excitation spectra were measured by setting the emission wavelength 
near the maximum that was found in the previous step, then the excitation 
wavelength was scanned from 200-350 nm using the same solution as shown in 
Figure 6.11. 
 
The optimum emission wavelength was obtained by fixing the excitation wavelength 
of the fluorescence detector at 270nm, and detecting the repeated injections in 
MELC of a standard formoterol solution after derivatisation with FMOC-CL at 
different emission wavelengths ranging from 565-610nm. Moreover, the optimum 
excitation wavelength was obtained by fixing the emission wavelength at 595nm, 
and detecting the repeated injections at different excitation wavelengths ranging 
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from 240-280nm. The maximum yield of the FMOC-formoterol derivative was 
obtained at excitation and emission wavelengths of 270 and 595nm respectively. 
 
 
Figure 6.11: Excitation and emission wavelength scan for the mixture of MELC mobile phase and 
formoterol solution.   
 
6.2.4.2.7. Selection of suitable stationary phase 
Since formoterol is a weakly basic compound, initial trials were carried out with 
various C18 reverse phase columns, and a Hichrom C18 (ODS1). Furthermore, Assi 
et al. (2005) used a similar stationary phase for the analysis of formoterol in in vitro 
specimens. The Hichrom C18 (ODS1) column showed better peak shapes and 
greater efficiencies. Therefore this was used as a column of choice for further 
studies. 
6.2.4.2.8. Effect of temperature 
Temperature has no significant effect on separation condition. Some experiments 
have been done to find out the suitable temperature for day to day use. It has been 
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found that increasing temperature from 20-30ºC has no marked effect on retention of 
formoterol. However, Snyder et al. (1998) found that a temperature of 30ºC was 
suitable and showed better peak resolution and sharp peaks. 
6.2.4.2.9. Stock solution 
The stock solution of formoterol was prepared by dissolving 0.5mg/L in methanol : 
water (60:40). Various concentrations ranging from 12 to 125ng/ml of formoterol 
solution were prepared from the stock solution by dilution with the solvent.  
6.2.4.2.10. Particle size of the mobile phase  
The preparation of the optimum mobile phase that consisted of 1.5% w/w SDS, 
0.7% w/w octane, 4% w/w butan-1-ol and 93.8% w/w of phosphate buffer 5mM was 
repeated on five different occasions and five repeated measurements were performed 
for each mobile phase. The particle size obtained for all mobile phases was less than 
41nm.  
6.2.4.3. Method Validation 
6.2.4.3.1. Specificity 
The specificity of formoterol derivative in the presence of mobile phase compounds 
and other possible degradation products was examined. Figures 6.12 and 6.13 show 
that there was no interference of any of these components with the formoterol 
derivative peak.  
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Figure 6.12: Chromatograms obtained from FMOC reagent (blank). 
 
 
Figure 6.13: Chromatograms obtained from formoterol (50ng/ml) after derivative with FMOC. 
Conditions: nanoemulsion consists of: (1.5% w/w) SDS, (0.7% w/w) octane, (4 % w/w) 
butan-1-ol, and (93.8% w/w) of phosphate buffer 5mM at 30ºC, flow rate 1ml/min and C18 
column ODS1(250mm x 4.6mm x 5µm). 
 
 6.2.4.3.2. Linearity 
The linearity was examined for formoterol aqueous solutions at six different 
concentrations ranging from 12 to 125ng/ml. The samples were injected in 
duplicates and the calibration curve was shown to be linear (Figure 6.14). The 
correlation coefficient (r
2
) in the regression square line of the five points calibration 
was 0.995 [Y=7.2613X + 28.766 (n=5)] 
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 Figure 6.14: Calibration curve of formoterol aqueous solution after FMOC-CL derivatisation.  
Conditions: as described in Fig 6.13. 
 
 
6.2.4.3.3. Sensitivity 
The LOD and LOQ of the MELC method for the determination of formoterol 
following pre-column FMOC-CL derivatisation were calculated using detection 
limit (DL=3.3s/m) and quantitation limit (QL=10s/m) equations respectively, where 
s is the standard deviation of the y-intercept and m is the slope of the calibration 
curve (see section 5.1.4.3). The LOD and LOQ were 4.1 and 12.3ng/ml respectively. 
6.2.4.3.4. Accuracy 
The accuracy of the assay was calculated by comparing the nominal formoterol 
concentration with the calculated concentration obtained from the linear regression 
line. Accuracy was assessed by replicate analysis (n=5) at known concentrations 
corresponding to low (12ng/ml), medium (75ng/ml) and high (125ng/ml). The 
results are shown in Table 6.1. 
Table 6.1: Accuracy of the assay 
 
True Mean 
(measured) 
Accuracy 
12 11.85 98.76 
75 74.38 99.17 
125 126.80 101.44 
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6.2.4.3.5. Precision 
The precision of an analytical method describes the closeness of replicate 
determinations of an analyte by an assay (Good Manufacturing Practice Guide, 
2000). The precision of the NELC pre-column FMOC-CL derivatisation method was 
examined by five determinations at known concentrations corresponding to low 
(12ng/ml), medium (75ng/ml) and high (125ng/ml) levels in the calibration range. 
Precision can be subdivided into intra-day precision (within-day or repeatability) and 
inter-day precision (between-day or reproducibility). The degree of precision is 
expressed as the relative standard deviation in terms of a percent (RSD%), which is 
also known as the coefficient variation (CV) and can be calculated by dividing the 
standard deviation (SD) of the calculated concentrations by the mean concentration 
(Mean) and multiplying by 100. Intra-assay CVs ranged from 1.08% to 1.93% and 
the inter-assay CVs ranged from 1.00% to 1.79% (Table 6.2).     
 Table 6.2: Intra-day and inter-day precision for formoterol in aqueous solution after FMOC-CL 
derivatisation. 
Formoterol 
concentration (ng/ml) 
Intra-day 
RSD% 
Inter-day 
RSD% 
12 1.93 1.02 
75 1.21 1.95 
125 1.08 1.79 
 
The repeatability of retention time of the FMOC-formoterol derivative was 
examined during the validation procedure of the analysis method after 
approximately 50 consecutive injections. The RSD% of the retention time for 
repeated injections (n=50) was calculated to be 0.83%.  
6.2.4.3.6. Stability  
The stability of the FMOC-formoterol derivative in the standard solution was 
examined by repeated injection of the same sample over a period of 5 days when 
stored at room temperature in amber Vail. The RSD% of peak high of the FMOC-
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formoterol derivative (n=5) was found to be 3.4% for aqueous solution. After 5 days 
the FMOC-formoterol derivative is not stable at room temperature because of more 
overlapping of hydrolysed peaks. Regarding the aqueous samples of formoterol 
solution (without derivatisation), it has been reported that they are stable for four 
months at refrigerated conditions (4ºC) and two months at room temperature (Assi, 
2006a).    
 
6.3. NELC optimisation for the analysis of formoterol in human urine 
Following the optimisation of the NELC method using aqueous formoterol standard, 
the method was re-optimised with the aim of achieving good resolution of the 
formoterol peak from urine sample peaks and to produce the shortest analysis time. 
6.3.1. Selection of detection technique 
A sensitive detection technique would help to detect low concentrations of 
formoterol in urine samples. A method reported earlier used electrochemical 
detection for formoterol in blood samples (Campestrini et al, 1997). Although this 
method is considered sensitive, it lacks reproducibility. Marzo et al. (2000) used 
tandem mass to detect formoterol in biological samples, which is expensive. 
Therefore, fluorescence detection was considered because of its good sensitivity and 
selectivity.  
 
As mentioned earlier formoterol has a secondary amino group which can react with 
derivatising agent such as FITC or FMOC. The FMOC derivatisation method was 
successfully validated for the determination of formoterol in aqueous samples (see 
section 6.2.4). On the other hand, the in vivo experiments revealed that FMOC was 
not useful for the determination of formoterol in urine samples due to the 
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overlapping of the formoterol peak with the urinary impurity peaks. This led to the 
utilization of UV detection.  
6.3.1.1. Ultra-violet detection 
A standard of formoterol stock solution was prepared (50µg/ml) in methanol and 
water (60:40 %v/v). A UV-visible spectrophotometer was used to determine the 
maximum wavelength ( max). The solution was scanned from 190-400 nm and 
formoterol showed a maximum absorbance at wavelength of 214nm (Figure 6.15).   
 
Figure 6.15: UV spectra for aqueous formoterol standard (50µg/ml) in methanol-water (60:40 %v/v), 
scan from 190-400nm. 
 
6.3.2. Selection of suitable stationary phase 
As formoterol is a weakly basic compound trials were first carried out with a range 
of C18 reverse phase columns to do the separation procedure. Preliminary studies 
were carried out using a Phenomenex Luna® C18 (150mm x 4.6mm x 5µm) and 
Hichrom C18 ODS1 (250mm x 4.6mm x 5µm) columns. However, comparison 
studies using the same NELC mobile phase showed that both of these columns 
performed similarly. However, the retention time for the formoterol peak was 
shorter with a Phenomenex Luna® C18 (150mm x 4.6mm x 5µm). 
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6.3.3. Effect of mobile phase pH 
The effect of the pH of the mobile phase was also studied, because pH can affect 
peak shape and retention time. Extremely high pH >7.5 and low pH <2.0 cause a 
break down of C18 chains in the stationary phase and also damage the stationary 
phase support (Walshe et al., 1995). In addition, the presence of residual silanol 
groups on the silica surface causes peak tailing problems and an extended runtime 
when operating at higher pH values (pH >5.5). At lower pH (≤3.0) the silanol groups 
are protonated, which eliminates the attractions between the ionised silanol groups 
and the NH2 group in formoterol (Walshe et al., 1995). Therefore, pH 3, 5 and 7 
were studied using a KH2PO4 buffer. Three separate buffers solutions were prepared 
and their pHs were adjusted to 3, 5 and 7. The Phenomenex Luna® C18 column was 
used for this experiment. Table 6.3 shows the effect of changing the mobile phase 
pH on the chromatographic behaviour of formoterol.  
Table 6.3: Chromatographic behaviour of formoterol following changes in mobile phase pH. 
Mobile phase pH 
Retention time 
(minutes) 
3.0 3.6 
5 5.9 
7 7.8 
 
It was found that pH 5 and 7 buffers increased the retention time of formoterol 
(Table 6.3) and also gave a poor peak shape which led to the decrease in peak 
efficiency. On the other hand the pH 3.0 buffer gave a faster retention time and the 
best peak efficiency. Therefore, the later pH was selected for further analysis. 
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6.3.4. Preparation of formoterol spiked urine (FSU) standard 
The blank urine samples were collected from twelve healthy volunteers (6 females 
and 6 males) and mixed. Formoterol was spiked in a 10ml urine blank to prepare a 
concentration of 400ng/ml, and further diluted with urine to obtain the working 
concentration range (6.25-40ng/ml). 
6.3.5. Solid Phase Extraction (SPE) method development  
The formoterol was extracted from the urine matrix in order to remove the majority 
of the biological components in the urine. A SPE that was reported by Nadarassan 
and co-workers, (2007) for concentration the urine forty times was adapted in this 
study. Formoterol was concentrated forty times by extracting a large volume of 
urine. The volume of distribution for formoterol is high and therefore its 
concentration in biological fluids is low which indicates that detection of the 
formoterol may be difficult without a concentration step. SPE was selected over 
other techniques, such as liquid-liquid extraction (LLE), for a number of reasons. 
The recoveries of analytes using liquid-liquid extractions are often low and result in 
increased volumes of solvent waste (Fritz, 1999b). The solid phase sorbent of SPE 
cartridges is very similar to those used in HPLC columns for separation. The 
interferences can then be selectively washed from the sorbent with the use of 
carefully selected wash solvents (Simmonds et al.,  (1994) . The SPE cartridges used 
were isolute HCX and HLB. The initial investigations were designed to examine the 
extent of retention of formoterol on the different cartridges. It was found that isolute 
HCX SPE cartridges gave poor recoveries (<63 %). For these reasons the cartridges 
were eliminated from further studies. However the HLB cartridge seemed more 
promising and this cartridge was considered further as mentioned below.  
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6.3.5.1 Optimisation of SPE cartridge 
A solid-phase extraction method using Oasis Hydrophilic-Lipophilic Balance 
Sorbent (HLB 30mg/1ml) cartridge (Sorbent Technology, UK) was reported by ( 
Mazhar and Chrystyn 2009) for the extraction of terbutaline and bamethane from 
urine. This method was adapted for the extraction of formoterol from urine matrix 
and further optimisation including the concentration of formoterol to forty times was 
carried out.  A 20ml sample reservoir was connected to the SPE cartridge. Each 
Oasis HLB cartridge was conditioned with 2ml methanol followed with 2ml of 
45mM potassium dihydrogen phosphate (pH 7). 10ml of spiked urine sample 
(10ng/ml) adjusted (if necessary) to pH 6.5-7.2 and mixed well for 30 seconds was 
applied to the cartridges followed by the addition of 2ml of 15mM potassium 
dihydrogen phosphate (pH 7), which was then followed by a full vacuum drying for 
2 min. Afterward, 1ml of ACN:H2O (02:98) was applied followed by full vacuum 
drying for 1 min and finally the cartridge was washed with 1ml of THF:H2O 
(0.25:99.75) followed by 2 min full vacuum drying. The analyte was then eluted 
from the cartridge into a sample tube using 2ml of CH3COOH:H2O (02:98) at low 
vacuum (less than 3 bar) for 2-3 min. After the samples were evaporated using a 
nitrogen stream at 120
˚
C for 35 min, the residue was reconstituted in 0.25ml mobile 
phase and 100μml was injected into the HPLC system.  
 6.3.6. Internal standard selection 
Some of the internal standards were examined, and their chromatographic behaviour 
was observed using the conditions optimised for the separation of formoterol. The 
results are summarised in Table 6.4. Compounds that had retention times less than 
that of formoterol were excluded from further investigation, as they would elute 
together with the urine metabolites. Compounds having retention times greater than 
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20 minutes were also excluded because they would give long analysis times. 
Salmeterol and feneterol yielded peaks closer to the formoterol peak. These 
compounds had good resolution with the formoterol peak.  
 
 
 
 
Table 6.4: The retention times of potential internal standards. 
 
 
 
Spiked urine samples of formoterol, salmeterol and feneterol were subjected to solid 
phase extraction to determine the relative behaviour of three compounds during the 
extraction procedure. Then the extracted samples were analysed using the optimised 
HPLC condition. Table 6.5 indicates the recoveries of the formoterol, salmeterol 
and feneterol as internal standards. HPLC conditions consisted of mobile phase-, 
1.5% w/w SDS, 0.7% w/w octane, 4% w/w butan-1-ol, and 93.8% w/w of phosphate 
Compound Retention time (minutes) 
Salmeterol 5.4 
Feneterol 5.1 
Salbutamol 3.59 
Terbutaline 3.68 
Bamethane 4.41 
Colterol 19.4 
Pindalol 4.6 
Tiotropium Bromide 16.3 
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buffer 5mM at 30ºC, flow rate 1ml/min and C18 column ODS1 (150mm x 4.6mm x 
5µm); = 214nm; column temperature 30C. 
Table 6.5: Recoveries of both the potential internal standards using the optimised SPE.  
 
Compounds 
% Mean (±SD) Recovery 
(n=10) 
Formoterol 97.53 (0.95) 
Salmeterol 58.67 (29.6) 
Feneterol 39.41 (23.4) 
In terms of reproducibility, using the SPE method salmeterol and feneterol gave 
recoveries of 58.67(29.6) and 39.41(23.4)% respectively (Table 6.5). Even if the 
recoveries were noticeably less when compared to formoterol, the internal standards 
would possibly have been useful, if they had shown consistent recoveries. The SPE 
procedure developed gave consistent recoveries for formoterol, thus the need for an 
internal standard was unnecessary, as (Ong et al, 1989) concluded.  
6.3.7. Bioanalytical method validation 
The validation procedure was carried out based on ICH (1995) guidelines for the 
validation of bioanalytical samples. Pooled urine samples spiked with aqueous 
formoterol standard were used for the study and preparation of standards. 
6.3.7.1. Specificity 
Specificity is the capability of the method to quantify the analyte in the existence of 
other components in the urine matrix. The specificity of the method was examined to 
ensure that there was no interference from components of endogenous material. Both 
the blank and spiked urine samples were assayed by HPLC. The peak of formoterol 
was well resolved and separated from the urine components (Figure 6.16 and Figure 
6.17). 
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Figure 6.16: Extracted blank urine matrix (pooled) using HLB cartridge. 
 
 
 
Figure 6.17: Extracted blank urine spiked with formoterol aqueous standard (30ng/ml) using HLB 
cartridge. Conditions: Nanoemulsion (1.5% w/w) SDS, (0.7% w/w) octane, (4 % w/w) 
butan-1-ol, and (93.8% w/w) of phosphate buffer 5mM, Phenomenex C18 Columbus, 
150mm X 4.6mm i.d  X 5µm. flow rate 1.0ml/min; ë= 214nm; column temperature 30 C. 
 
6.3.7.2. Linearity  
Different concentrations were prepared ranging from 6.25 to 40ng/ml (see section 
6.3.4) including the lower (LOQ) and covering the predicted range. The standards 
were prepared in urine matrix and then formoterol was extracted with HLB SPE.  
Blank samples were also analyzed along with the calibration standards. The linearity 
of the calibration standards was evaluated over the range 6.25 to 40ng/ml. The 
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extracted formoterol samples were injected in duplicates. The calibration curve 
(Figure 6.18) showed a linear response and gave a regression coefficient (r
2
) of 
0.9906 (y = 0.9262X + 14.71). 
 
 
 
Figure 6.18: Calibration curve constructed using the peak height against the urine formoterol 
concentration. For operating parameters see Fig 6.17. 
6.3.7.3. Sensitivity 
The sensitivity of the analytical method was expressed as the lower limit of 
quantification (LOQ), which is the minimum concentration of formoterol that can be 
quantitatively determined. This corresponds to a peak height to base line ratio of at 
least 10:1 while the limit of detection (LOD) corresponds to a peak height to base 
line ratio of 3:1. LOQ is accepted if the analyte peak response is identifiable, 
discrete and reproducible with a precision of 20% and accuracy of 80%-120% 
(FDA, 2001). Formoterol in urine at a concentration of 6.25ng/ml was extracted and 
injected on five separate days (inter-day and intra-day) to determine the precision of 
the formoterol peak. 
  NELC to determine formoterol drugs                                                      Chapter 6  
 
 
179 
The limit of detection (LOD) and limit of quantification (LOQ) were 1.8ng/ml and 
5.5ng/ml respectively. The precision study revealed a relative standard deviation of 
<3.7% (n=10) for the formoterol peak and an average accuracy of 95%. 
6.3.7.4. Recovery and Accuracy  
The recovery was studied by comparing the detector response of extracted 
formoterol urine standard at three concentrations levels: low (6.25ng/ml), medium 
(25ng/ml) and high (37.5ng/ml) with the detector response of the formoterol 
standards spiked in extracted blank urine matrix. The measurements were performed 
using five determinations per concentration. Recovery was determined by comparing 
the peak height of the extracted formoterol urine standard with the peak height of the 
formoterol standard externally spiked with extracted blank urine matrix. The method 
showed excellent and consistent recoveries, and the mean recoveries for the studied 
concentrations ranged from 91.06 to 98.80 (Table 6.6).  
The accuracy of the method was assessed by replicate analysis (n=5) of the extracted 
formoterol urine standards at known concentrations that included low (6.25ng/ml), 
medium (25ng/ml) and high (37.5ng/ml), and by comparing them with the true 
concentration of formoterol. The accuracy of the bioanalytical method was greater 
than 98.09% (Table 6.6). 
Table 6.6: Accuracy data comparing the actual concentration with the observed spiked urine 
formoterol concentrations. 
 
 
 
 
 
 
True value 
(ng/ml) 
Actual 
(ng/ml) 
Accuracy % Recovery % 
6.25 6.21 99.36 91.06 
25 24.81 99.24 98.80 
37.5 38.21 101.89 94.66 
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6.3.7.5. Precision 
Precision was studied using five determinations at known concentration levels 
corresponding to low (6.25ng/ml), medium (25ng/ml) and high (37.5ng/ml) levels in 
the calibration range. The degree of precision is expressed as the relative standard 
deviation (RSD). Intra-day and inter-day precision were determined using multiple 
analysis (n=5) of spiked urine specimens. This study was repeated for five days to 
determine the precision between days (inter-day). The precision expressed as inter-
day RSD% ranged from 1.68 to 4.89% and intra-day RSD% ranged from 1.09 to 
2.33% (Table 6.7). 
Table 6.7: Precision intra-day and inter-day for formoterol. 
 
 
Formoterol 
concentration (ng/ml) 
 
Intra-day 
RSD% 
 
Inter-day 
RSD% 
 
6.25 
 
 
1.77 
 
1.68 
 
25 
 
 
2.33 
 
4.89 
 
37.5 
 
 
1.09 
 
0.74 
6.3.7.6. Stability 
This study examined the stability of formoterol in the urine matrix. The stability of 
formoterol was examined by repeated injections (n=5) of low (6.25ng/ml) and high 
(37.5ng/ml) concentrations of formoterol spiked urine standards at different times 
over a period of 5 days, when stored at room temperature for 24 hours and analysed. 
The mean recovery from samples ranged from 96 to 103 on comparing with freshly 
prepared standards. 
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Similarly, the long term stability study showed that formoterol urine standards were 
stable for 4 months when stored at +4°C, with an average recovery >95%. Three 
repeated injections of each level of concentration near the low (6.25ng/ml) and high 
(37.5ng/ml) range of the calibration curve were prepared and frozen at -20° C for 24 
hours. The samples were thawed at room temperature and analysed. The samples 
were refrozen for 24 hours under the same conditions. The freeze-thaw cycle was 
repeated two more times, and then analysed on the third cycle. No decrease of 
formoterol concentration in urine was detected after exposing samples to three 
freeze/thaw cycles and accuracy ranged from 94 to 98% after freeze-thaw stability 
testing.  
 
6.4. Assay of formoterol from the dosage form (Oxis
®
 Turbuhaler) 
6.4.1 Introduction 
Dry Powder Inhalers (DPIs) are a popular alternative to MDIs which deliver drugs to 
the lung in powder form for the treatment of pulmonary disease. The introduction of 
DPIs has eliminated the need for propellant. The active drug is delivered to produce 
a local or systemic action by the pulmonary route using a dry powder formulation 
(Islam and Gladki, 2008). 
 
DPIs have some advantages over MDIs, as the formulation for DPIs is one-phase, 
and as solid particle mixtures they are more stable than MDIs. Also, they reduce the 
need for hand-breath coordination as DPIs are only activated while the patient 
inhales. However, the emitted dose depends on the patient’s inspiratory airflow 
(Chrystyn, 2007b).  The first DPI for the administration of pharmaceuticals, 
described in 1949, was a patent by Fields, the so-called Aerohaler. It was the first 
commercially available DPI for the delivery of isoprenaline sulphate (Clark. A., 
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1995). In 1988 the development of multi-dose DPIs was pioneered by Darco who 
produced the Turbuhaler
®
 (AstraZeneca, Lund, Sweden) (Wetterlin. K.. 1988). The 
Turbuhaler
®
 has been used to deliver carrier free particles of the -agonist such as 
formoterol and the steroid such as budesonide (Pedersen, 1994). 
 
Turbuhaler® was chosen for the study because it is a worldwide prescribed inhaler 
in the treatment of pulmonary dysfunction. The present study was also carried out 
with the aim of determining the uniformity of the dose emitted from the Oxis® 
Turbuhaler. The pharmaceutical performance of inhaled products can be 
characterized by the total emitted dose, the fine particle dose and the aerodynamic 
particle size distribution. The NELC method was used to assay the content of the 
emitted dose and the fine particle dose of the Oxis® Turbuhaler. 
6.4.2. Procedure 
6.4.2.1. Dose content uniformity 
A method was used to measure the dose emission uniformity of the Oxis® 
Turbuhaler (AstraZeneca, UK) containing 12µg of formoterol fumarate per dose 
using Dose Sampling Apparatus described in (USP, 2005b). The instrument was 
assembled as per the schematic diagram in Figure 6.19. The emitted dose uniformity 
was assessed by collecting ten individual doses (dose numbers 2, 3, 4, 34, 35, 36, 37, 
58, 59 and 60) of the entire dose available (60 doses) from the Oxis® Turbuhaler at 
a flow rate of 54.6l/min, corresponding to a pressure drop of 4kPa across the inhaler. 
The flow duration was 4.1s, to allow a volume of 4l to be drawn through the inhaler. 
After the dose was discharged into the apparatus, the inhaler device was detached 
and the vacuum tubing (T2) was disconnected. Each dose was collected and then 
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was transferred to a 50ml volumetric flask. This was diluted up to the appropriate 
volume prior to quantitative HPLC analysis. 
6.4.2.2. Particle Size Distribution 
The particle size distribution and the fine particle mass from the Oxis® Turbuhaler 
(12g) were measured using the Andersen MKII Cascade Impactor. The flow rate 
through the mouthpiece was set at a pressure drop of 4kPa across the inhaler. Ten 
consecutive doses were discharged into the Andersen MKII Cascade Impactor and 
for each dose the pump was switched on for 4.1 seconds (equivalent to an inhaled 
volume of 4L drawn through the inhaler) with the inhaler in-situ ready to deliver 
each dose.   
 
The inhalation time was set using the relation described in (USP, 2005a).  
T = (60 sec x X)/Q 
T = Time duration consistent for withdrawal of 4 litres of air from the inhaler 
Q = Airflow which produces a pressure drop of 4kPa 
X = 4L to be drawn through the inhaler 
 
Figure 6.19: Schematic design showing the method for measuring the dose emission for 
formoterol in the Oxis® Turbuhaler device. 
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6.4.3. Results and discussion  
The chromatographic peak and the retention of the formoterol in the dose emission 
of the Oxis® Turbuhaler are shown in Figure 6.20. 
 
Figure 6.20: Chromatogram obtained from formoterol as the dose emission of Oxis® Turbuhaler 
conditions: nanoemulsion consists of: (1.5% w/w) SDS, (0.7% w/w) octane, (4 % w/w) butan-1-ol, and 
(93.8% w/w) of phosphate buffer 5mM at 30ºC, flow rate 1ml/min. 
 
The HPLC data for the dose emission was compared with the nominal dose of the 
Oxis® Turbuhaler (Table 6.8). The RSD value is high because of the high inter-dose 
emission variability from the Oxis® inhaler (Tarsin et al., 2004b). 
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Table 6.8: The mean (±SD) total emitted dose (% nominal dose) from the Oxis® Turbuhaler at an 
inhalation rate of 54.6l/min using a 4l inhalation volume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fine particle dose for formoterol was 5.44g. Figure 6.21 illustrates the amounts 
(µg) of formoterol deposited in the Anderson Cascade Impactor and it also shows that 
most deposition occurs between stages 1-4. The ideal particle size should fall within 
this optimal range of 2-6µm (stages 1-3) and the results from this study (Figure 6.21) 
confirm that formoterol has the potential to reach the lower peripheral regions of the 
lung. The mass median aerodynamic diameter (MMAD) was 2.66 and the geometric 
standard deviation (GSD) was 1.68. The closer the GSD lies to 1, the more likely the 
particle distribution is homogenous and therefore it can be suggested that particle 
distribution is good and uniform. 
Dose 
no 
% Label dose 
emitted 
2 72.09 
3 80.06 
4 69.83 
34 77.34 
35 66.73 
36 72.8 
37 56.73 
58 64.73 
59 69.73 
60 73.62 
Mean 70.366 
± SD 6.6140 
%RSD 9.399 
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Fig 6.21: Mean particle depositions of formoterol (g) in Anderson Cascade Impactor (ACI) at a 
pressure drop of 4kPa across the inhaler. 
 
6.4.4 Clinical volunteer studies  
In vivo pharmacokinetic methods (using plasma or urine samples) can be used to 
assess relative lung deposition for drugs. The difficulty with the use of plasma  
pharmacokinetics is that plasma or serum drug concentrations are low because the  
inhaled doses are small and the volume of distribution is large, especially for polar and 
basic (β-agonist) drugs which have a high renal clearance. Mascher et al. (2006) have 
assessed the pharmacokinetic studies after inhaled administration of formoterol. The 
amount of formoterol was quantified using a tandem mass spectrometry technique. 
Drugs which are excreted in the urine are found in more concentrated levels in the 
urine than in the serum. This means that the absorption of relatively low doses of 
inhaled drug may be detected. 
 
After the NELC method was developed and validated for spiked urine samples of 
formoterol, it was applied clinically for the determination of formoterol in urine 
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samples of healthy volunteers using the Oxis® Turbohaler (dose 12µg per actuation). 
One dose was inhaled per study. The volunteers were given urine collection containers 
and asked to collect and pour their urine into the container. Each volunteer provided a 
urine sample 15 minutes before the administration of the dose (a blank) and then at 24 
hours following the dose. Their urine samples were collected at 24 hours post-
inhalation of each study day. The volume of each urine sample was recorded. Samples 
were then extracted by the established methods (see section 6.3.5). The prepared 
samples were then injected onto the chromatographic system connected to UV 
detector, with the wavelength λ= 214nm. The results (Figure 6.22) indicated that in 
the face of the presence of interfering peaks the NELC method gives a good and 
baseline separation of the formoterol peak from any endogenous interfering peak. 
 
Figure 6.22: Chromatogram obtained from formoterol in urine after 24 hours post-inhalation from an 
Oxis
®
 Turbohaler (12µg). Nanoemulsion: (1.5% w/w) SDS, (0.7% w/w) octane, (4 % w/w) 
butan-1-ol, and (93.8% w/w) of phosphate buffer 5mM, Phenomenex C18 Columbus, 
150mm X 4.6mm i.d  X 5µm. flow rate 1.0ml/min; λ= 214nm; column temperature 30C. 
 
In conclusion, the urinary pharmacokinetic method can be successfully employed 
using the NELC method in the determination of the relative lung bioavailability of 
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formoterol. The cumulative amounts of formoterol excreted in the urine over the 24 
hrs reflect the lung bioavailability was 4.79 µg. 
6.4.5. Conclusions 
The NELC method described has been optimised and validated for quantitative 
determination of formoterol in both aqueous and urine samples. Currently the 
conventional HPLC methods used for analysis of formoterol in aqueous solution are 
different to the methods used for analysis of formoterol in urine, while the NELC 
method uses the same mobile phase for both aqueous and urine sample analysis. Also, 
the NELC method offered a much faster analysis run time for formoterol in urine (Rt 
= 3.54 min) compared with the previously reported conventional HPLC method (Rt = 
20 min). The method was also applied to the determination of the content of the 
emitted dose of the Oxis® Turbuhaler. 
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Chapter 7 
Nanoemulsion high performance chromatography (NELC) analysis 
for hydrophobic drugs such as salmeterol xinafoate and fluticasone 
propionate in aqueous samples 
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CHAPTER (7) Nanoemulsion high performance chromatography 
(NELC) analysis for hydrophobic drugs such as salmeterol 
xinafoate and fluticasone propionate in aqueous samples 
 
7.1. Introduction 
7.1.1. Salmeterol xinafoate   
Salmeterol xinafoate (SX) is generally only prescribed for severe persistent asthma 
and COPD following previous treatment with a short-acting β2-agonist such as 
salbutamol and is concurrently prescribed with a corticosteroid, such as budesonide 
(Johnson et al., 1993). The main difference between salmeterol and salbutamol is the 
duration of action lasts approximately 12 hours in comparison with the 4-6 hours for 
salbutamol, which can be attributed to a long carbon side chain in salmeterol 
(D’Alonzo and Tolep, 1997).  
7.1.1.1. Mechanism of Action   
SX (lipophilic) binds to β2-receptors in the lungs through its long carbon side chain, 
and on bronchiolar smooth muscle. β2-receptor stimulation in the lung causes 
relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial 
airflow. It has been documented that salmeterol is prolonged in duration, but slow in 
onset of action (Ball et al. , 1991, Linden et al, 1996). The IUPAC approved 
chemical name of SX is: 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy) 
hexylamino] ethyl] phenol 1-hydroxy-2-naphthoate, and it has the following 
chemical structure: 
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Figure 7.1: Chemical structure of salmeterol xinafoate; (Sweetman, Martindale (Eds) 2009) 
 
SX is a white powder with a molecular weight of 603.8. Its molecular formula is 
C25H37NO4•C11H8O3. The presence of a long carbon side chain together with 
aromatic rings gives a hydrophobic property to SX, and as one would expect it is 
sparingly soluble in water, freely soluble in methanol and slightly soluble in 
isopropanol, chloroform, and ethanol (Merck. Index., 2009).  
7.1.1.2. Pharmacokinetics  
As the therapeutic dose of SX is small, systemic levels are low or undetectable after 
inhalation of recommended doses. However, the plasma protein binding is 
considerably high (96%). 
 
7.1.2. Fluticasone propionate   
Fluticasone propionate (FP), a medium-potency synthetic corticosteroid, is used 
topically to relieve inflammatory pain and also orally for the treatment of asthma 
(Crim et al., 2001).  
7.1.2.1. Mechanism of action  
Inflammation is an important component in the pathogenesis of asthma. 
Corticosteroids have been shown to inhibit multiple cell types (e.g. eosinophils, 
mast cells, neutrophils) and mediator secretion or production (e.g. leukotrienes, 
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histamine) involved in the asthmatic response. These anti-inflammatory actions of 
corticosteroids contribute to their efficacy in treating asthma. FP has the chemical 
name of: S-(fluoromethyl)-6α-9-difluoro-11β-17-dihydroxy-16α-methyl-3-
oxoandrosta-1,4-diene-17β-carbothioate, and the chemical structure is as follows: 
 
Figure 7.2: Chemical structure of fluticasone propionate. (Sweetman, Martindale (Eds) 2009) 
 
FP is a white powder with a molecular weight of 500.6, and the empirical formula is 
C25H31F3O5S. Because of numerous alkyl groups and cyclic hydrocarbons, FP is 
very similar to SX in terms of hyrdophobicity, and so it is practically insoluble in 
water,  but freely soluble in dimethyl sulfoxide (DMSO) and dimethylformamide 
(DMFA), and slightly soluble in methanol and 95% ethanol.  
7.1.2.2. Pharmacokinetics  
The majority of the FP delivered to the lung is systemically absorbed. In contrast, 
the oral systemic bioavailability of FP is negligible (<1%), primarily due to 
incomplete absorption and pre-systemic metabolism in the gut and liver. Less than 
5% of a radiolabelled oral dose is excreted in the urine as metabolites. The volume 
of distribution averages 4.2 L/kg. The percentage of FP bound to human plasma 
proteins averages 91%.  
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A combination inhaler of SX and FP has been shown to be more effective than 
doubling the steroid dose to improve the control treatment of asthma (Dahl et al. , 
1997, Weersink et al., 1997). These two drugs are formulated both as dry powder 
inhalers and as pressurized metered dose inhalers both individually and as a 
combination formulation.  
 
The aim of this present work is primarily to exhibit the ability of NELC mobile 
phase to separate SX and FP analytes as hydrophobic compounds in aqueous 
samples and find out it is potentiality over the conventional mobile phase and to 
develop a NELC method to determine the contents of an emitted dose for this 
combination.  
 
7.2. Method development 
 
7.2.1. Preparation of NELC mobile phase 
As a starting point the same mobile phase to that for terbutaline and salbutamol was 
chosen (see section 5.1.3.1), the NELC mobile phase of 1.5% (w/w) Brij35, 0.5% 
(w/w) ethyl acetate, 2.5% (w/w) butan-1-ol, and 95.5% (w/w) 5mM phosphate 
buffer (see Chapter 5, terbutaline and salbutamol) was employed. But no separation 
was achieved and it was decided to use the mobile phase of formoterol, which has 
been studied in section 6.2.4.2. Therefore, the NELC mobile phase was prepared by 
weighing 1.5% (w/w) SDS, 0.7% (w/w) octane, 4% (w/w) butan-1-ol, and 93.8% 
(w/w) of phosphate buffer 5mM to volumetric flask. However, it was noticed that 
further procedure is required.  
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7.2.2. Effect of surfactant concentration 
The SDS concentration was chosen to cover the range between 0.5 to 2.5%. When 
the concentration was below 0.8% w/w, the system could not solubilise the oil and 
the microemulsion did not form. Raising the concentration to more than 2% caused 
an increase in column backpressure. As a result the optimum was found to be 1.5% 
w/w.  
7.2.3. Effect of co-surfactant concentration  
The concentration of co-surfactant butan-1-ol was varied from 3.3-8% w/w. the 
upper limit was chosen because outside this range the microemulsion did not form. 
However, in practice increasing the butan-1-ol concentration to 6% w/w had little 
effect on the separation and conversely decreasing the butan-1-ol concentration to 
3.4% w/w led to an overlap in the peaks due to the early retention time. The 
optimum choice was 4% w/w.  
7.2.4. Effect of oil concentration   
As mentioned before (see section 6.2.4.2.4) the standard concentration of oil 
(octane) under normal conditions was 0.8% w/w. However, to check for any 
improvement in separation performance further concentration ranges were tested by 
varying the concentration from 0.1 to 1% w/w, where no more oil could be 
solubilised by the surfactant system. The outcome of these experiments was that at 
0.2% w/w the corresponding retention times for budesonide, salmeterol and 
fluticasone were increased. However, at 1% w/w poor reproducibility was shown, 
which suggests that the microemulsion system is unstable. Overall the peak retention 
was decreased with increasing microemulsion oil content, which shows that an 
increase in the oil concentration can improve the solubilising power of the eluent. 
The optimum choice was 0.7% w/w.   
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7.2.5. Effect of pH 
 Since the pKa values of salmeterol at 25ºC are 10.3 (for a phenolic group) and 8.3 
(for a secondary amino group) then based on these values it would be more suitable 
to use a low pH buffer. Different low ranges of pH were examined and the optimum 
pH that gave the best peak shap and best separation was found to be 3.  
7.2.6. Selection of detection technique 
Detection of salmeterol and other drugs in biological fluids is often problematic. In 
this case a sensitive detection technique would help to detect low concentrations of 
salmeterol in urine samples (Lehner et al., 2004). There are no data on the degree to 
which inhaled salmeterol undergoes first pass metabolism. This is most likely due to 
the very low plasma concentrations reached after inhalation of therapeutic doses of 
salmeterol and also to problems in developing an analytical method that is sensitive 
enough to determine these concentrations (Adkins J and McTavish, 1997). The 
initial reported method determined plasma concentrations of salmeterol using gas 
chromatography-mass spectrometry (Higton et al., 1992). This method was 
sensitive, but the application is not easy and therefore it was restricted to a few 
specialised laboratories. In 1993, ( Colthup et al.) described a HPLC method 
fluorescence detiction for the determination of salmeterol with respect to 
endogenous plasma components and identified metabolites in rat and dog plasma. 
The method was sensitive to 1μg/L, but unfortunately it was not sensitive enough to 
determine plasma and urine concentrations in humans.  
7.2.6.1. Ultra-violet detection 
To the best of my information, the earliest  UV spectrum for salmeterol base was 
shown is in the study reported by Michael et al. (2000). A UV-visible 
spectrophotometer was used to determine the maximum wavelength ( max). The 
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solution was scanned from 190–440 nm and salmeterol showed maximum 
absorbance at a wavelength of 214nm (Figure 7.3 a).   
 
 
 
Figure 7.3: UV spectra for aqueous solution of (a) salmeterol λmax 214nm, (b) fluticasone propionate 
λmax 240nm, and (c) budesonide λmax 244nm as internal standard. Scan from 190-440 nm 
 
 
In order to study the appropriate wavelengths to the assay, all three compounds, SX, 
FP and also budesonide, as I.S. were examined (see Fig.7.3(a)–(c)). At a minimum 
UV absorption for SX there was a maximum absorption for FP at 240nm. Hence, the 
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selection of 228nm was shown to be close to the absorption maxima of SX, FP and 
budesonide.  
7.2.7. Selection of suitable stationary phase 
As mentioned before (see section 6.2.4.2.7), and since salmeterol is a weakly basic 
compound like formoterol, a Phenomenex Luna® C18 (150mm x 4.6mm x 5µm) 
column was used. It gave good peak shapes, high efficiencies, base line resolution 
and a short analysis time for salmeterol, fluticasone and budesonide. Therefore, this 
was used as the column of choice for this study. 
7.2.8. Effect of temperature 25–50˚C 
One of the parameters that may affect separation was temperature and therefore 
some experiments were carried out to find out the suitable temperature for day to 
day use (Figure 7.4). It was found that temperature had no significant effect on 
separation condition.  
 
Figure 7.4: Effect of temperature in salmeterol, fluticasone proinate and budesonide. The nanoemulsion consists 
of: 1.5% (w/w) SDS, 0.7% (w/w) octane, 4% (w/w) butan-1-ol, and 93.8% (w/w) of phosphate buffer 5mM, flow 
rate 1ml/min and Phenomenex Luna® C18 (150mm x 4.6mm x 5µm) column.  
 
The experminets of method development led to the optimum mobile phase which is: 
SDS 1.5%, butanol 4%, octane 0.7% and phosphate buffer 5mM 93.8% (w/w). The 
particle size of the mobile phase was measured using same procedure as explain in 
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preveous section (4.3.1.1) and it was  40.2 nm. This particle size is in nanoemulsion 
region.   
7.3. Results and Discussion 
7.3.1. Method validation 
The developed method (shown in Figure 7.6) was validated, and the validation 
procedure was based on ICH  ( 1996) guidelines. 
7.3.1.1. Selectivity  
The specificity of salmeterol and fluticasone in the presence of mobile phase 
compound, internal standard (budesonide) and other possible degradation products 
was examined. Figures 7.5 and 7.6(a), show no interference of these components 
with the salmeterol or fluticasone peaks. Figure 7.6(a), also shows that fluticasone 
and salmeterol were eluted at 3.88 and 4.72 min respectively. The nanoemulsion 
consists of: 1.5% (w/w) SDS, 0.7% (w/w) octane, 4% (w/w) butan-1-ol, and 93.8% 
(w/w) of phosphate buffer 20mM, flow rate 1ml/min and Phenomenex Luna® C18 
(150mm x 4.6mm x 5µm) column. 
 
 
 
Figure 7.5: Chromatograms obtained (blank),  
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In comparison with the conventional HPLC the most rapid method was reported by 
(Murnane et al 2006),  SX and FP were separated retention time of 5.23 and 7.01 
min, respectively figure 7.6 (b). It is clear that NELC offered shorter analysis time 
with good base line resolution between the peaks.  
 
Figure 7.6 (a): Chromatograms obtained from salmeterol, fluticasone (50µg/ml) and the internal 
standard budesonide.  
 
 
 
Figure 7.6 (b) : Chromatogram of (A) standard mixture of SX (6 µg/ml) and FP (10 µg/ml) overlaid 
with a chromatogram of (B) solvent blank. The mobile phase was a mixture of methanol–0.6% (w/v) 
aqueous ammonium  acetate solution (75:25%, v/v), filtered through a 0.45 µm nylon membrane 
(Whatman International Ltd., Maidstone, UK) and degassed. The mobile phase flow rate was 
1.0mLmin−1.and detection was at 228 nm. 
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7.3.1.2. Linearity 
Linearity was evaluated for salmeterol and fluticasone aqueous solutions at five 
different concentrations ranging from 2.5 to 20µg/ml. The samples were injected in 
duplicates and the calibration curve was shown to be linear (Figures 7.7 and 7.8). 
The correlation coefficients (r
2
) in the regression square line of a five point 
calibration in salmeterol and fluticasone were 0.989 and 0.999 and the equations 
were [Y=0.093X + 0.0494 and Y=0.122X + 0.0556 (n=5)] respectively.  
 
 
Figure 7.7: Calibration curve of salmeterol aqueous solution.  
 
 
 
 
 Figure 7.8: Calibration curve of fluticasone propionate.  
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7.3.1.3. Sensitivity 
The LOD and LOQ of the NELC method for the determination of salmeterol and 
fluticasone were calculated using a detection limit equations (DL=3.3s/m) and 
quantitation limit (QL=10s/m). The LOD and LOQ found were 0.57-0.58 and 1.73-
1.76µg/ml respectively. 
7.3.1.4. Accuracy 
The accuracy of three different concentrations levels corresponding to low 
(2.5µg/ml), medium (10µg/ml) and high (20µg/ml) was measured (n=5 for each 
level). The results are shown in Table 7.1. 
Table 7.1: Accuracy of the assay. 
 
True 
(µg/ml) 
Observed 
concentration  
salmeterol 
(µg/ml) 
Accuracy % 
salmeterol 
Observed 
concentration  
fluticasone 
(µg/ml) 
Accuracy % 
fluticasone 
2.5 2.52 100.72 2.55 102.04 
10 9.76 97.65 9.96 99.65 
20 20.31 101.57 20.39 101.97 
     
 
 
7.3.1.5. Precision  
Precision was assessed by five determinations at known concentrations 
corresponding to low (2.5µg/ml), medium (10µg/ml) and high (20µg/ml) levels in 
the calibration range. The same study was repeated for 5 days to determine the inter-
day variation. The intra- and inter-day variations of SX and FP were determined by 
calculating the relative standard deviation. The intra-day RSD% ranged from 0.21 to 
0.67 and 0.23 to 0.47% and inter-day RSD% ranged from 0.59 to 0.90 and 0.43 to 
1.77% respectively (Table 7.2).    
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Table 7.2: Intra-day and inter-day precision for salmeterol and fluticasone in aqueous solution. 
 
Salmeterol and 
Fluticasone  
concentration 
(µg/ml) 
Intra-day 
RSD% 
Inter-day 
RSD% 
Intra-day 
RSD% 
Inter-day 
RSD% 
Salmeterol Fluticasone 
2.5 0.67 0.72 0.47 1.77 
10 0.21 0.59 0.23 0.56 
20 0.42 0.901 0.29 0.43 
7.3.1.6. Stability 
Reference solutions were stored in the refrigerator at +4◦C for 6 weeks and re-
analysed in an injection sequence employing freshly prepared standard solutions. 
The concentration after such storage conditions and on comparison with a freshly 
prepared standard was 95.2%. Longer storage periods may be possible but were not 
assessed in this study. 
7.3.1.7. Robustness 
The robustness of an analytical method is a measure of its capacity to resist changes 
due to small variations in method conditions, and in this case it was assessed as a 
function of changing the SDS, buffer concentration, 1-butanole and pH. The changes 
ranged over ±5% of the target (experimental condition ((USA, 2005b).  
 
7.3.2. Application of NELC mobile phase for the assay of salmeterol 
and fluticasone in dosage form (Seretide®100 Accuhaler)  
7.3.2.1. Dose content uniformity 
An in-vitro method was used to measure the dose emission uniformity of the  
commercially available Seretide
®
 Accuhaler (GlaxoSmithKline, UK) containing 
50/100µg salmeterol/fluticasone propionate per dose and  using the dose sampling 
apparatus described in USP 2005 (see Figure 5.12). 
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The emitted dose uniformity was assessed by collecting ten individual doses (dose 
numbers 2, 3, 4, 34, 35, 36, 37, 58, 59 and 60) of the entire dose available (60 
doses). The doses were collected from the Seretide
®
 Accuhaler at a flow rate of 
69L/min corresponding to a pressure drop of 4kPa across the inhaler. The flow 
duration was 3.5s; which is equivalent to a volume of 4L drawn through the inhaler. 
After the dose was discharged into the apparatus, the inhaler device was detached 
and the vacuum tubing (T2) disconnected. Each dose was collected and then was 
transferred to a 20ml volumetric flask. This was diluted up to appropriate volumes of 
mobile phase prior to quantitative HPLC analysis. 
7.3.2.1.1. Results and discussion 
The HPLC data for the dose emission were compared with those of the nominal dose 
of Seretide
®
 Accuhaler (Table 7.3). In-vitro studies have shown that a combination 
of salmeterol with fluticason in blisters (Accuhaler
® 
, Glaxo Smithkline) shows little 
difference in the dose emission (Ashurst et al, 1998). Unlike turbuhaler, the emitted 
dose from  Seretide
® 
Accuhaler was more accurate, consistent and closer to the label 
claim. Therefore, Seretide
® 
Accuhaler could be recommended for patients because 
consistent and reliable dosage emission from inhaler is essential for the management 
of patients prescribed inhaled medication.   
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Table 7.3: The mean (±SD) total emitted dose (% nominal dose) from the Seretide
®
100 Accuhaler at 
an inhalation rate of 69 L/min using a 4 L inhalation volume.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dose 
Number 
% Label dose 
emitted 
(salmeterol) 
2 86.88 
3 90.09 
4 86.62 
34 83.45 
35 90.36 
36 87.77 
37 85.5 
58 81.14 
59 85.02 
60 81.84 
Mean 85.87 
± SD 3.14 
RSD% 3.65 
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7.4. Conclusion 
The method described in this study has been shown to be reliable, precise, and 
accurate. The NELC offered faster analysis times comparing with conventional 
HPLC. The method has been applied to the determination of the content of the 
emitted dose of the Seretide
®
 Accuhaler. 
 
Dose 
Number 
% Label dose 
emitted 
(fluticasone) 
2 74.52 
3 75.34 
4 79.69 
34 76.5 
35 84.20 
36 77.59 
37 79.34 
58 68.72 
59 73.30 
60 76.76 
Mean 76.56 
± SD 4.15 
RSD% 5.41 
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General conclusions 
High performance liquid chromatography has been widely used for more than 40 
years as an analytical method for sample separation in pharmaceutical preparation 
and biomedical research. HPLC has a wide range of applications including checking 
purity in the development of drugs and quality assurance in the process of quality 
control of final products. A conventional HPLC instrument uses and generates on a 
daily basis large volumes (over 1 litre) of organic solvents (mobile phase) that must 
be disposed of as chemical waste. Analysis of samples that are complex in nature, 
such as plasma, urine, and those samples that contain multi-components with a wide 
range of polarity, can be very difficult using isocratic conventional HPLC. Therefore 
gradient HPLC is usually employed for the analysis of these samples. However, 
gradient HPLC has many disadvantages including poor robustness and long 
equilibration times. Recently microemulsion HPLC was introduced which has the 
potential to overcome the limitations of conventional and gradient HPLC. 
 
Initially, different microemulsion systems were developed using different types of 
surfactants including ionic surfactants (SDS) and non-ionic surfactants (Tween 80, 
Brije35). The phase diagram for these systems was examined. It was found the 
microemulsion region for the microemulsion system that includes SDS is wider 
compared with other solutions which include non-ionic surfactants. Also, it was 
noticed that when using SDS as a surfactant the solution droplet size for the 
microemulsion system increased with increases in the concentration of the oil. Also, 
a nanoemulsion system was formed at very low concentrations of oil. In addition, 
increasing the concentration of SDS/butanol above 70% formed turbid solutions. 
Tween80 formed a nanoemulsion system with the presence of sorbitol and octane. 
  Conclusion and future work                                                                      Chapter 8  
 
 
208 
The average size of droplets in the solution was 22.5nm. The nanoemulsion was 
formed in the concentration range of 10-20% w/w of Tween80/sorbitol and 0-
2%w/w octane. However, the region of the nanoemulsion was very narrow and 
therefore it was not considered as a mobile phase. Replacing the Tween80 with 
another non-ionic surfactant (Brij35) formed a solution in the nanoemulsion region 
in the concentration range of 2-5%w/w Brij35/butanol and 0.5-2.9% w/w.  
 
The main aim of this work was to investigate the potential of nanoemulsion as a 
mobile phase for the separation of complex samples and to explore the capabilities 
of NELC for the determination of drugs with different physiochemical properties in 
their pharmaceutical preparation and in urine samples. These drugs included 
terbutaline, salbutamol, formoterol, salmeterol and fluticasone. Initially, 
nanoemulsion mobile phase prepared with SDS-octane-butanol-phosphate buffer 
was used for the analysis of the hydrophilic drugs terbutaline and salbutamol. 
However, it failed to give baseline separation for terbutaline from the internal 
standard, which could be due to the fact that terbutaline and bamethane are 
hydrophilic drugs and are highly protonated at low pH. The protonated form of 
terbutaline and bamethane can have an ionic interaction with the SDS molecules 
rather than partitioning between oil droplets and the aqueous phase. Therefore SDS 
was replaced with the non-ionic surfactant Brij35. The nanoemulsion consisted of 
Brij35-ethylacetate-butanol-phosphate buffer all (w/w). The mean particle size of the 
mobile phase was 8.89nm. The method was optimized for the different experimental 
parameters including concentration of surfactant, concentration of co-surfactant, 
concentration of oil, mobile phase pH and column temperature. The NELC method 
was extended for the analysis of salbutamol and for the simultaneous analysis of 
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salbutamol and terbutaline in aqueous solutions. The method was validated with 
respect to linearity, accuracy, precision, sensitivity, and robustness.  
 
The method was further extended for the individual and simultaneous determination 
of terbutaline and salbutamol in urine samples. However, the addition of an ion pair 
(OSA) at a concentration of 1.1% w/w was necessary to achieve the separation of 
both terbutaline and salbutamol from the urine matrix components. The NELC 
bioanalytical method was validated with regards to linearity, accuracy, precision, 
sensitivity, and robustness. The accuracy of the method was greater than 98.5% and 
recovery was >987.6.  
 
In the second stage the nanoemulsion mobile phase was used for analysis of 
lipophilic drugs including formoterol, salmeterol and fluticasone. Formoterol has 
low absorbance in the UV region. Thus, derivatisation with a suitable absorbance 
enhancing or fluorescence-producing agent is necessary to increase the detectability 
of these compounds by producing a highly detectable product. The selection of a 
new derivatising reagent was based on the chemical structure of formoterol and the 
efficacy of derivatising reagents in reacting with the hydroxyl groups or amino of 
formoterol. Formoterol was determined following pre-column derivatisation with 9-
fluorenylmethylchloroformate (FMOC-CL) as a fluorescent detection reagent. The 
developed method was optimised at various factors and showed good validation 
data. Then the method was used for the determination of formoterol in an Oxis
®
 
Turbohaler. Although the same mobile phase was successfully extended for the 
separation of formoterol in urine, the fluorescence detection technique was not 
useful for the detection of formoterol in urine samples due to the overlapping of the 
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formoterol peak with endogenous peaks. The solid phase extraction method was 
employed to concentrate the final analyte (40 times) so that UV detection could be 
used to determine the low concentration of formoterol in urine samples. The method 
was validated and an acceptable assay precision %CV <4.89 inter-day and %CV 
<2.33 intra-day was achieved.  
 
This method can be used to determine the concentration of formoterol in urine 
samples to identify the relative lung deposition following inhalation. Moreover, the 
NELC method gave a much faster analysis time for formoterol (Rt=3.54min) 
compared with the conventional HPLC method (Rt=20min). Salmeterol and 
fluticasone propionate were detected by UV at 228nm. The developed NELC 
method was optimised at various factors and showed good validation data. The 
standard calibration curve in aqueous samples was linear. The LOD and LOQ were 
0.57-0.58ng/ml and 1.73-1.76ng/ml respectively. The RSD% of intra-day and inter-
day precision were <2%, and the accuracy was >97.6%.  
 
The factors of surfactant, co-surfactant and oil contents were investigated for all 
mobile phases in order to produce the best separation.  Some parameters were found 
to have a large influence on the selectivity of the separation. The retention time for 
the examined drugs decreased with increases in oil concentration, which may be 
attributed to the fact that the solubilising capacity of the eluent for the drugs is 
improved at high concentrations of oil. On the other hand, it was found that 
increasing the concentration of the surfactant and co-surfactant had little effect on 
the separation and peaks resolution of either hydrophilic or lipophilic drugs.  
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Finally, the solvents that are used as mobile phase for the conventional HPLC, 
including acetonitrile, possess properties that make them less preferable from a 
green analytical chemistry perspective: they are flammable, volatile and toxic. 
Consequently, HPLC waste solvents including acetonitrile, THF and methanol must 
be disposed of as chemical waste, which is costly and increases the laboratory’s 
environmental waste-disposal burden. In addition acetonitrile is an expensive 
solvent, as brought to the fore during a worldwide shortage in 2009, when limited 
availability caused prices to shoot up (MAJORS, 2009). Nanoemulsion systems are 
an environmentally friendly alternative to the traditional solvents of the mobile 
phase for liquid chromatography. In this research project the potential was 
demonstrated for replacing conventional HPLC with a greener analytical chemistry, 
which is nanoemulsion mobile phase. 
 
In summary, the use of oil-in-water nanoemulsion as mobile phase was successfully 
applied for the analysis of both hydrophilic and lipophilic drugs in aqueous and 
urine samples. The NELC method replaced several different HPLC methods, each of 
which required a separate set of HPLC. It has been shown that nanoemulsion mobile 
phases are capable of separating compounds with a wide range of solubility and 
polarities. Hydrophilic and lipophilic compounds can be rapidly eluted due to the 
unique two phases oil and water composition of the eluent.    
 
It was shown that NELC provides a faster analysis time of inhalation products in 
aqueous and urine samples compared to conventional HPLC. Also, NELC methods 
use less expensive solvents, and so there are considerable savings in both cost and 
time, which can improve efficiency within quality control. It is proposed that this 
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volume of work has been important in showing the possibilities and range of 
application which can be achieved using NELC. It is hoped that these studies can be 
carried forward and that many applications of NELC can be added to the range of 
usage in the future. 
 
 
Future work 
There is much potential for future work on NELC. Further additions to the 
nanoemulsion could be investigated, such as different types of surfactants, co-
surfactants, oils, and so on. Also, further applications of the technique to 
pharmaceutical analysis could be studied. The work in the thesis was carried out 
using oil-in-water nanoemulsion. It is believed that the reversed water-in-oil system 
should also be investigated.   
 
Recently, polymer based reversed phase columns have been introduced. These 
columns are chemically stable and allow applications in the pH ranges from 0 to 14. 
It can therefore be suggested that this type of column can be used with nanoemulsion 
mobile for the analysis of basic drugs at high pH, because they are available in the 
neutral form at high pH, which could enhance the incorporation of these drugs in the 
oil droplets of the mobile phase. This also eliminates the problem caused by 
attraction between hydrophilic drugs and silanol groups that exist in conventional 
columns. 
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